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Risk factors for cardiovascular disease (CVD) include obesity, ethnicity and hypertension. High-
density lipoprotein (HDL) has traditionally served as a marker for CVD risk. Latest studies, 
however, propose that the composition and subclass distribution and the anti-atherogenic function 
of HDL are more accurate predictors of CVD risk. We therefore explored whether obesity, 
ethnicity, exercise and hypertension may modulate HDL composition, subclass and function in 
three different sample populations of patients affected with these CVD risk factors.  
Methods: 
The first study sample population consisted of black and white obese and normal-weight South 
African women (n=40). In the second sample population, obese black South African women were 
randomly assigned to exercise (combined aerobic and resistance exercise 4 times/week) or 
control (sedentary) conditions for 12-weeks (n=32). The third sample population included Nigerian 
out-patients, divided into healthy controls, hypertensive patients and hypertensive patients with 
heart failure (HF) (n=80). HDL composition measurements included apolipoproteins A1 and M 
(ApoA1 and ApoM), paraoxonase (PON1) and platelet activating factor acetylhydrolase (PAF-AH) 
expression (using Western blotting) and sphingosine-1-phosphate (S1P) content (using mass 
spectometry). Levels of large, intermediate and small HDL subclasses were measured using the 
Lipoprint® system. HDL functionality was assessed by measuring PON1 activity, PAF-AH activity, 
reverse cholesterol efflux capacity, HDL-mediated activation of endothelial nitric oxide synthase 
(eNOS) and quantification of the expression of vascular cell adhesion molecule in endothelial 
cells. 
Results: 
In all sample populations, HDL-cholesterol concentration was not different between groups. PON1 
activity was lower in white compared to black women (0.49±0.09 U/L vs 0.78±0.10 U/L, p<0.05). 
Obese black women had lower PAF-AH activity compared to obese white women (9.34±1.15 U/L 
vs 13.89±1.21 U/L, p<0.05). Compared to normal-weight women, obese women had lower large 
HDL, greater intermediate and small HDL. Compared to the sedentary control condition, exercise 
training was associated with a decrease in PON1 activity (-8.7±2.4% vs +1.1±3.0%, p<0.05), PAF-
AH serum expression (-22.1±8.0% vs +16.9±9.8, p<0.005) and small HDL subclasses (-
10.1±5.4% vs +15.7±6.6%, p<0.005). S1P content in HDL was lower in hypertensive and HF 
patients compared to controls (165 ± 55 vs 201 ± 73 pmol/mg, p < 0.05). HDL subclass distribution 
was different in hypertensive and HF patients with lower large HDL (48 ± 15 vs 63 ± 7%, p<0.005), 
higher intermediate (45 ± 7 vs 34 ± 5%, p<0.005) and small HDL (7 ± 9 vs 2 ± 4%, p<0.05). In 
contrast to HDL from control patients, HDL from all hypertensive patients failed to activate eNOS. 
Conclusions: 
In all three sample populations, there were associations between CVD risk factors and measures 
of HDL quality. HDL subclass distribution differences were associated with obesity and 
hypertensive heart failure, both in cross-sectional studies and in an exercise intervention study. 
In African sample populations, consideration of HDL quality rather than total HDL quantity may 




CHAPTER ONE: LITERATURE REVIEW 
1. Introduction 
Cardiovascular disease (CVD) is the leading cause of death worldwide (Mathers and Loncar, 
2006; World Health Organization, 2011). From a reported 16.7 million deaths in 2002, global 
cardiovascular related deaths are estimated to rise to 23.3 million by 2030 (Mathers and 
Loncar, 2006). No longer mainly prevalent in developed or high-income countries, ischemic 
heart disease is also predicted to be the leading cause of death in low-income countries by 
2030 (Mathers and Loncar, 2006). In an African setting, progressive changes in socio-
economic status has raised the burden of preventable cardiovascular disease (Akinboboye et 
al., 2003; Mayosi et al., 2009; Sliwa et al., 2012). Individuals in newly-industrialised countries 
have improved access to Westernized diets with greater wealth and status often linked to 
increased inactivity and potential obesity. 
The Global Burden of Diseases, Injuries and Risk Factors study of 2010 indicated that much 
of the burden of CVD in sub-Saharan Africa can be attributed to haemorrhagic stroke, 
hypertension and heart failure (HF), whilst there was a relatively low incidence of 
atherosclerosis and ischemic heart disease (Moran et al., 2013). Recent studies, however, 
indicate tremendous growth in the rates of ischemic heart disease in North Africa and sub-
Saharan Africa (Kakou-Guikahue et al., 2016; Traina et al., 2017). Indeed, myocardial 
infarction, cardiomyopathy and coronary artery disease continue to increase and contribute to 
the burden of CVD in sub-Saharan Africa (Keates et al., 2017). In a clinical setting, incidence 
of periprocedural myocardial infraction in a tertiary South African hospital are even consistent 
with international rates (Tsabedze et al., 2016). Clearly, the epidemiological climate of CVD in 
Africa is unique, and is demonstrative of an epidemiological transition. It therefore remains 
important to use applicable measures to assess the CVD risk in these populations. 
Blood lipids have traditionally served as accurate risk factors for cardiovascular events. Higher 
low-density lipoprotein cholesterol (LDL-C) and lower high-density lipoprotein cholesterol 
(HDL-C)  favour cardiovascular risk (Gordon et al., 1977; Barter and Rye, 1996; Kontush et 
al., 2003). The protective capacity of HDL can be attributed to several atheroprotective 
functions, including reverse cholesterol transport (RCT), antioxidative, anti-inflammatory, anti-
apoptotic and anti-thrombotic properties (reviewed by Nofer et al. 2002). It would then seem 
intuitive that decreased levels of HDL-C would be associated with increased CVD risk. This 
has been confirmed in the literature by epidemiological studies that show a negative 
correlation between HDL-C and CVD risk (Acharjee et al. 2013; Gordon et al. 1989; Gordon 
et al. 1977; Sharrett et al. 2001). More recently, however, the trend has been to move away 
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from total HDL as a strict marker of CVD risk in favour of measures of functionality and 
composition of HDL (Egom et al., 2013; Santos-Gallego, 2015). 
HDL composition refers to the relative concentration of different subclasses, defined by 
density, electrophoretic mobility, particle size and lipoprotein composition (Asztalos & 
Schaefer 2003). Differences in HDL subclasses relate not only to differences in HDL 
functionality but also have the potential as independent predictors of CVD risk (Asztalos & 
Schaefer 2003; Berrougui et al. 2007; Camont et al. 2013; Julia et al. 2010; Kontush et al. 
2003; Lee et al. 2010; Martin et al. 2014; Rader 2003; Stampfer et al. 1991). 
This review explored the apparent disparities between the “quantity “and the so-called “quality” 
of the HDL particle in relation to CVD risk. Accordingly, HDL function, composition and 
subclass were examined as a possible marker of CVD risk. In this regard, the structural 
significance of HDL, its multiple anti-atherosclerotic functions and the distribution of individual 
subclasses will be proposed as improved measures of CVD risk in place of traditional HDL-C 
measurement. 
2. HDL, the smallest of the plasma lipoproteins 
Plasma lipoproteins are water-soluble macromolecules made up of a complex of lipids, namely 
cholesterol, triglycerides, and phospholipids, as well as lipoprotein-specific proteins known as 
apolipoproteins (Morrisett et al., 1975). Lipoproteins are classified according to density, 
particle size, electrophoretic mobility or affinity chromatography (Assmann 1982; Asztalos et 
al. 2011; Mahley et al. 1984). Chylomicrons are the largest lipoproteins with a diameter of 70-
1000nm (Figure 1). They are synthesized in the intestine and transport dietary cholesterol and 
triglycerides from the site of absorption (Mahley et al., 1984). Triglycerides from the 
chylomicrons are enzymatically digested by plasma lipoprotein lipase, liberating fatty acids for 
energy or storage by adipocytes. Lipoproteins generated by the hydrolysis of triglycerides 
associated with chylomicrons are known as chylomicron remnants (Mahley et al., 1984). Very 
low-density lipoproteins (VLDL) are 30-90 nm particles with a density less than 1.006 g/ml, 
which transport triglycerides and cholesterol from the liver (Mahley et al., 1984). Hydrolysis of 
VLDL-associated triglycerides by hepatic or plasma lipoprotein lipase generates cholesterol-
enriched lipoproteins including intermediate-density lipoproteins (IDL) (density = 1.006-1.019 
g/ml) and LDL (density = 1.019-1.063 g/ml), which are the principal cholesterol transporting 
lipoproteins (Mahley et al., 1984). HDL, the smallest (8-12 nm in diameter) and most dense (> 
1.21 g/ml) of all lipoproteins perform protective roles through the removal of cellular 
cholesterol. The formation of HDL is a complex and intricate process, which will now be 













Figure 1. Lipoprotein heterogeneity. Adapted from (Ridker, 2014)  
2.1 The formation of HDL 
HDL, like other lipoproteins, exist in their mature form as spherical complex structures 
comprising a lipid bilayer surrounding a hydrophobic core of triglycerides and cholesteryl 
esters. HDL does, however, originate as discoidal particles, formed within the liver or 
assembled from lipid and apolipoprotein constituents in circulation (Hamilton et al., 1976). In 
combination with a phospholipid bilayer, discoidal HDL are surrounded by at least two 
apolipoproteins (Rye and Barter, 2014).  
Apolipoprotein A1 (ApoA1) is the most abundant of the lipoproteins present in HDL, followed 
by ApoAII, ApoAIV and ApoE. ApoA1, mainly synthesised in the liver, undergoes an initial 
enzymatic cleavage, rendering a mature form which undergoes lipidation in the endoplasmic 
reticulum (Stoffel et al., 1983; Gillard et al., 2009). Lipid-poor ApoA1 generates discoidal HDL 
complexes following the transfer of phospholipids and acceptance of cholesterol from cell 
membranes by ATP-binding Cassette Transporter A1 (ABCA1)  (Wang et al., 2001). The 






Figure 2. Biogenesis of discoidal High-Density lipoproteins. ApoA1 can be synthesized in the liver where 
interaction with ATP binding Cassette Transporter A1 (ABCA1) forms discoidal HDL complexes (A). Lipid-
free or lipid-poor ApoA1 can acquire phospholipids and cholesterol from cell membranes (B) or triglyceride 
rich lipoproteins (C) to generate discoidal HDL by alternative means (Rye and Barter, 2014). 
Lecithin cholesterol acyltransferase (LCAT) is responsible for the conversion of discoidal HDL 
into mature spherical molecules, forming a gradient of unesterified cholesterol between other 
lipoproteins (VLDL and LDL), peripheral cells and HDL (Asztalos et al., 2007). Conversion of 
discoidal HDL to spherical HDL involves hydrolysis of phospholipids in the discoidal HDL to 
generate lysophosphatidylcholine and free fatty acid groups (Rye and Barter, 2014). LCAT 
transfers these fatty acyl groups to cholesterol to form the hydrophobic cholesteryl esters 
which moves to the core of the particle leading to a change in HDL particle conformation 
(Asztalos et al., 2007). This reaction also depletes discoidal HDL of unesterified cholesterol 
and forms the gradient between HDL and VLDL or LDL.  
All of the processes required for the formation of mature HDL are subject to regulation by 
additional factors including ApoA1 availability, phospholipid composition and discoidal HDL 
size, all of which alter LCAT activity (Jonas et al., 1989; Bolin and Jonas, 1996; Scott et al., 
2001). HDL function and physiology are associated with several key protein and lipid 
components including the apolipoproteins, paraoxonase (PON) and sphingosine-1-phosphate 
(S1P). These components control HDL formation and are linked with overall HDL functionality. 
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2.2 Key components in HDL 
2.2.1 Apolipoproteins 
Apolipoproteins are proteins, associated with lipoproteins and perform following functions: 
structural components and ligands for ell surface receptors. As previously alluded to, the 
apolipoproteins are key structural components of lipoproteins and serve as definitive markers 
used to distinguish lipoproteins from each other. ApoA1 is the most abundant lipoprotein in 
HDL, comprising 64% of the HDL protein mass (Gillard et al., 2009). ApoA1 is essential for 
RCT (Scott et al., 2001; Temel et al., 2002). ApoA1 also activates LCAT and it is postulated 
that much of the anti-atherogenic and cardioprotective effects of HDL may be linked to the 
influence of ApoA1  (Temel et al., 2002). 
The functional relevance of ApoA1 was first shown in studies examining administration of 
reconstituted HDL (rHDL) comprised of ApoA1 and phosphatidylcholine discs in cell culture 
models (Stein et al., 1976). The presence of ApoA1 significantly improved RCT (Stein et al., 
1976). Further, depletion of ApoA1 in transgenic mice or anti-ApoA1 antibodies reduces LCAT 
activity, impairs RCT and increases vulnerability to atherosclerosis (Parks et al., 1995; Temel 
et al., 2002; Montecucco et al., 2011). A study focussed on a genetic variant of ApoA1, which 
exists in inhabitants of a village in Italy where these individuals have very low incidence of 
atherosclerosis despite having low HDL-C levels (Sirtori et al., 2001). A minor structural 
variation, produces a functionally superior ApoA molecule (ApoA1-Milano) (Nissen et al., 
2003). It was confirmed in a randomized trial, using recombinant ApoA1-Milano, that this 
genetic aberration results in an apolipoprotein whose minor structural changes endow an 
improved anti-atherosclerotic function (Nissen et al., 2003).  
2.2.2 Key enzymes and HDL 
Although a variety of enzymes including Platelet Activating Factor Acetyl Hydrolase (PAF-AH), 
whose role and functions will be reviewed in section 2.4.5, LCAT and Phospholipid Transfer 
Protein (PLTP) have been shown to be associated with HDL, PON is considered as the most 
prominent enzyme in promoting key functions of HDL (Durrington et al., 2001).  
There are three isoforms of PON including PON1, PON2 and PON3. Whilst PON2 is located 
intracellularly, PON1 is the major factor contributing to the antioxidant function of HDL (James 
and Deakin, 2004; Mackness and Mackness, 2015). HDL provides a hydrophobic environment 
necessary for PON1 activity (James and Deakin, 2004). There is little association between 
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PON1 and other lipoproteins implying that precise interactions may be required to fulfil the 
antioxidant effects of PON1. 
Specificity of the binding of PON1 to HDL relies on HDL heterogeneity, the peptide 
composition (apolipoproteins) and overall HDL composition (phospholipid components) to 
promote a highly specialised association (James and Deakin, 2004). 
Additionally, PON1 and ApoA1 appear to be important for each other. The presence of ApoA1 
in HDL structure is critical in maintaining the stability of the PON1 activity (Deakin et al., 2002). 
Supplementary to the protein content, the lipid composition of HDL is key in regulating a 
number of HDL functions. 
2.2.3 Key lipids and HDL 
The three major lipid groups in HDL include triglycerides, cholesterol and phospholipids. 
Although the cholesterol content of HDL has long served as the measure of choice in 
correlating CVD risk, it is in fact phospholipids which predominate the HDL lipidome (Camont 
et al., 2013). Of these, the negatively charged phospholipids including phosphatidylcholine are 
the most abundant (Larijani et al., 2000). Another important phospholipid, S1P, is enriched in 
the smaller HDL subpopulations (Kontush et al., 2007; Lee et al., 2010).  
S1P is a signalling molecule, capable of triggering a diverse and interconnected string of 
signalling pathways involved in multiple cell function including cell survival (Somers et al., 
2012). In the plasma, S1P is bound and transported by HDL, with which it exhibits tighter 
binding than other lipoproteins, such as LDL (Murata et al., 2000). The diverse 
atheroprotective functions of HDL and the mechanisms by which these effects are achieved 
have been in many cases linked to the S1P content of HDL. These include, preventing 
ischemic injury (Theilmeier et al., 2006; Frias et al., 2012); reducing cytotoxicity (Kimura et al., 
2001; Kontush et al., 2007); inducing prostacyclin release (Liu et al., 2012) and preventing 
LDL oxidation (Kontush et al., 2007). 
In vivo, the major cellular source of S1P is the haematopoietic cells including erythrocytes, 
platelets and leukocytes (Pappu et al., 2007). In plasma, there is a significant surplus of S1P, 
far exceeding the available binding sites at S1P receptors (Murata et al., 2000). The majority 
of free S1P, however, is biologically inactive with active S1P remaining in the lipoprotein form 




2.2.4 Key proteins regulating HDL 
Phospholipid transfer protein (PLTP) 
PLTP is critical in modulating the size and composition of the HDL molecule and, along with 
other regulators such as cholesteryl ester transfer protein (CETP), is implicated in the 
generation of distinct subpopulations of HDL (Tall et al., 1983; Jauhiainen et al., 1993). 
Remodelling of HDL by PLTP is subject to the phospholipid transfer capacity as it can facilitate 
the transport of phospholipids between HDL and other lipoproteins (Jauhiainen et al., 1993). 
PLTP mediated remodelling is regulated by at least three factors, including the HDL 
apolipoprotein composition, lipid composition and enzymatic activity of PLTP (Hattori, 2010). 
Remodelling by PLTP generates an unstable fusion product via two pathways, producing two 
populations of HDL comprised of large and small spherical HDL products (Settasatian et al., 
2001). Therefore PLTP, depending on the site of expression, can control the generation of a 
variety of HDL subclasses (Curtiss et al., 2006). 
Cholesteryl ester transfer protein (CETP) 
The function of CETP is the transfer of triglycerides, cholesteryl esters and phospholipids 
between lipoproteins (Zilversmit et al., 1975). CETP induces exchanges between lipoproteins 
which results in the transfer of triglycerides from VLDL to HDL and cholesteryl esters from 
HDL to VLDL (Hopkins and Barter, 1980). These exchanges alter HDL structure, causing 
changes in HDL particle size, ApoA1 composition and result in significant remodelling of HDL 
(Clay et al., 1991).  
CETP activity also causes a reduction in HDL-C concentration in plasma, evidenced in rodent 
models with decreased CETP activity (Inazu et al., 1990). Observations such as these have 
prompted many large scale clinical trials which seek to selectively inhibit CETP. In addition to 
decreasing HDL levels, CETP induces a pro-atherosclerotic pathology, causing a shift in the 
lipid profile, generating VLDL and LDL at the expense of HDL (Hime, 2010). ApoA1 
dissociation, caused by CETP has also been hypothesised to not only hinder removal of 
excess cholesterol but also lead to its accumulation (Curtiss et al., 2006). 
Therefore, as a result of HDL remodelling, a number of subpopulations or subclasses of HDL 





2.3 HDL heterogeneity 
It was first demonstrated, using agarose gel electrophoresis, that lipoproteins can be 
separated on the basis of their mass: charge ratio (Asztalos et al. 2011). Non-denaturing, two 
dimensional gel electrophoresis as a modification of earlier methods has permitted accurate 
delineation of HDL subclasses (Asztalos et al. 2011). Indeed, electrophoresis techniques have 
undergone great refinement and now allow for not only separation of HDL into subclasses but 
also quantification of the relative distributions of each subclass.  
The nomenclature of HDL subclasses is largely dependent on the methods used for separation 
which, in addition to electrophoresis, can also include immunoaffinity chromatography and 
ultracentrifugation (Asztalos et al. 2011).The latter utilizes differences in the protein/lipid ratio 
of each of the subclasses, permitting sequential floatation (Lindgren et al., 1972). Combination 
of a number of techniques can, in principal separate HDL into 2 distinct subclasses, HDL2 and 
HDL3, which themselves can be further subdivided into additional subgroups (Figure 3) 
(Williams et al., 1992; Rosenson et al., 2011). HDL separation by 2D gel electrophoresis has 
also permitted the identification of preβ-HDL, an immature form of HDL, possibly discoidal 
HDL particles, which most actively participate in RCT (Asztalos and Schaefer, 2003; 
Rosenson et al., 2011). Often preβ-HDL is grouped together with HDL3, which along with 




Figure 3. Schematic diagram of HDL subclasses and protein associations. PAF-AH: Platelet activating 
factor acetylhydrolase; PON1: paraoxoanse; PLTP: phospholipid transfer protein; LCAT: 
lecithin:acetyltransferase and CETP: cholesteryl ester transfer protein. (Davidson et al., 2009) 
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HDL3 is more dense, protein-rich and structurally smaller and lighter than HDL2 (Chapman, 
1986). HDL2, conversely, is enriched in lipids, containing greater cholesteryl ester and 
triglyceride molecules than HDL3 (Williams et al., 1992). Proteomic analysis of the HDL 
subclasses indicated that distinct protein clusters were present in HDL3 (Davidson et al., 
2009), with S1P preferentially associated with HDL3 (Kontush et al., 2007). Proteins 
exclusively associated with HDL3 include PON1 and PON3, PAF-AH and ApoJ while HDL2 
was only associated with ApoCI/CII,CIII and ApoE (Davidson et al., 2009). Therefore, HDL 
subclasses can be distinguished on the basis of size, density and composition.  
The Lipoprint® System, presents a new approach to quantifying the relative distributions of 
HDL subclasses using gel electrophoresis and in this case designates them as large, 
intermediate and small subclasses (Hoefner et al., 2001). We hypothesize that in this case 
HDL2 would be represented by large HDL and HDL3 by intermediate and small HDL. 
2.4 Anti-atherogenic functions of HDL 
HDL performs atherosclerotic functions through multiple ways including RCT, antioxidative, 
anti-inflammatory, and anti-thrombotic functions as well as regulation of endothelial 
homeostasis (Figure 4). The reverse cholesterol efflux pathway or RCT is the principal anti-
atherogenic function of HDL and serves to prevent the onset of atherosclerosis, halting 
formation of atherosclerotic plaques and lesions. In order to understand the need for RCT, the 
pathogenesis of atherosclerosis will first need to be described. 
 





2.4.1 Pathogenesis of atherosclerosis 
Atherosclerosis is a disease centred on chronic inflammation. Changes in the homeostasis of 
the endothelium, together with an increase in oxidative stress, precede the initial onset of 
atherosclerosis (Ross, 1999). Oxidative stress, in the form of free radicals whose generation 
is caused by factors such as cigarette smoking, hypertension and infection, leads to the injury 
of the endothelial cell layer (Ross, 1999). Oxidative injury to the endothelium results in 
increased endothelial permeability of monocytes and lymphocytes caused, in part, from an 
increase in the expression of endothelial adhesion molecules (Ginter and Simko, 2013). The 
resulting endothelium dysfunction promotes the influx of LDL into the intima where it 
undergoes oxidation.  
The so called “oxidative-modification hypothesis” of atherosclerosis proposes that the primary 
mechanism for atherosclerosis development is through the oxidation of LDL to form oxidized 
LDL (OxLDL) (Diaz et al., 1997). Uncontrolled uptake of OxLDL by internalized monocytes 
which have now differentiated into macrophages can later lead to the formation of foam cells, 
















Figure 5. Physical mechanism of atherosclerosis (A) 
and unstable complex plaque formation during 
atherosclerosis (B). Monocytes adhere to the 
endothelial cell layer and once infiltrated into the 
lumen, acquire oxidized LDL and differentiate into 
macrophages. Macrophages increase cytokine 
release promoting further monocyte adhesion and 
cholesteryl ester accumulation within monocytes, 
forming foam cells which contribute to the formation 
of unstable plaques (5B). Plaque rupture and 
disruption of the fibrous cap, as a result of 
macrophage related release of proteolytic enzymes, 
cause leakage of prothrombotic materials into the 
circulation prompting downstream thrombus 
formation. 5A adapted from (Ginter and Simko, 2013) 




Foam cell formation begins with internalization of cholesterol in the form of oxidized LDL 
(which increases Monocyte Chemotactic Protein-1, MCP-1, expression) (Figure 5A) (Ginter 
and Simko, 2013; Yu et al., 2013). The lipoproteins are then delivered to lysosomal bodies 
within the macrophages where cholesteryl esters are hydrolysed to generate free cholesterol 
(Yu et al., 2013). To prevent free cholesterol-related cytotoxicity, the free cholesterol is re-
esterified and leads to the accumulation of excess cholesteryl esters, forming foam cells 
(Figure 5A) (Yu et al., 2013). 
Macrophages and lymphocytes will continue to aggregate and multiply within a newly 
developing atherosclerotic lesion, continually producing cytokines and growth factors. Under 
chronic conditions, this leads to the recruitment of smooth muscle cells and platelets and 
generation of advanced lesions  (Bombeli et al., 1998; Ross, 1999). Continued formation of 
foam cells, smooth-muscle cell proliferation and platelet activation promote plaque instability, 
rupture of the protective fibrous cap and release of thrombogenic material into the circulation, 
forming a thrombus which can lead to arterial occlusion (Figure 5B) (Bombeli et al., 1998; 
Ross, 1999; Ginter and Simko, 2013). 
2.4.2 Reverse Cholesterol Efflux 
The RCT pathway is routinely described as being the main conduit for the atheroprotective 
effects of HDL. The original pathway delineated by Glomset, involves the physiological 
removal of cholesterol from peripheral tissues and cells, to be transported by HDL, to the liver 
for excretion in the bile and faeces (Figure 6) (Glomset, 1968). The majority of peripheral cells 
are incapable of catabolizing free cholesterol and in order to circumvent cholesterol related 
toxicity, cholesterol is effluxed to carriers like HDL (Rader et al., 2009).  
There are several pathways by which cholesterol efflux occurs. These include efflux to lipid-
free ApoA1 mediated by ABC transporter ABCA1, efflux to HDL particles mediated by ABCG1, 
efflux to mature HDL particles mediated by scavenger receptor type 1 (SRB1) and passive 
diffusion (Figure 6) (Castro and Fielding, 1988; Hobbs and Rader, 1999; Bortnick et al., 2000; 
Wang et al., 2004; Kennedy et al., 2005; Prosser et al., 2012). Passive diffusion of cholesterol 
involves desorption of free cholesterol molecules from the donor water-lipid interface and 
diffusion through the aqueous phase until absorption by a receptor (Berrougui et al., 2007). 
Each of the other processes involves interaction with transporter/receptor molecules. These 
are critical in maintaining HDL functionality either through direct management of cholesterol 
efflux or by triggering downstream signalling pathways. These pathways can then induce 
antioxidant, anti-inflammatory or anti-thrombotic effects. Each of the key receptor and 
transporter molecules which control RCT will now be discussed. 
12 
 
ABCA1 interacts specifically with lipid-free ApoA1 to form immature HDL particles, however, 
it also interacts with caveolin-1, which mediates cholesterol homeostasis by controlling 
cholesterol transport (Wang et al., 2001; Lin et al., 2007).  
ABCG1 facilitates cholesterol efflux to HDL particles, particularly in human aortic endothelial 
cells (Wang et al., 2004; Kennedy et al., 2005; Terasaka et al., 2008). The SRB1 receptor is 
distinctive in that it can promote cholesterol efflux in both directions, promoting efflux of 
cholesterol from macrophages to HDL but also promoting HDL cholesterol uptake in some 
cases (Rothblat et al., 1999). ABCA1, ABCG1 and SRB1 all control different aspects of RCT, 
mediating cholesterol transfer between ApoA1 and HDL (Figure 6). All three remain critical in 










Figure 6. Reverse cholesterol transport (RCT). Lipid-poor ApoA1 is produced by the liver and acquires free 
cholesterol (FC) through interaction with ABCA1 to form discoidal HDL molecules which mature into 
spherical HDL through the action of LCAT, whilst lipid-poor ApoA1 effluxes cholesterol accumulated in 
macrophages through ABCA1. Cholesterol is further effluxed and converted into cholesteryl esters (CE) 
in HDL through interaction with macrophage ABCG1 and can also be accumulated from peripheral tissues. 
HDL can deliver cholesterol directly to the liver through SRB1 interaction or indirectly via initial transfer to 
ApoB-lipoproteins, rich in triglycerides (TG), mediated by CETP, which then bind to the liver. Hepatic 
cholesterol is excreted into the bile and ultimately via the intestine, is excreted in the faeces. (Rader et al., 
2009) 
The relevance of CETP in cholesterol transport must not be overlooked. Some HDL-derived 
cholesterol delivered to the bile, is first transported to ApoB containing lipoproteins. This 
indicates that cholesterol effluxed to HDL can then be exchanged with LDL and VLDL to 
facilitate excretion (Schwartz et al., 2004). 
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RCT serves as the primary function of HDL with many pathways being initiated by exchanges 
between HDL and the relevant transporters (ABCA1, ABCG1 and SRB1). These pathways 
may indeed trigger signalling cascades which can then perform the other anti-atherosclerotic 
activities usually associated with HDL. Cholesterol efflux capacity exhibits a strong, inverse 
correlation with prevalent coronary and peripheral atherosclerosis (Yvan-Charvet et al., 2007; 
Out et al., 2008; Tall et al., 2008; Khera et al., 2011; Ishikawa et al., 2015),  as well as the 
incidence of atherosclerotic cardiovascular events (Rohatgi et al., 2014; Saleheen et al., 
2015).  
However, the relationship between CVD risk and RCT is not without controversy. There are 
paradoxical examples of positive associations between RCT and increased risk and incidents 
of cardiovascular events, often as a result of compositional differences in subject HDL (Nestel 
et al., 2012; Li et al., 2013). 
Key to the pathogenesis of atherosclerosis is the loss of structural viability of the endothelial 
cell layer. Much of the HDL function, other than RCT in principal, centres on the attenuation 
of endothelium dysfunction often via antioxidative effects. 
2.4.3 Antioxidant functions of HDL 
The pathogenesis of atherosclerosis can largely be attributed to atherogenic modification of 
LDL. These modifications include glycation, oxidation and glycoxidation (Soran and 
Durrington, 2011). Oxidation or glycation of LDL can render it cytotoxic to endothelial cells, 
smooth muscle cells and macrophages (Schwartz et al., 1991). As mentioned previously, 
OxLDL can be more readily endocytosed by macrophages, yielding atherogenic foam cells 
and triggers release of MCP-1, prompting further recruitment of monocytes to the endothelial 
cell layer (Barter et al., 2004; Yu et al., 2013) Other than RCT, a principal function of HDL 
would involve halting LDL oxidation as a means of counteracting the deleterious downstream 
effects of OxLDL (Figure 7). 
 
Figure 7. Antioxidative function of HDL and proposed mechanism. PON1: Paraoxonase and PAF-AH: 
Platelet activating factor acetylhydrolase.  
14 
 
HDL inhibits metal ion induced oxidation of LDL and lipid peroxidation (Hessler et al., 1979; 
Parthasarathy et al., 1990; Navab et al., 2000). As described previously, a key structural 
component of HDL is PON1. It was first demonstrated that HDL protects the endothelial cell 
layer from OxLDL related cytotoxicity by diminishing lipid peroxide formation (Mackness et al., 
1991). This is accomplished by enzymatic hydrolysis of lipid hydroperoxides and oxidized 
phospholipids in LDL by PON1 (Mackness et al., 1993a). Animal studies have confirmed the 
importance of PON1 in the prevention of LDL oxidation.  
Transgenic mice overexpressing PON1 demonstrated an improved protection of LDL 
oxidation, whilst avian models where PON1 is absent from HDL structure could not protect 
against metal ion induced oxidation of LDL (Mackness et al., 1998; She et al., 2009). HDL, 
isolated from PON1 knockout mice lost their capacity to protect against LDL oxidation in an in 
vitro cell culture model, wherein HDL failed to inhibit monocyte recruitment with the HDL 
molecule rendered dysfunctional and proatherogenic (Shih et al., 1998). 
PON1 plays a principal role in HDL prevention of LDL oxidation (Durrington et al., 2001). It is 
important to consider that the enzyme requires stabilisation with ApoA1, which itself has been 
shown as a powerful antioxidant (Navab et al., 2000; Deakin et al., 2002; Nofer et al., 2002).  
Studies on HDL functionality have utilized quantification of PON1 enzymatic activity to 
determine the antioxidant function of HDL (Aicher et al., 2012; Kappelle et al., 2012; Eroglu et 
al., 2013; Breton et al., 2014). More general assays quantifying antioxidant capacity and 
activity such as the dichlorofluorescein (DCF) and Oxygen Radical Absorbance Capacity 
(ORAC) have been applied to HDL directly (Aicher et al., 2012; Breton et al., 2014).  
 2.4.4 Anti-inflammatory functions of HDL 
OxLDL increases monocyte recruitment by triggering the expression of MCP-1 and 
inflammatory responses in damaged endothelial cells (Assmann and Gotto, 2004; Barter et 
al., 2004). Activated monocytes adhere to the endothelial layer via adhesion molecules 
expressed by endothelial cells. These molecules include Vascular Cell Adhesion Molecule 
(VCAM), Intercellular Adhesion Molecule (ICAM) and E-selectin (Kume et al., 1992; Li et al., 
1993; Calabresi et al., 2003; Barter et al., 2004). ICAM is constitutively expressed by 
endothelial cells and interacts with leukocyte-specific integrins. VCAM and E-selectin are 
expressed in response to pro-inflammatory cytokines such as tumour necrosis factor alpha 
(TNF-α) or in response to the lysophosphatidylcholine content of LDL (Kume et al., 1992; 
Davies et al., 1993; Gomaraschi et al., 2008). Following monocyte binding to the endothelial 
cell layer, monocytes enter the intima and become trapped, with OxLDL preventing their exit 
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through the arterial wall through phenotypic modification of the monocytes (Quinn et al., 1987). 
HDL exerts anti-inflammatory functions through inhibition of adhesion molecule expression 
and interaction with inflammatory cells. 
HDL down-regulates the expression of adhesion molecules such as VCAM, ICAM and E-
selectin in endothelial cells (Figure 8) (Cockerill et al., 1995; Calabresi et al., 2003; 
Gomaraschi et al., 2008). The mechanism is not very well understood. It has been suggested 
that nitric oxide related suppression of the nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κβ) pathway, cyclooxygenase-2 activation and prostacyclin production 
are possible candidates (Cockerill et al., 1999; Schmidt et al., 2006; Murphy et al., 2009). The 
lysosphingolipid component of HDL activates phosphatidyl-inositol-3 (PI-3) and Akt kinases to 
trigger nitric oxide synthesis by endothelial nitric oxide synthase (eNOS) which inhibits TNF-α 
activation (Schmidt et al., 2006). Although the inhibition of the expression of adhesion 
molecules remains one of the anti-inflammatory actions of HDL, it also interacts directly with 
inflammatory cells to circumvent an inflammatory response. 
 
Figure 8. Anti-inflammatory function of HDL and proposed mechanism. VCAM: Vascular cell adhesion 
Molecule and ICAM: Intercellular adhesion molecule  
Monocyte production of inflammatory cytokines such as TNF-α and Interleukin-1 is dependent 
on contact activation with T-lymphocytes (Hyka et al., 2001). The ApoA1 component of HDL 
inhibits the production of cytokines in monocytes in a dose-dependent manner. This occurs 
by inhibition of contact activation of monocytes by T-cells by HDL binding to the surface of 
activated T-cells (Hyka et al., 2001). HDL and ApoA1 reduce monocyte activation, by inhibiting 
expression of monocyte integrin CD11b, which binds to endothelial adhesion molecules such 
as ICAM (Murphy et al., 2008). HDL inhibits monocyte spreading and chemotaxis (Diederich 
et al., 2001; Kim et al., 2013), implicating the actions of eNOS and SRB1 (Murphy et al., 2008, 
2009). 
Assays seeking to quantify the anti-inflammatory function of HDL, quantify expression of 
adhesion molecules in endothelial cells (Calabresi et al. 2002; Cockerill et al. 1995; 
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Gomaraschi et al. 2008) or assess the chemotaxis of monocytes toward a gradient produced 
by endothelial cell culture following pre-treatment with HDL and inflammatory drugs (Kim et 
al., 2013).  
2.4.5 Anti-thrombotic functions of HDL 
Alterations in the balance between coagulation and fibrinolysis can promote the onset of 
atherosclerosis (Nofer et al., 2002). The aggregation and activation of platelets, are associated 
with arterial thrombosis (Mineo et al., 2006). Thrombus formation can trigger downstream 
ischemic events and arterial thrombosis is inversely correlated with HDL-C levels (Gordon et 
al., 1977; Deguchi et al., 2005). HDL controls blood coagulation and inhibits platelet activation 
via several anti-thrombotic functions (Figure 9). 
.  
Figure 9. Anti-thrombotic function of HDL and proposed mechanisms. PAF-AH: Platelet activating factor 
acetylhydrolase and eNOS: Endothelial nitric oxide synthase 
The direct link between HDL and thrombus formation can be elucidated using animal models. 
Using an arterial thrombosis rat model, Li et al, demonstrated reduced platelet aggregation, 
time to thrombus formation and thrombus weight, when animals were infused with  
antioxidative ApoA1 (Li et al. 1999). There are three biochemical mechanisms by which 
thrombosis occurs and are collectively known as Virchow’s triad; dysfunction of cells within 
the vascular wall, disturbed blood flow and dysfunction of the blood components (Mineo et al., 
2006). The antiapoptotic effects and pro-angiogenic effects of HDL, largely related to HDL-
mediated activation of nitric oxide pathways are mechanisms of preventing the first cause of 
thrombosis. The regulatory roles played by HDL in preventing blood component dysfunction 
and blood flow will be focussed on specifically in this section detailing anti-thrombotic HDL 
functions.  
The blood coagulation process induces the activation and aggregation of platelets via the 
thrombin blood coagulation cascade (Griffin et al., 1999). Using the activated protein C and 
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protein S anticoagulant pathways, HDL inactivates coagulation Factor V (Griffin et al., 1999). 
HDL performs direct effects on platelets, demonstrated by the effects of administration of rHDL 
in diabetic patients (Calkin et al., 2009). Platelet activation and aggregation was markedly 
reduced following administration of rHDL (Calkin et al., 2009). 
Down-regulation of platelet activating factor (PAF), inhibition of the release of Weibel-Palade 
bodies for platelet-endothelial cell interaction, prostacyclin release and down-regulation of 
thromboxane A2 synthesis all serve as potential mechanisms for HDL-mediated inhibition of 
platelet activation (Fleisher et al., 1982; Stafforini et al., 1987; Brill et al., 2011; Camont et al., 
2013). PAF is a potent activator of platelets, monocytes and leukocytes (Stafforini et al., 1987). 
The metabolism of PAF in the blood is almost completely regulated by the PAF-AH enzyme 
and the enzyme is a structural component of both LDL and HDL (Stafforini et al., 1987). 
Enzymatic hydrolysis of PAF by PAF-AH renders it physiologically inactive and as such, the 
association of this enzyme with HDL relates to the anti-thrombotic activities of HDL (Stafforini 
et al., 1987; Durrington et al., 2001). 
Another primary anti-thrombotic action of HDL is activation of prostacyclin release. 
Prostacyclin is an arachidonic acid-derived lipid mediator and is as a powerful inhibitor of 
platelet activation. Prostacyclin promotes smooth muscle relaxation and reduces the release 
of growth factors that promote smooth muscle cell proliferation (Vane and Botting, 1995). HDL 
increases prostacyclin release by endothelial cells via two mechanisms. The first involves HDL 
cholesteryl esters serving as arachidonic acid donors for prostacyclin production by the 
cyclooxygenase-2 enzyme. The second involves an increase in cyclooxygenase-2 expression 
(Fleisher et al., 1982; Cockerill et al., 1999). S1P increases the production of cyclic Adenosine 
Monophosphate (cAMP) in smooth muscle cells, which induces prostacyclin production by 
increasing cyclooxygenase-2 expression (Damirin et al., 2005). PAF-AH activity and 
prostacyclin release mediate the anti-thrombotic effects of HDL, while HDL can also reduce 
thromboxane A2 production directly in platelets (Camont et al., 2013). Thromboxane A2 is 
responsible for platelet activation. 
Therefore, to assess the anti-thrombotic functions of HDL, the activity of PAF-AH (Stafforini et 
al., 1987; Daniil et al., 2011), the levels of thromboxane A2 (Camont et al., 2013) or 
prostacyclin (Fleisher et al., 1982) can be measured. 
 
2.4.6 Maintenance of endothelial homeostasis 
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Maintenance of the homeostasis of the endothelial cell layer is imperative in the prevention of 
the development of atherosclerotic lesions. HDL controls proliferation and vasorelaxation of 
endothelial and smooth muscle cells, prevents endothelial apoptosis and has also been 
recently implicated as a mediator in stem cell recruitment (Chen et al., 1986; De Souza et al., 
2010; Yvan-Charvet et al., 2010).  
HDL has been shown, in combination with growth factors and serum components, to stimulate 
the proliferation and migration of endothelial cells, as well as the proliferation of smooth muscle 
cells (Ross and Glomset, 1973; Libby et al., 1985; Chen et al., 1986; Murugesan et al., 1994). 
Smooth muscle cell proliferation contributes to the pathogenesis of atherosclerosis. Promotion 
of proliferation by HDL seems counterintuitive, however, proliferation seems to only be 
induced by higher concentrations of HDL normally present following loss of the endothelium 
(Libby et al., 1985). Under these conditions, smooth muscle growth may then contribute to 
plaque stability, replenishing cells lost from the fibrous cap (Nofer et al., 2002). Aside from 
promoting proliferation, HDL limits vasorelaxation through modulation of eNOS. 
Modulation of eNOS activity by HDL has been demonstrated in both cultured endothelial cell 
and animal models (Besler et al., 2011). Mechanistically HDL stimulates eNOS activity through 
SRB1 and S1P receptor 1 and 3 (Yuhanna et al., 2001; Nofer et al., 2004; Igarashi et al., 
2007). HDL induces Akt phosphorylation and intracellular calcium ion release, which play roles 
in a sequence of activation steps also involving Src Tyrosine kinase, PI-3 kinase and Erk1/2 
MAP kinase, leading to phosphorylation of eNOS at Ser-1177 (Mineo and Shaul, 2003; Nofer 
et al., 2004). The activation of eNOS by HDL is hindered by OxLDL which causes 
displacement of eNOS and reduced activation (Blair et al., 1999). Additionally, OxLDL displays 
endothelial cytotoxicity (Figure 10). 
 
Figure 10. HDL regulation of endothelial homeostasis and proposed mechanisms. eNOS: Endothelial nitric 
oxide synthase. 
OxLDL induced cytotoxicity of endothelial cells is critical in atherosclerosis development and 
HDL serves as a powerful antiapoptotic agent in endothelial cells. Cell death, as a result of 
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growth factor or serum depravation, was reduced in endothelial cells by HDL (Kimura et al., 
2001; Nofer et al., 2001). Under inflammatory conditions, cytokines such as TNF-α, together 
with OxLDL are cytotoxic to endothelial cells while HDL is antiapoptotic (Sugano et al., 2000; 
Kimura et al., 2001; Frias et al., 2009; De Souza et al., 2010). It is well established that HDL 
prevents apoptosis in endothelial cells, however, maintenance of the integrity of the 
endothelium and the atheroprotective effects extend to diverse interactions with other cell 
types including cardiomyocytes. In this situation, HDL has been shown to perform an anti-
ischemic function by attenuating doxorubicin induced cardiotoxicity in cardiomyocytes (Frias 
et al., 2009). Mechanisms implicate both ApoA1 and S1P, which acts via ERK1/2 pathways 
(Frias et al., 2009). 
It is clear that HDL demonstrates a wide variety of anti-atherogenic functions that relate to 
reverse cholesterol efflux; the association of HDL with enzymes, apolipoproteins and 
sphingolipids and the inherent ability of HDL to activate eNOS, a powerful factor in triggering 
protective signalling pathways. Due to the functional prowess of HDL, circulating levels of 
HDL-C have traditionally served as a risk factor for CVD. This central focus has been a subject 
of great scrutiny in recent publications and brings into question the factor of quality over 
quantity of HDL. 
3. The validity of HDL-C as a risk factor of CVD risk: Quality versus Quantity 
It was first shown by the Framingham study that there is a direct negative association between 
HDL-C and CVD risk (Gordon et al. 1977). In terms of clinical relevance, it is presently the 
cholesterol component of HDL that is of primary importance. A wide range of retrospective 
and prospective epidemiological studies have consistently demonstrated its inverse 
correlation with the incidence of atherosclerotic disease (Gordon et al., 1977; Assmann et al., 
1996; Barter and Rye, 1996; Goldbourt et al., 1997). In the Emerging Risk Factors 
Collaboration, which compiled results from 68 observational studies, it was shown that an 
increase in 0.39 mmol/L of HDL-C translated into a reduction of 29% risk for subsequent 
coronary heart disease (Di Angelantonio et al., 2009). HDL-C concentration is thus still 
incorporated in clinical guidelines as one of the primary parameters for assessing CVD risk 
(Piepoli et al., 2016).  
Perhaps surprisingly, cholesterol is a relatively minor component of HDL. It only represents 
15% by weight, whilst its distribution within HDL subclasses also varies across the HDL density 
spectrum. It raises the question of how this asymmetrically distributed steroid can accurately 
reflect the protective effect of such a heterogeneous lipoprotein species. In a recent large-
scale population study, composed of the CANHEART (Cardiovascular Health in Ambulatory 
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Care Research Team) cohort, associations between HDL-C levels and cardiovascular and 
non-cardiovascular deaths of individuals living in the same environment were evaluated (Ko 
et al., 2016). The study included 631 762 individuals and concluded that complex associations 
exist between HDL-C levels and sociodemographic, lifestyle, comorbidity factors and 
mortality. As a result, HDL-C was unlikely to be a reliable cardiovascular-specific risk factor 
(Ko et al., 2016). Whilst genetic variants causing increases in LDL-C were associated with 
increases in CVD risk, those associated with increasing HDL-C had weak associations with 
changes in CVD risk (Voight et al., 2012). 
Recent clinical trials that attempted to reduce cardiovascular risk by pharmacologically 
increasing the HDL-C have been unsuccessful (Kühnast et al., 2015). This has provoked a re-
think of the mechanisms by which HDL may protect the vascular system, giving weight to the 
argument that HDL functionality and discrete properties attributed to different HDL subclasses 
may better explain links between HDL and CVD risk. The following section addresses the 
failings of recent clinical trials in attenuating CVD risk by raising HDL-C. 
3.1 Failures of large scale clinical trials raising HDL-C 
Statins 
Statins inhibit the hepatic synthesis of cholesterol through inhibition of 3-hydroxyl-3-methyl-
glutaryl-coenzyme A reductase (Istvan and Deisenhofer, 2001). Statins have the most 
widespread application of the different lipid lowering agents owing to an active reduction in 
LDL-C levels (Opie and Gersh, 2013). While the major beneficial effect of statins is attributed 
to its strong capacity to decrease LDL-C, it also increases (approximately 5-10%) HDL-C 
levels. Despite this, it is not yet established whether statins reduce CVD risk through the 
increase in HDL-C levels (Jafri et al., 2010). 
CETP inhibitors 
As described previously, CETP is a hydrophobic glycoprotein secreted from the liver and 
circulates in plasma bound to HDL. CETP reduce circulating HDL-C levels by transferring 
cholesteryl ester from HDL to larger lipoproteins, such as chylomicrons, VLDL and LDL, in 
exchange for triglycerides.  
Four CETP inhibitors have reached late-stage clinical development: torcetrapib, dalcetrapib, 
anacetrapib and evacetrapib, all with disappointing results. Torcetrapib was the first tested on 
a large scale in patients with a history of CVD and was administered in combination with statin 
therapy (Barter et al., 2007). Lipid profile results were very promising with a 72% rise in HDL-
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C, however, despite this substantial rise, there was an increased risk of death for patients in 
the treatment group (Barter et al., 2007). It was postulated that torcetrapib has several off-
target effects including raising systolic blood pressure (Barter et al. 2007). In the Stable 
Coronary Heart Disease Patients With Recent Acute Coronary Syndrome (dal-OUTCOMES) 
trial, dalcetrapib was tested in patients with acute coronary syndrome (Schwartz et al., 2012). 
Treatment had no significant effect on cardiovascular outcomes, and concerns were 
highlighted over CETP inhibitor related side-effects in patients (Schwartz et al., 2012). Of the 
remaining two trials, the Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein 
Inhibition With Evacetrapib in Patients at a High Risk for Vascular Outcomes (ACCELERATE) 
trial was terminated by the pharmaceutical company as non-effective (Lincoff et al., 2017), 
and the results of the Randomized Evaluation of the Effects of Anacetrapib Through Lipid-
modification (REVEAL) trial are expected late 2017. 
Niacin 
Niacin is the most efficient HDL-C raising drug. Mechanisms of action include non-competitive 
inhibition of hepatocyte microsomal diacylglycerol acyltransferase-2 (DGAT2), an enzyme 
which catalyses the final reaction involved in triglyceride synthesis (Ganji et al., 2002) and 
selective inhibition of ApoA1 uptake without influencing de novo synthesis (Jin et al., 1997). 
Widespread application of niacin treatment has been limited by adverse side-effects. 
In the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: 
Impact on Global Health Outcomes (AIM-HIGH) trial, patients with established CVD along with 
low HDL-C were maintained on statin or ezetimibe treatment prior to treatment with niacin 
(Boden et al., 2011). While a substantial 25% increase in HDL-C was noted, niacin therapy 
had no influence on primary CVD events or secondary endpoints indicating no clinical benefit 
of the therapy (Boden et al., 2011). The Heart Protection Study 2 - Treatment of HDL to 
Reduce the Incidence of Vascular Events (HPS2-THRIVE) produced similarly futile results 
(HPS2-THRIVE Collaborative Group, 2013). The combination of slow release niacin treatment 
and simvastatin in patients with a history of CVD, resulted in an increase in myopathies and 
non-fatal side-effects, despite a rise in HDL-C (HPS2-THRIVE Collaborative Group, 2013). In 
contrast, however, a meta-analysis including 11 trials using niacin treatment indicated a 
significant reduction in CVD events (Lavigne and Karas, 2013). There is therefore, however, 
no conclusive evidence supporting niacin treatment as effective as reducing CVD risk by 




Fibrates do not reduce LDL-C to the same extent as statins, however, they are still widely 
prescribed, in many cases as a secondary treatment in combination with statins (Moutzouri et 
al., 2010; Katsiki et al., 2013; Opie and Gersh, 2013). The mechanism of action of fibrate 
activity is broad and can be summarised as: induction of lipoprotein lipolysis; induction of 
hepatic fatty acid uptake; increased removal of LDL particles; inhibition of cholesterol and 
triglyceride exchange between HDL and VLDL; stimulation of HDL production via induction of 
hepatic synthesis of ApoA1 and ApoAII and reduced production of VLDL due to reduction of 
free fatty acid to the liver (Vu-Dac et al., 1995; Berthou et al., 1996; Staels et al., 1998).  
Clinical trials which assessed the influence of fibrates on HDL-C in patients were the Helsinki 
Heart study (Frick et al., 1987) and the Veterans Affair High-density lipoprotein Intervention 
(VA-HIT) trial (Rubins et al., 1999). In both trials, a moderate rise in HDL-C was accompanied 
by a reduction in the incidence of coronary heart disease (Frick et al., 1987; Rubins et al., 
1999). Similar findings were made using benzafibrate in the Benzafibrate Infarction Prevention 
(BIP) trial (BIP Study Group, 2000). In contrast to this, were the results from the Action to 
Control Cardiovascular Risk in Diabetes (ACCORD) lipid trial (ACCORD Lipid Group, 2010). 
Fenofibrate used in combination with simvastatin therapy failed to significantly increase HDL-
C or lower risk overall, however, in specific sub-set of patients, such as those with high 
triglyceride and low HDL-C, patients did benefit from the treatment with reduction in risk 
(ACCORD Lipid Group, 2010).  
A possible explanation of the failure of the majority of these clinical trials relates to the concept 
of dysfunctional HDL. Under these conditions, even if a particular individual may possess a 
higher HDL-C, functional impairment of HDL may have consequences for risk of CVD.  
3.2 Dysfunctional HDL associated with disease 
The concept of dysfunctional HDL relates to a total loss of HDL function wherein the normal 
anti-atherogenic lipoprotein starts displaying pro-atherogenic properties, often as a result of 
structural changes (Kontush et al., 2013; Serban et al., 2014; Rosenson et al., 2016). 
Dysfunctional HDL was first demonstrated during acute phase response under inflammatory 
conditions in human patients (Van Lenten et al., 1995). Dysfunctional HDL had a loss in PON1 
and PAF-AH activities, along with a loss in the ApoA1 content, rendering it pro-inflammatory 
(Van Lenten et al., 1995). Similarly, during acute phase response, acute phase proteins such 
as serum amyloid A (SAA), a pro-inflammatory protein, replaces ApoA1 in HDL structure 
(Cabana et al., 1996). Binding of SAA to proteoglycans can immobilize HDL in the arterial wall, 
preventing it from performing anti-atherogenic functions (Lewis et al., 2004). Increased SAA 
content in HDL increases CVD risk due to SAA modifying vascular properties of HDL 
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(Zewinger et al., 2015). Triglyceride enrichment in the HDL core can cause inhibition of HDL 
function (Cabana et al., 1996; Brites et al., 2000). Triglyceride content may also alter ApoA1 
conformation causing inhibition of ApoA1 and HDL functions (Curtiss et al., 2000). Subsequent 
to findings from acute phase response, a number of other pathologies and conditions have 
elucidated the phenomenon of dysfunctional HDL. 
HDL is the major carrier of lipid hydroperoxides in vivo, which have increased susceptibility to 
oxidation and therefore causes loss of function of HDL (Bowry et al., 1992; Shao and 
Heinecke, 2009). Myeloperoxidase can interact with ApoA1, causing nitration and chlorination, 
resulting in generation of pro-atherogenic HDL with loss in ABCA1-mediated RCT (Pennathur 
et al., 2004; Zheng et al., 2004; Huang et al., 2014). Myeloperoxidase also inactivates 
paraoxonase through oxidation of Tyr171 on PON1 (Huang et al., 2013). 
Dysfunctional HDL is characteristic in patients with coronary artery disease, presenting with a 
pro-inflammatory HDL phenotype when compared to controls (Ansell et al., 2003; Besler et 
al., 2011; Sattler et al., 2015). In chronic renal disease, the HDL functions are impaired and 
the capacity to promote cholesterol efflux, the antioxidant and anti-inflammatory effects are 
diminished compared to HDL from healthy subjects (Vaziri, 2015). Recent data suggests the 
role of carbamylation in this process (Sun et al., 2016). HDL can become dysfunctional in 
patients with diabetes mellitus as a result of glycation of HDL (Nobécourt et al., 2010; Brinck 
et al., 2016). This has also been shown in patients with insulin resistance, whilst smoking has 
been linked with producing dysfunctional HDL subclasses due to an increased susceptibility 
to glycation (McMillen et al., 2005; Song et al., 2015). Additionally, platelets can modify native 
HDL, resulting in a dysfunctional and pro-thrombotic form of HDL (Blache et al., 2012). 
An important consideration when examining the link between HDL levels, CVD risk and overall 
HDL functionality is the subclass distribution of HDL.  
Each HDL subclass, as a result of their differences in composition, can perform different 
functions. The relevance of each subclass as independent predictors of CVD risk as well as 
functional superiority between subclasses will now be discussed. 
3.3 Anti-atherosclerotic functions of HDL2 and HDL3 
The contribution of each of the HDL subtypes to overall HDL functionality has been a subject 
of significant debate in the recent literature. From early mechanistic studies in fibroblasts which 
reported a difference in the capacity of different HDL subclasses to efflux cholesterol, there 
seems to indicate a possibility of a functionally superior HDL subclass (Oram et al., 1981). 
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Linking a specific HDL subclass as a more accurate predictor of risk is challenging due to the 
results of mechanistic studies and taking into account the results of epidemiological studies.  
Early reports suggest HDL3 has increased cholesterol efflux capacity compared to HDL2 
(Oram et al., 1981). Improved cholesterol efflux by HDL3, was attributed to enrichment with 
negatively charged phospholipids (Camont et al., 2013). The vast majority of mechanistic 
studies into HDL subclass functionality, point toward HDL3 as the functionally superior 
subclass. The outcomes of pre-clinical studies, which have compared HDL3 and HDL2 are 
summarized in Table 1.  
Table 1. Data from pre-clinical studies distinguishing HDL subclasses on the basis of 
functionality. 
 
A recent study sequentially isolated each HDL subfraction from healthy human subjects, and 
quantified functionality in five assays (Camont et al., 2013). These included the cholesterol 
efflux capacity, antioxidative, antithrombotic, antiapoptotic and anti-inflammatory functions of 
HDL2 and HDL3. In all of the assays, HDL3 proved significantly superior to HDL2 regarding 
basic HDL functionality (Camont et al., 2013). The authors postulated that a difference in lipid 
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composition of HDL3 could be a possible explanation for these observations and indeed, 
structural analysis of rHDL mimicking HDL2 and HDL3 has proven useful in illustrating how 
these differences may affect functionality (Camont et al. 2013; Curtiss et al. 2000). 
Conformational changes in the HDL3 lipidome allow enhancement of the mobility of the active 
region of ApoA1, permitting improved surface access, increasing ApoA1 related functionality 
(Curtiss et al. 2000; Kontush & Chapman 2010). Another important lipid component of HDL3 
is S1P which is almost exclusively associated with the smaller HDL subclass (Kontush et al., 
2007; Lee et al., 2010).  
As discussed in section 4.3, the anti-atherogenic function of S1P as a signalling molecule may 
often relate directly to HDL functionality (Mineo et al., 2006). The S1P component of HDL has 
been shown to induce nitric oxide release (Nofer et al., 2004); prevent ischemic injury and 
trigger cardioprotective signalling pathways (Theilmeier et al., 2006; Frias et al., 2012); reduce 
OxLDL related cytotoxicity (Kimura et al., 2001; Kontush et al., 2007); induce prostacyclin 
release via activation of cyclooxygenase-2 (Liu et al., 2012) and together with HDL3, prevent 
LDL oxidation (Kontush et al., 2007). Additionally, the S1P component of HDL3 increases the 
release of platelet activator inhibitor, which negatively modulates fibrinolysis in vivo, 
contributing to an increase in CVD risk (Lee et al., 2010). 
Patients with coronary artery disease had a lower S1P concentration in HDL which could be 
raised using in vitro S1P loading (Sattler et al., 2010, 2015). This observation was extended 
to patients with coronary in stent restenosis (Jing et al., 2015) and in type 2 diabetic patients 
(Brinck et al., 2016). S1P is inversely correlated with glycated haemoglobin (HbA1c) in type 2 
diabetic patients and the concentration of S1P is directly correlated with its cardiac specific 
anti-apoptotic capacity (Brinck et al., 2016). Other than the benefits of association with S1P, 
HDL3 has been distinguished from HDL2 as a superior HDL subclass in additional mechanistic 
studies. 
Regarding the anti-inflammatory and antiapoptotic functions of HDL, HDL3 was shown to 
inhibit TNF-α induced expression of VCAM in HUVEC cells to a greater extent than HDL2 
(Ashby et al., 1998). HDL3 also showed improved cytoprotection of HMEC-1 cells from OxLDL 
(De Souza et al., 2010). HDL3 demonstrates a more potent antioxidant capacity than HDL2 
and is itself, less prone to oxidation than the larger subclass (Kontush et al., 2003; Shuhei et 
al., 2010). Mechanistically, HDL3 prevents LDL oxidation and inhibits generation of lipid 
hydroperoxides, which are transferred from LDL to HDL3 (Zerrad-Saadi et al., 2009). In 
addition to this mechanism, the superior antioxidant function of HDL3 can relate to selective 




In apparent contrast, HDL2 was shown to elicit improved free cholesterol efflux when 
compared to HDL3, owing to an improved phospholipid content (Yancey et al., 2000). 
However, the difference between HDL2 and HDL3 in cholesterol efflux observed by Yancey 
et al., was pronounced in SRB1 expressing cells. HDL2 has been shown to exclusively 
promote cholesterol efflux by SRB1 (Yancey et al., 2000; Asztalos et al., 2005; Favari et al., 
2009; Julia et al., 2010). Using rHDL as analogues, it was shown that preβ-HDL and HDL3 
promote ABCA1 mediated cholesterol efflux (Asztalos et al., 2005; Favari et al., 2009). This 
indicates that each HDL subclass may promote cholesterol efflux via different receptors with 
smaller HDL molecules promoting ABCA1 mediated efflux and larger molecules promoting 
SRB1 mediated efflux. Both HDL3 and HDL2 equally promote ABCG1 mediated transport 
(Favari et al., 2009; Rothblat and Phillips, 2010). Regarding further functionality based studies, 
HDL2 was shown, in a rather novel mechanism, to more actively prevent LDL associations 
with proteoglycans, thereby inhibiting LDL entrapment and atherosclerosis (Umaerus et al., 
2012). 
3.4 HDL2 and HDL3 as a better index of CVD risk 
Early epidemiological studies describe HDL2 as more accurate risk indicator for CVD. Indeed, 
myocardial infarction survivors had low levels in HDL2 (Brugger et al., 1986), and HDL2 was 
inversely correlated with coronary heart disease risk (Johansson et al., 1991). Modern studies 
continue to argue for HDL2 as a risk factor. A large study of 4594 healthy patients 
demonstrated that a decrease in HDL2 was associated with increased CVD risk (Musunuru et 
al., 2009). Similarly patients with acute coronary syndrome displayed lower levels of HDL2 
and higher levels of HDL3 (Tian et al., 2014). 
In contrast, post-hoc analysis of two prospective studies, the IDEAL (Incremental Decrease in 
End Points through Aggressive Lipid Lowering) trial and the EPIC (European Prospective 
Investigation into Cancer and Nutrition)-Norfolk case-control study, showed that a very high 
concentration of HDL2 particles, may be associated with increased rather than decreased 
CVD risk (van der Steeg et al., 2008). Kavo et al., studied HDL from patients who survived a 
myocardial infarction (MI) at a young age (≤35 years) and healthy control subjects and showed 
that MI patients had reduced preβ-1 and HDL3 and elevated HDL2 (Kavo et al., 2012). Martin 
and colleagues, analysed the data from two cohorts, the Translational Research Investigating 
Underlying disparities in acute Myocardial infarction Patient’s Health Status (TRIUMPH) and 
Intermountain Heart Collaborative Study (IHCS), which indicated that lower HDL3, rather than 
lower HDL2 and lower total cholesterol, was an improved predictor of mortality in myocardial 
infarction patients (Martin et al., 2015). These data are confirmed by the recent results of the 
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secondary analysis of the AIM-HIGH Study which indicate that the levels of HDL3 and no other 
lipoprotein fractions, were predictive of cardiovascular events (Albers et al., 2016). 
Pre-clinical and new epidemiological data seem to indicate that HDL3 may be an improved 
predictor of CVD risk suggesting that HDL heterogeneity is an important consideration of HDL 
quality vs quantity. Large scale clinical trials have failed to show an attenuation in CVD risk, 
despite significant increases in HDL-C. Additionally, dysfunctional HDL may lead to increased 
risk and the heterogeneity of the HDL population itself, have clearly shown that a routine 
measurement of HDL-C concentration does not adequately predict risk (Chang et al., 2017). 
Having outlined the diverse functions performed by HDL, biochemical measurement of these 
functions as well as subclass distribution may be more relevant means to assess CVD risk. 
For example, HDL function was impaired in patients with myocardial infarction independent of 
the HDL-C levels (Annema et al., 2016). 
To summarize, the quality vs quantity debate of HDL; two individuals may have equivalent 
HDL-C values, however, an individual with better HDL functionality may have lower risk of 
CVD. This may be due to dysfunctional HDL in the other individual linked to structural changes 







Figure 11. Quality vs quantity of HDL in relation to cardiovascular disease risk. Adapted from (Woudberg 
et al. 2016). Literature suggests that HDL3 is associated with improved HDL function. 
Measurement of HDL function and subclass in patients at risk of CVD due to traditional risk 
factors will be important in illustrating this. Therefore, the concluding section considers such 





4. Cardiovascular risk factors and HDL function and subclass 
There are multiple contributors or risk factors for CVD, however, few have a greater negative 
impact on disease outcomes than dietary intake, smoking, obesity, ethnicity and hypertension. 
These 5 examples will be focussed on owing to their potential impact, not only on disease risk 
but also on HDL functionality, composition and subclass distribution.  
4.1 Diet 
4.1.1 Diet heart hypothesis 
The earliest study that examined the influence of diet on atherosclerosis was conducted in 
1908, where high dietary intake of cholesterol in rabbits promoted the onset of atherosclerosis 
(Ignatowski, 1908). Studies in human populations carried out by Keys began to show how high 
dietary fat and carbohydrates increase the risk of CVD (Keys, 1957). Populations with the 
greatest intake of saturated fat had the highest serum cholesterol whilst follow-up indicated 
that these groups also had the highest incidence of coronary artery disease (Keys, 1980). The 
so-called “diet-heart hypothesis” originally detailed how dietary fats, carbohydrates and salt 
increased LDL-C, lead to obesity and contributed to hypertension (Figure 12) (Rossouw, 
1983). 
 
Figure 12. Summary of the “diet-heart hypothesis”. Adapted from (Rossouw, 1983). 
The relationship between diet and CVD has been extensively reviewed by Dalen and Devries, 
who concluded that, whilst the majority of dietary interventions (low-fat, low-cholesterol) 




2014). In contrast, the Mediterranean diet is cardioprotective despite unchanged lipid content 
of LDL-C and total cholesterol  A meta-analysis of observational and cross-sectional studies 
on adherence to the Mediterranean diet showed decreased risk of metabolic syndrome and 
inverse associations with waist circumference, blood pressure and low HDL-C concentrations 
(de Lorgeril et al., 1999; Dalen and Devries, 2014; Godos et al., 2016). As reviewed below, 
the Mediterranean diet is the only diet which has demonstrated a beneficial effect on HDL 
function and subclass. 
4.1.2 The Mediterranean diet 
What is the Mediterranean diet? 
The diet is characterised by key features including: use of olive oil, fruit and nuts, vegetables, 
non-refined cereals and legumes as main sources of fibre, and plant-derived antioxidants such 
as vitamins and polyphenols (Zamora-Ros et al., 2012, 2013); frequent consumption of fish 
as the primary source of protein and poly-unsaturated fatty acids (Marventano et al., 2015); 
moderate consumption of red wine (Giacosa et al., 2013) and low consumption of meats and 
sweets (Di Daniele et al., 2014).  
The Mediterranean diet and HDL subclass and function 
Mechanisms of action for the Mediterranean diet include: prevention of oxidative modification 
of lipids and DNA (Mitjavila et al., 2013); anti-inflammatory effects including decreasing the 
expression of monocyte adhesion molecules (Mena et al., 2009); modulation of the 
metabolomics profile (Martínez-González et al., 2016) and modulation of gene expression 
related to CVD (Castaner et al., 2013). Antioxidant and anti-inflammatory effects have 
functional implications for HDL and indeed, olive oil, a principal component of the diet, 
improved HDL cholesterol efflux (Hernáez et al., 2014), increased PON1 activity (Loued et al., 
2013) and reduced endothelial ICAM expression (Hernáez et al., 2016). Olive oil consumption 
also lead to changes in HDL subclass distribution, increasing HDL2 levels, as well as 
increasing LCAT activity and HDL antioxidative capacity (Farràs et al., 2015). 
Supplementation with olive oil improved HDL expression of ApoA1, PON1 and other proteins 
related to HDL-induced cardioprotection (Pedret et al., 2015). Similarly to olive oil, other 
components of the Mediterranean diet have been individually shown to improve HDL function. 
This includes the mono-unsaturated fatty acid component of the diet, which improved 
circulatory endothelial function, reduced adhesion molecule expression (including ICAM and 
VCAM), expression of von Willenbrand factor and tissue factor pathway inhibitor, which are 
responsible for coagulation (Pérez-Jiménez et al., 1999). 
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In the first study of its kind, Hernáez et al, showed that adherence to the Mediterranean diet 
improved HDL function and altered HDL particle size versus low-fat diets (Hernáez et al., 
2017). Adherence to the diet increased cholesterol efflux, improved HDL induced cholesterol 
esterification and decreased CETP activity. Compared to a low-fat diet, the Mediterranean diet 
increased PON1 activity, increased HDL capacity to prevent LDL oxidation and increased 
eNOS activity (Hernáez et al., 2017). Increases in HDL particle size were however equivalent 
to the effect resulting from the low-fat diet (Hernáez et al., 2017). Examining HDL subclass 
distribution itself, analysis of dietary intake of young adults showed significant correlations 
between increased sugar and saturated fat consumption and shifts in HDL and LDL subclass 
distribution, favouring decreases in size in both HDL and LDL (Bogl et al., 2013). Analysis of 
the lifestyle habits of 290 healthy men indicated that physical activity, moderate alcohol intake 
and consumption of mono-unsaturated fatty acids in their diet favourably increased HDL2 
concentrations (Parlesak et al., 2014).  
4.2 Smoking 
Cigarette smoking is the second most common cause of death worldwide and is responsible 
for approximately 6 million worldwide deaths annually (World Health Organization, 2015). 
Cigarette smoking is therefore also an independent risk factor for CVD (Pearl, 1938; Doll and 
Hill, 1956; Hammond and Horn, 1958; Bazzano et al., 2003). The harmful mechanisms of 
action from smoking include endothelial dysfunction (Celermajer et al. 1993; Ijzerman et al. 
2003); increased oxidative stress (Tangiwa et al., 1994); inflammation in the form of increased 
expression of VCAM, ICAM and E-selectin (Bermudez et al., 2002; Mazzone et al., 2002), 
increased monocyte adhesion (Kalra et al., 1994) and changes in the lipid profiles of the 
smoker. Smokers have higher total cholesterol, LDL-C and triglycerides with lower HDL-C 
compared to non-smokers (Craig et al., 1989; Nakamura et al., 2009). Additionally, smoking 
is associated with increases in LDL oxidation (Heitzer et al., 1996; Pech-Amsellem et al., 
1996). With deleterious consequences for the smoker’s lipid profile together with biochemical 
effects relating to the endothelium, it is intuitive that smoking will also have negative 
consequences for HDL function and subclass (Figure 13). 
Notably, smoking reduces PON1 activity (Nishio and Watanabe, 1997; James et al., 2000); 
ApoA1 content and synthesis (Sigurdsson et al., 1992; Richard et al., 1997) and LCAT activity 
(McCall et al., 1994). Although still debated, there may be smoking-related alterations in the 
activities of CETP and hepatic lipase (He et al., 2013). HDL apolipoproteins are also 
susceptible to increased oxidative modification due to cigarette smoking whilst HDL treated 
with cigarette smoke extracts had reduced cholesterol efflux capacity (McCall et al., 1994; 
Ueyama et al., 1998). Regarding HDL subclass distribution, smoking was associated with 
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significant decreases in HDL particle size, although the latter effect was significant in women 
only (Moriguchi et al., 1991; Freeman et al., 1998; Imamura et al., 2002; Beauchamp et al., 
2010). 
 
Figure 13. Negative effects of cigarette smoking on HDL. CETP: Cholesteryl ester transfer proteinand 
LCAT: Lecithin cholesterol acyltransferase. 
4.3 Obesity 
Approximately 23% of the worldwide burden of ischemic heart disease can be attributed to 
obesity, with obesity prevalence doubling since 1980 (World Health Organization, 2014). The 
deposition of adipose tissue in obesity contributes to development of hypertension, insulin 
resistance, hyperglycaemia and metabolic syndrome (Kopelman, 2007). Volume expansion 
and an increase in cardiac output causes structural changes in the heart, increasing wall stress 
and resulting in wall thickening and eventually hypertrophy (Pascual et al., 2003; Kopelman, 
2007). There is a 3.6x greater risk for coronary artery disease for each unit increase in body 
mass index (BMI) whilst obesity is a contributory factor for cardiac failure in more than 10% of 
patients (Kopelman, 2007). Accordingly, BMI serves as an independent predictor of risk for 
CVD (DeVallance et al., 2015).  
4.3.1 Obesity is associated with changes in serum lipids 
Dyslipidaemia progressively develops with increasing degrees of abdominal fatness, resulting 
in an increase in LDL-C and triglyceride concentrations (Terry et al., 1989; Williams et al., 
1995; Nieves et al., 2003; Goff Jr, 2005). However, longitudinal data suggest that, in a South 
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African cohort, HDL-C concentrations are maintained over time despite increases in body 
weight (Chantler et al., 2015). With little effect on HDL-C concentrations, functional impairment 
of HDL has been shown in obese adolescents as a result of reduced HDL-induced activation 
of eNOS (Matsuo et al., 2013). Smaller HDL particle size has been observed in obese 
European populations compared to normal-weight individuals (James et al. 1997; Magkos et 
al. 2012; Tian et al. 2006). A primary means of intervention includes a combination of exercise 
and dietary control. The effect of exercise on HDL will now be discussed. 
4.3.2 Exercise training interventions restore lipid profiles in obese subjects 
A systematic review of dietary and exercise interventions in obesity concluded that inclusion 
of an exercise in the intervention improved weight loss, reduced dyslipidemia and insulin 
resistance (Wood et al., 1988; Lavie and Milani, 1997; Hawley, 2004; Curioni and Lourenco, 
2005; Ohta et al., 2005). Expectantly, exercise training reduced CVD risk in the Health 
professionals Follow-up study (Tanasescu et al., 2002). Exercise interventions are either 
aerobic, or resistance based interventions or a combination.  
There are, however, a number of conflicting reports regarding the effects of aerobic exercise 
training on blood lipids in overweight adults (Klancic et al., 2016). A recent meta-analysis 
aimed to clarify the extent of aerobic exercise interventions on blood lipids. Analysis of studies 
from North America, Europe, Asia and Australia indicated that exercise training was 
associated with  decrease in triglycerides, but it did not influence total cholesterol, LDL-C or 
HDL-C (Cai and Zou, 2016). However, in another study including type 2 diabetic patients, as 
little as 30 minutes of moderate intensity, daily exercise training increased HDL-C (Argani et 
al., 2014). The results of studies examining the effects of exercise training on lipid parameters 
have been confounded by several variables which influence lipid biology including genetics, 
diet and environmental factors. Further, it is therefore difficult to delineate the hemodynamic 
effects of exercise training from its effects on body fat composition and weight loss  (Blazek et 
al., 2013). Meta-analysis of trials between 1955 and 2003 indicated a marginal, 2% increase 
in HDL-C (Kelley and Kelley, 2006). Further, analysis of trials involving aerobic exercise 
training alone concluded that a mean increase in HDL-C of 2.5 mg/dl was associated with 
exercise (Kodama et al., 2007).  
4.3.2.1 Exercise interventions alter HDL subclass and function 
Whilst some exercise intervention studies failed to show changes in HDL-C, there has been 
demonstrations of improvements in HDL function (Blazek et al., 2013). An American study of 
mainly obese black individuals showed that a mild walking intervention (6 months) resulted in 
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weight loss, decrease in HDL-C, decrease in cholesterol efflux and antioxidant capacity, but 
with no effect on PON1 activity (Aicher et al., 2012). A 3 month aerobic exercise intervention 
in Brazilian metabolic syndrome patients increased PON1 activity and RCT, with no change 
in HDL-C (Casella-Filho et al., 2011). Cycle ergometer training for 6 weeks in elderly Japanese 
patients was associated with an increase in HDL-C and LCAT activity (Riedl et al., 2010). After 
a 9 week aerobic intervention in a population from the Czech Republic, participants had a 
weight reduction, with no change in HDL-C (Lesna et al., 2009), while an increase in RCT was 
only significant in individuals with substantial weight loss (Lesna et al., 2009). Finally, type 2 
diabetic Brazilian patients in a 4 month program had improved HDL antioxidant function and 
an altered subclass distribution (Ribeiro et al., 2008). Other than the aforementioned studies, 
little is known regarding the benefits of an exercise intervention on the functional and structural 
properties of HDL, particularly in ethnic populations at high risk of type 2 diabetes (Sukala et 
al., 2012). 
4.4 Ethnicity 
There has been an increase in non-communicable diseases throughout Africa (Mayosi et al., 
2009), largely driven by an aging population, as well as Westernization of dietary and exercise 
trends (Akinboboye et al., 2003; Mayosi et al., 2009). This can be demonstrated by the 
“immigrant effect”. For example, the prevalence of type 2 diabetes shows a rising gradient 
from black Africans to African American and African migrants (JC et al., 1999). A comparison 
of local Cameroonians and migrants in Paris showed a younger age of diagnosis of type 2 
diabetes in the migrant patients (Choukem et al., 2014). This may be attributed to earlier 
diagnosis of metabolic disorders, due to an improved access to health care, or may be due to 
marked changes in the socioeconomic environment, including shifts in dietary intake toward a 
Westernized diet (Choukem et al., 2014). Conversely, access to drugs might improve some 
health outcomes. Notably, African diabetic migrants displayed greater HDL-C concentrations 
than matched African diabetic patients, most likely due to access to statin therapy, which is 
available in more developed countries (Choukem et al., 2014). It is clear that large parts of 
Africa are under-going an epidemiological transition. Before attributing these changes to all 
individuals in an African setting, it is important to consider how different ethnic groups display 
distinct risk profiles of CVD. 
4.4.1 Ethnicity specific CVD risk 
A number of studies have characterised ethnicity-specific differences in CVD risk in non-
African populations, particularly focusing on minority groups (Castelli et al., 1977; Cappuccio, 
1997; Frank et al., 2014). A systematic review of cardiovascular risk factors in North 
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Americans concluded that African American populations exhibit higher obesity, diabetes and 
high blood pressure than white American populations (Gasevic et al., 2015), resulting in a 
greater risk for coronary artery disease, stroke and cardiovascular outcomes than their white 
American counterparts (Lloyd-Jones et al., 2009; Duke et al., 2012; McTigue et al., 2014). The 
review attributes the higher risk in African Americans to a poor socioeconomic status, lack of 
education and lack of access to adequate health care system compared to white Americans 
(Mensah et al., 2005). Metabolic profiling has indicated a unique set of risk factors, relating to 
prevalence of different CVD within black or African populations.  
Despite possessing similar risk factors to African Americans, black Africans present with 
different CVD compared to African Americans, most likely due to a difference in 
epidemiological transition between Africa and America. Comparing black Africans to white 
Africans, black Africans present with higher blood pressure, diabetes mellitus, hypertension 
and cerebrovascular disease (Chaturvedi et al., 1993; Cappuccio et al., 1997; Fowkes et al., 
2006; Mayosi et al., 2009; Golden et al., 2012). In contrast, coronary heart disease remains 
less common in black African populations. Less than 10% of black African patients present 
with ischemic heart disease, a CVD much more routinely associated with white population and 
patients in developed countries (Rossouw, 1983; Akinboboye et al., 2003; Mayosi, 2007; Sliwa 
et al., 2008; Agyemang et al., 2009). Within South Africa, cholesterol-attributable mortality was 
higher in white compared to black populations, with only 1.8% mortality attributable to ‘sub-
optimal’ cholesterol levels in the South African black population (Norman et al., 2007).  
4.4.2 Ethnicity-specific lipid profiles 
Differences in the susceptibility to CVD in Africa may be a result of distinct ethnic-specific lipid 
profiles. Populations of African descent have lower total-cholesterol, LDL-C and triglycerides 
than their white counterparts (Sundquist et al., 2001; Agyemang et al., 2009; Frank et al., 
2014). It was generally thought that the lower incidence of coronary heart disease in black 
African populations may be attributed to their greater HDL-C, which has been consistently 
shown in African American, compared to white Americans (Castelli et al., 1977; Chaturvedi et 
al., 1994; Grundy et al., 2014). Within Africa, high HDL-C concentrations were associated 
almost exclusively with black African populations (Steyn et al., 1991; Seedat et al., 1992; 
Akinboboye et al., 2003; Alberts et al., 2005; Sumner et al., 2011). Studies from the early 
1990’s in South Africa indicated that the majority of the black population presented with high 
protective HDL-C/triglyceride ratios (Steyn et al., 1991; Seedat et al., 1992). However, recent 
South African studies have shown that HDL-C does not differ in black population, compared 
to white and other ethnic groups (Table 2). 
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Table 2. Findings of South African population studies comparing HDL-C levels 




Black (n=458) 16-69 years 




ratio in the majority 
of patients 

















Men (53%) and 
women (47%) 






Women Lower HDL-C in 
black compared to 
white 







(Ellman et al., 
2015) 
In the Heart of Soweto study, black African patients had lower total cholesterol, LDL-C and 
triglycerides compared to Indian, white and mixed ethnic groups, however HDL-C did not differ 
between ethnic groups (Sliwa et al., 2012). Similarly, South African white women presented 
with higher total cholesterol, triglycerides and LDL-C concentrations than black women, but 
HDL-C concentrations did not differ by ethnicity (Punyadeera et al., 2001). In contrast, 
Goedecke et al,  showed that black women from the Western Cape region in South Africa 
presented with lower HDL-C, than their white counterparts, despite lower triglycerides and 
total cholesterol (Goedecke et al., 2010). This was further confirmed by Ellman et al,  even 
after adjusting for differences in total fat mass and visceral adipose tissue mass (Ellman et al., 
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2015). These studies consistently showed that HDL-C concentrations are similar or lower in 
black African women compared to white pre-menopausal women. There is an emerging body 
of evidence from population studies suggesting that any protective lipid profile in black 
populations cannot be linked to a higher HDL-C, as previously shown in American populations. 
This may then have implications for HDL function. 
4.4.3 Ethnicity-specific effects on HDL function 
African Americans had equivalent activity levels of PON1 despite having similar 
concentrations of HDL-C compared to white Americans (Gaillard et al., 2011). PON1 
polymorphisms, such as L-55M, which results in reduced serum PON1 activity, are less 
frequent in Asian and black populations (Phuntuwate et al., 2005; Healy et al., 2015; Mackness 
and Mackness, 2015). There is further evidence to suggest that there are ethnic-specific 
differences in HDL function. Functional impairment of HDL in South Asians was postulated as 
contributing to an increased risk of coronary artery disease (Dodani et al., 2008). Compared 
to Caucasians, South Asians had impaired HDL antioxidative and anti-inflammatory function 
(Bakker et al., 2016). African Americans had impaired endothelial vasodilation response 
compared to white American populations, whilst endothelium dysfunction in metabolic 
syndrome patients was ethnicity-specific with African Americans having a greater endothelial 
dysfunction  (Stein et al., 1997; Gainer et al., 2001; Rosenbaum et al., 2002; Lteif et al., 2005). 
These studies therefore suggest that ethnicity as a risk factor for CVD not only results in 
specific risk profiles for different populations but also is associated with differences in HDL 
functionality. 
4.5 Hypertension and heart failure  
The burden of hypertension 
Hypertension related complications account for 9.4 million deaths worldwide annually (World 
Health Organization, 2013). Increased burden of hypertension is as a result of an aging 
population, increased inactivity and poor dietary habits (Bello, 2013). Hypertension, commonly 
referred to as “high blood pressure” is defined by the Seventh Joint National Committee Report 
(JNC7) in two stages pertaining to systolic blood pressure between 140 and 159 mmHg (stage 
1) and systolic blood pressure exceeding 160 mmHg (stage 2). Raised systolic blood pressure 
is associated with several cardiovascular complications including ischemic heart disease and 
stroke (Forouzanfar et al., 2017). Chronic increased systolic blood pressure is also the 
principal cause of left ventricular hypertrophy (Verdecchia et al., 1990). Transitioning to HF, 
the left ventricle is dilated with reduced ejection fraction, often as a result of coronary artery 
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disease or myocardial infarction, although this is still debated (Izzo, 2004; Drazner, 2005). HF 
prevalence is increasing worldwide (Go et al., 2013). Hypertension is indeed a major cause of 
HF in developing countries and the burden of congestive cardiac failure is high in Nigerian 
hospitals (Mendez and Cowie, 2001; Onwuchekwa and Asekomeh, 2009). In a cohort of 1 515 
patients, hypertensive HF was the most common form of HF in Abuja, Nigeria (Ojji et al., 
2013). 
Between 1990 and 2015, deaths due to raised systolic blood pressure increased, and remains 
the highest contributor to disability adjusted life years (DALY’s) (GBD 2015 Disease and Injury 
Incidence and Prevalence Collaborators, 2016; Forouzanfar et al., 2017).  
Age standardized DALY’s are highest in Oceania and central and sub-Saharan Africa with up 
to 20-25% adult Nigerians, for example, being hypertensive (Ogah, 2006; Forouzanfar et al., 
2017). Recent studies, however, speculate that the prevalence of hypertension may be as 
high as 42% in Nigerian populations with many individuals being unaware of their illness (Ulasi 
et al., 2011). American Heart Association statistics indicate that black populations are at 
substantially higher risk than Caucasian or white populations (Mozaffarian et al., 2015). 
Additional risk in black populations can be attributed to a diet higher in sodium and lower in 
potassium, low in-takes of fruits and vegetables and lack of physical activity (Bello, 2013). An 
additional factor is a heightened sensitivity and production of aldosterone, the primary sodium 
retaining hormone (Tu et al., 2014). Genetic aberrations in epithelial sodium channels, specific 
to the ENaC gene, are also likely contributors to higher hypertension in black populations 
(Rayner and Spence, 2017).  
4.5.1 Hypertension, heart failure and HDL subclass and function  
The pathogenesis of hypertension proposes a number of causal factors relating to diet, renal 
function and stress (Oparil et al., 2003). Endothelial dysfunction has been a recent important 
consideration, particularly in light of HDL functionality research. Nitric oxide, as previously 
stated, is a potent vasodilator, inhibits platelet adhesion and inhibits the migration and 
proliferation of smooth muscle cells (Oparil et al., 2003). Nitric oxide related vasodilation is 
reduced in hypertensive patients (Oparil et al., 2003). HDL stimulates eNOS activity through 
the binding of S1P receptors (Nofer et al., 2004; Igarashi et al., 2007; Besler et al., 2011) whilst 
polymorphisms in the eNOS gene have also been associated with hypertension (Miyamoto et 
al., 1998; Kishimoto et al., 2004). In addition, much of the functional impairment of eNOS has 
been attributed to increased oxidative stress in the endothelium (Cai and Harrison, 2000). 
Considering the functional link to eNOS as well as the antioxidative properties of HDL, it is 
intuitive to postulate that impaired HDL function may be associated with hypertension. Indeed, 
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recent literature suggests that dysfunctional HDL is characteristic in pulmonary hypertension 
patients (Ross et al., 2015), while HDL subclass distribution may be associated with changes 
in the hypertensive disease state (Zhang et al., 2015). 
Diagnosis of HF is primarily performed using echocardiography. However, echocardiography 
is not easily accessible in low-resource environments, particularly in Africa (Ogah et al., 2006). 
Echocardiography requires expensive equipment and skilled staff. As a result, there is a need 
to establish novel biomarkers of heart disease which can distinguish HF patients from those 
with hypertension (Ojji et al., 2013). Whilst brain natriuretic peptide (BNP) is currently 
recognised as the most sensitive biomarker for HF, preliminary data may suggest that HDL 
and HDL subclass may be possible biomarkers for use in this regard (Zhang et al., 2015). The 
Lipoprint® System does not require specialised training and can be readily established in a 
diagnostic laboratory. Similarly to hypertension, increased oxidative stress has been shown 
as a key mediator in the pathogenesis of HF (Okonko and Shah, 2014), implying that HDL 
function may be related to HF. Studies have shown that there was a notable reduction in HDL-
associated PON1 activity in patients with systolic HF (Tang et al., 2011). In patients with 
chronic HF, HDL antioxidative function was a strong and independent predictor of mortality 
(Schrutka et al., 2016). An observational study in an Arab population at high risk of HF showed 
low levels of PON1 activity (Gugliucci et al., 2015). In addition to PON1 activity and HDL 
antioxidative function, in acute HF patients, cholesterol efflux capacity contributes to, but is 
not a significant independent risk factor, for hospital mortality (Potocnjak et al., 2016).  
Conclusion 
CVD is the leading cause of preventable death worldwide. The relationship between HDL and 
CVD risk has been well established. Biogenic synthesis of the HDL particle is a complex 
process, which can be modulated at multiple points, and together with remodelling processes 
can generate distinct HDL populations capable in many cases of eliciting functions with 
different degrees of efficacy. Functions include the reverse cholesterol efflux pathway, which 
removes cholesterol from foam cells, preventing the development of atherosclerotic lesions. 
In addition, HDL demonstrates antioxidative, anti-inflammatory, antithrombotic and 
antiapoptotic functions. This wide range of anti-atherosclerotic functions has often been the 
reason for several large-scale trials aimed at increased HDL levels to reduce risk. The 
outcomes of these trials have failed to reduce CVD risk. Special consideration of the HDL 
“quality” rather than “quantity” is required to more accurately determine CVD risk. The 
concentrations and individual functions of HDL subclasses, including HDL2 and HDL3 could 
therefore be more useful in determining risk of particular CVD. CVD risk factors have varied 
influence over the functionality and composition of HDL sub-populations. Measurement of 
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HDL ”quality” in populations at risk of CVD may therefore serve as a more accurate indicator 



































CHAPTER TWO: AIMS AND HYPOTHESIS 
1. SUMMARY 
CVD is the leading cause of death worldwide and is becoming an increasing burden in African 
countries due, at least in the past, to rapid urbanization and a rapid shift to Westernized 
lifestyle trends (Mayosi et al., 2009). HDL is the smallest of the circulating lipoproteins and 
displays a number of anti-atherogenic functions including reverse cholesterol transport, 
antioxidative, anti-inflammatory and anti-thrombotic activities (Nofer et al., 2002). 
Epidemiological studies have shown strong negative associations between the concentration 
of HDL-C and the risk of CVD (Gordon et al., 1977). The cholesterol content of HDL is, 
however, only a minor component of a lipoprotein, whose complexity only increases with 
continuing research. The HDL particle is made of a number of enzymes including PON1 and 
PAF-AH, as well as structural proteins and S1P  (D. Stafforini et al., 1987; Durrington et al., 
2001; Kontush et al., 2007; Gillard et al., 2009). All of these structural components contribute 
to HDL function. Accurate quantification of HDL functionality and the elucidation of distinct 
HDL subclasses, reportedly with unique functional properties themselves, have brought into 
question the validity of simply quantifying HDL-C as means of assessing CVD risk (Camont et 
al., 2013). Although HDL-C concentration is still included in the clinical guidelines as one of 
the primary parameters for assessing cardiovascular risk, failures of large-scale clinical trials, 
the discovery of so-called “dysfunctional HDL” and the findings of population studies have 
suggested that the quality of the HDL, the functionality and distribution of individual HDL 
subclasses, rather than the overall quantity of HDL should be considered to better define the 
risk for CVD. 
Traditional CVD risk factors include obesity, ethnicity and hypertension. Obesity prevalence 
continues to increase worldwide and has deleterious consequences for the lipid profile of 
patients, including changes in HDL function and subclass (James et al., 1997; Goff Jr, 2005). 
A proposed intervention to limit CVD risk associated with obesity is exercise training and early 
data in the literature suggest that, in addition to improving cardiovascular health, exercise 
training can alter HDL function and composition (Argani et al., 2014). Very little is known about 
the differences in lipid profiles function to ethnicity and whether changes in lipid profiles are 
associated with differences in CVD risk factors. Hypertension is the most prevalent risk factor 
for CVD in central and sub-Saharan Africa and often progresses to hypertensive HF (Mendez 
and Cowie, 2001; Sliwa et al., 2008; Onwuchekwa and Asekomeh, 2009). Pathophysiological 
contributions to hypertension include endothelial dysfunction, whose structural integrity in vivo 
is associated with normal HDL composition and function. However, whether hypertension may 
be associated with early changes in HDL subclass and function is unknown. 
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2. STUDY AIM 
The current project aims to explore whether specific cardiovascular risk factors such as 
hypertension, ethnicity and obesity may be associated with differences in HDL subclass 
distribution and functionality. Exercise, as an intervention in obese black South African 
women, will also be assessed for its possible effectiveness at improving HDL function and 
modifying HDL subclass distribution.  
3. HYPOTHESIS 
We hypothesize that cardiovascular risk factors such as obesity and hypertension will be 
associated with a shift in HDL subclass distribution and will adversely impact on HDL 
functionality. We also hypothesize that this effect may be ethnicity-dependent. Furthermore, 
we hypothesize that an exercise intervention will attenuate the negative effects of obesity on 






















4. STUDY OBJECTIVES 
To explore the above hypothesis, the following objectives will be addressed: 
      To assess HDL subclass and functionality in normal-weight and obese black and white 
South African women (Chapter 4) 
HDL subclass will be assessed in blood sera using the Lipoprint® system. 
HDL functionality will be assessed by measuring HDL antioxidative activity (PON1 
activity and ORAC assay), the anti-thrombotic activity (PAF-AH activity) and HDL anti-
inflammatory properties (reduction of VCAM expression in human umbilical vein 
endothelial cells, HUVEC). 
 
        To assess whether a 12- week exercise intervention in obese black women may be 
associated with a change in HDL subclass and functionality (Chapter 5). 
HDL subclass will be assessed in blood sera using the Lipoprint® system. HDL 
functionality will be assessed by measuring HDL antioxidative activity (PON1 activity 
and ORAC assay), the anti-thrombotic activity (PAF-AH activity) and HDL anti-
inflammatory properties (reduction of VCAM expression in HUVEC) and reverse 
cholesterol efflux. 
 
        To assess whether hypertension with/without HF in Nigerian black men and women is 
associated with differences in HDL composition, subclass distribution and function (Chapter 
6).  
HDL subclass will be assessed in blood sera using the Lipoprint® system.  
HDL composition will be assessed by measuring HDL content in ApoA1, ApoM and 
S1P. 
HDL functionality will be assessed by measuring HDL antioxidative activity (PON1 
activity), anti-thrombotic activity (PAF-AH activity), HDL anti-inflammatory properties 
(reduction of VCAM expression in HUVEC) and HDL vasodilatory properties (activation 
of eNOS). 
Prior to analysis of patient samples, a method for isolation of pure HDL-C from low volume 










































 HDL functionality: 
• Antioxidant activity 
• Reverse cholesterol efflux 
• Anti-thrombotic effect 
• Anti-inflammatory effect 
• Vasodilatory effect 
HDL subclass and composition: 
• Subclass distribution measured by 
the Lipoprint® system  
• Apolipoprotein A1 
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CHAPTER THREE: OPTIMIZATION OF THE ISOLATION OF PURE HDL FROM LOW 
VOLUME SERUM SAMPLES TO CRITICALLY ASSESS THE FUNCTIONALITY OF HDL 
1. INTRODUCTION 
Experimental models are available to assess the functionality of HDL such as the anti-
atherosclerotic functions including antioxidative, anti-inflammatory and anti-apoptotic effects. 
Most of these models require a primary isolation of HDL from serum. This step is critical as it 
is important to attain a pure sample devoid of albumin contamination or other lipids, which 
would affect analysis and conclusions of any study. Classical HDL isolation methods utilize 
density shift ultracentrifugation alone and are performed using large volumes (5 ml) of serum 
(Bronzert and Brewer, 1977). These techniques often fail to remove contaminating 
concentrations of albumin. For functionality assays of HDL involving the use of animal samples 
or when only limited volumes of serum are available (<1 ml), a technique for efficient isolation 
of pure HDL is essential.  
There are a number of techniques available for HDL isolation including the traditional method 
described by Bronzert & Brewer (Bronzert and Brewer, 1977). As an alternative, Wiebe & 
Smith assessed six different methods of HDL isolation, all of which employed an initial 
precipitation step to remove ApoB-containing lipoproteins including LDL and VLDL (Wiebe 
and Smith, 1985). Indeed, inclusion of this first step is important to obtain isolated functional 
HDL with adequate yields (Wiebe and Smith, 1985). An example of a method employing initial 
removal of LDL and VLDL is the Gidez method (Gidez et al., 1982). Prior removal of other 
lipoproteins allows HDL to be differentially floated above the albumin layer during 
ultracentrifugation. The first isolation technique tested was a “scaled-down” version of 
traditional methods (Bronzert and Brewer, 1977). The protocol was adapted to low-volume 
serum samples (200 µl) and the samples were centrifuged at different time intervals to 
optimize HDL isolation. Ethanol precipitation was incorporated as means of better purifying 
the final sample. The Gidez method was then compared to traditional methods.  
The aim of this study was to optimize a technique for the isolation of pure HDL from 
low volume serum samples. Requirements included isolation of a sample devoid of 





2. MATERIALS AND METHODS: 
2.1 HDL isolation using ethanol precipitation 
For the isolation of HDL from serum samples with minimal volume, the method described by 
Bronzert & Brewer, was first considered (Bronzert and Brewer, 1977). HDL was isolated by 
density shift centrifugation with 200 µl of serum dissolved in potassium bromide to adjust the 
density to 1.060 g/ml. Sera were transferred to thick-wall polycarbonate ultracentrifuge tubes 
(Beckman, cat 343775) and centrifuged at 200 000g at 15°C for 2.5, 5, 7, 9 and 16 hours. 
Following centrifugation, the upper, middle and lower fractions within each tube were collected 
in 50 µl aliquots. Fraction samples were dialysed against PBS (Phosphate buffered saline, pH 
7.4) in Spectra/Por 2 RC membrane (12 000-14 000 kDa) (GIC Scientific, cat 132676) 
overnight at 4°C with a single buffer change after at least 90 minutes. Following dialysis, 
aliquots of each sample were added to two volumes of ice cold ethanol and centrifuged at 
10 000g for 5 minutes at 4ºC in a Microcentaur microcentrifuge (MSE). This yielded 
“precipitated fractions” and was performed as a means of removing contaminating proteins in 
a modification to the method proposed by (Li et al., 2012). Protein concentration was 
determined by the method described by Markwell et al (Markwell et al. 1978).   
2.2 HDL isolation using the Gidez method 
A second method was proposed wherein the primary step involved removal of ApoB 
containing lipoproteins (including LDL) (Gidez et al., 1982). Briefly, serum samples were gently 
mixed with 1/10 volume of a mixture containing 1 part heparin (Mucosal, Fresenius, 500 iu/ml) 
and 2 parts 1.12 M Manganese Chloride solution. Samples were centrifuged at 10 000g for 1 
hour at 4°C. The supernatant was dialysed against PBS in Spectra/Por 2 RC membrane 
(12 000-14 000 kDa) (GIC Scientific, cat 132676) for 1 hour to affect salt removal. 200 µl 
aliquots were then dissolved in sodium bromide (275.5 mg/ml of supernatant), transferred to 
thick-wall polycarbonate ultracentrifuge tubes (Beckman, cat 343775) and centrifuged at 
223 000g at 4°C for 5, 16, 18 and 20 hours in independent experiments performed in triplicate. 
The upper 70 µl and lower fraction samples were dialysed against PBS (pH 7.4) in Spectra/Por 
2 RC membrane (12 000-14 000 kDa) (GIC Scientific, cat 132676) overnight at 4°C with a 
single buffer change after at least 90 minutes. Protein concentration was determined by the 
method described by Markwell et al (Markwell et al. 1978).  
2.3 SDS-PAGE analysis of HDL purity 
In order to analyse the efficiency of each of the isolation protocols, samples were equally 
loaded (10 µg of protein) onto a 12% reducing SDS-PAGE (Sodium dodecyl-sulfate 
polyacrylamide gel electrophoresis) gel (Laemmli, 1970). Gels were stained with Coomassie 
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Blue and photographed using Gel DocTM EZ Imager (Bio-Rad). For quantification of HDL, LDL 
and albumin levels in each fraction, densitometry was determined using Quantity One 
software. In this case, relative intensity is calculated by dividing intensity of the approximately 
500 kDa band (corresponding to ApoB) and the 28 kDa band (corresponding to ApoA1) by the 
same band in the serum reference lane. For quantification of HDL purity relative to albumin, 
relative intensity is calculated by dividing intensity of the approximately 28 kDa band by the 
intensity of the albumin band (at approximately 70 kDa) to quantify ApoA1/Albumin ratio.  
2.4 Oxygen Radical Absorbance Capacity (ORAC) Assay 
The ORAC assay measured total antioxidant capacity and was used in this case to assess 
the functionality of HDL following isolation. Isolated HDL fractions were diluted 1:100 and 
precipitated samples diluted 1:40 in phosphate buffer (pH 7.4). For analysis of whole serum, 
samples were added in two volumes of ice cold ethanol and centrifuged at 10 000g for 5 
minutes at 4°C in a Microcentuar microcentrifuge (MSE). Supernatants were diluted 1:363 in 
phosphate buffer. All sample antioxidant capacity were analysed using the ORAC assay 
described by (Cao et al., 1993) . Briefly, Trolox standards by diluted the stock solution (100 
mM) in phosphate buffer to give a dilution range of 10 nM to 0.078 nM. Fluorescein (3’, 6’ – 
dihydroxyspiro[isoberyofuran – 1[3H], 9’[9H] – xanthen] – 3-one) and AAPH (2,2’ – azobis (2-
amidinopropane) dihydrochloride) were prepared fresh in phosphate buffer. The working 
fluorescein solution of fluorescein was 95.7 nM and AAPH equated to 32.1 µM per well. Trolox 
standards as well as HDL samples (50 µl) were added to wells in 96-well plates (AEC-
Amersham) along with AAPH and fluorescein. Fluorescence was measured over time using 
(plate reader) (Excitation 485nm, Emission 520nm). 
2.5 Chemicals 
Unless otherwise stated, all chemicals were of analytical grade, supplied by Sigma Aldrich (St. 
Louis, Missouri, United States). Purified HDL was a generous gift from Dr Miguel Frias from 
the University of Geneva. 
2.6 Statistical analysis 
All results represent mean ± standard error of mean (SEM). For comparisons of relative 







3.1 Traditional HDL isolation utilizing ethanol precipitation 
The electrophoresis gel of whole serum, upper, middle and lower ultracentrifugation fractions, 
both precipitated and non-precipitated is presented in Figure 16. None of the upper, middle 
and lower fractions produce pure samples of HDL or other lipoproteins. Indeed, density shift 
ultracentrifugation employed in this assay produced an upper fraction characterised by large 
protein bands (>170 kDa), corresponding to ApoB, present in LDL Albumin contamination, 
evidenced by a 70 kDa band was present predominantly in middle and lower fractions. A 
protein band of 26 kDa was present in all samples and corresponded to ApoA1 of HDL. 
Addition of ethanol removes, to a large extent, the 70 kDa albumin band present in all lanes, 
yielding a more concentrated 26 kDa ApoA1 in each of the precipitated samples. This was 














Figure 16. 12.5% Reducing SDS-PAGE gel of upper, middle and lower serum fractions following 
centrifugation for 5 hours. Density-shift ultracentrifugation was carried out on serum aliquots using 
potassium bromide. Samples were centrifuged at 200 000g for 5 hours at 15°C and upper, middle and lower 
fractions were extracted in 50 µl aliquots. Aliquots of these samples were added to two volumes of ice cold 
ethanol and centrifuged at 10 000g for 5 minutes. The resulting supernatants as well as upper, middle and 














►ApoB of LDL 
►ApoA1 of HDL 
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Testing the antioxidant function of isolated HDL 
Using the ORAC assay, the antioxidant capacity of HDL from lower fractions, contaminated 
with serum albumin, indicated a significant decrease in antioxidant capacity in isolated 
fractions following ethanol precipitation (3 474 ± 205 vs 16 317 ± 3 947 nmol/ml Trolox 
equivalents (TE), p < 0.05) (Figure 17).  
 
 
Figure 17. Effect of ethanol precipitation on antioxidant function in lower fractions. The lower fractions, 
following ultracentrifugation for 5 hours, were precipitated with two volumes of ethanol and analysed using 
the Oxygen radical Absorbance Capacity (ORAC) assay as a measure of total antioxidant capacity. TE: 














Testing the effect of ethanol precipitation on HDL antioxidant function 
In order to clarify whether loss of antioxidant function was due to removal of serum 
antioxidants such as albumin or as a result of ethanol effects on HDL; purified HDL was 
precipitated in the same manner and ORAC analysis was carried out (Figure 18). 
Commercial HDL, was precipitated by ethanol using the same method as described 
previously. Figure 18 indicates that the total antioxidant functions of nascent and precipitated 
HDL were not significantly different from each other. 
 
Figure 18. Effect of ethanol precipitation on antioxidant functionality of purified HDL. Previously isolated 
HDL was added to two volumes of ethanol and was centrifuged at 10 000g for 5 minutes. The resulting 
supernatant was assayed using the ORAC assay as a measure of total antioxidant capacity. TE: Trolox 
equivalents (n=3). Results are represented as means ± SEM.  
 
Optimization of traditional methods using difference centrifugation times 
In order to further optimize the method, isolation by centrifugation, was carried out at different 
time points and upper, middle and lower fractions were analysed by SDS-PAGE, as previously 
described. Densitometry allowed relative quantification of HDL and LDL by measuring the 
bands intensity corresponding to ApoA1 and ApoB, respectively. 
Figure 19 indicates a time dependent relationship between HDL content, albumin 
contamination and LDL content. In the upper fraction, the electrophoresis gel (Figure 19A) 
indicates that the albumin contamination was evident in the shorter centrifugation time of 2.5 
hours. When time was extended to 5 hours and longer, the albumin level decreased. 
Densitometry, shown in Figure 19B, quantified “LDL” and “HDL” using band intensity of the 
ApoB (>170 kDa) and ApoA1 (26 kDa) bands. There were no significant differences between 
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LDL and HDL content for each of the centrifugation times in the upper fractions. Unexpectedly, 
HDL was present in the upper fraction. 
The electrophoresis gel pattern and densitometric data of the middle fraction is represented 
in Figure 19C and D. Whilst, according to the gel pattern alone, it appeared that albumin 
contamination was minimal for the 16 hour centrifugation time, this was still present to an 
unsatisfactory level. A time dependent relationship between HDL content and centrifugation 
time was present for the middle fraction. Centrifugation of serum for 7 hours produced 
significantly greater HDL levels of 1.89 AU ± 0.09 compared to the 2.5, 5 and 16 hour intervals 
(1.06 ± 0.06; 1.41 ± 0.18 and 1.37 ± 0.05, respectively). Since the 7 and 9 hour centrifugation 
times were not significantly different from each other, either duration would be appropriate for 
more efficient HDL isolation in the middle fraction. Of concern, was that along with albumin 
contamination, LDL was also present in all middle fractions for the 7 and 9 hour centrifugation 
times. 
As expected, no LDL was present in the lower fraction, however, no time dependent 
relationship between HDL content and centrifugation time was evident (Figure 19E and F). 
HDL levels in the lower fraction were lower than the middle fraction indicating that HDL was 
localised in the middle and upper fractions, and not in the lower fraction. Albumin was again 
present in the lower fraction regardless of centrifugation time. 
In summary, using this initial methodology based on traditional HDL isolation techniques, 
isolation of HDL by density-shift ultracentrifugation was unable to isolate pure HDL. The 
addition of ethanol led to a sample devoid of albumin contamination, but the concentration of 
isolated HDL was not sufficient. We, therefore, aimed to establish an alternative technique for 
HDL isolation using the method described by Gidez et al which involves prior precipitation of 




Figure 19. Optimization of centrifugation duration for HDL isolation. Density of serum samples was 
adjusted using potassium bromide before samples were centrifuged at 200 000g at 15°C for 2.5, 5, 7, 9 and 
16 hours. Upper (A), middle (C) and lower samples (E) were collected in 50 µl aliquots and were loaded 
onto 12.5% reducing SDS PAGE gels. Densitometry quantified LDL and HDL levels for each time point by 
measuring ApoB (>170 kDa) and ApoA1 (26 kDa) bands respectively. Densitometry of upper (B), middle (D) 
and lower (F) fractions at each duration of centrifugation. (n=3) Data represented as means ± SEM. ** p < 





3.2 HDL isolation via the Gidez method 
The Gidez method permitted effective removal of ApoB lipoproteins. Following HDL isolation, 
using the Gidez method, upper and lower fractions for each centrifugation time were run on 
SDS-PAGE gels and densitometry of ApoA1 and albumin was determined. The ratio of ApoA1 
























Figure 20. Optimization of centrifugation duration for HDL isolation using new mini-prep isolation 
employing Gidez method. ApoB containing lipoproteins were precipitated using heparin and manganese 
chloride. Supernatants were desalted and density adjusted with sodium bromide prior to 
ultracentrifugation at 223 000g for 5, 16, 18 and 20 hours. The upper fraction  in each ultracentrifuge tube, 
along with the remaining lower fraction were analysed on 12.5% reducing SDS-PAG gels (A) and 
densitometry of albumin (70 kDa) and ApoA1 (26 kDa) band intensity in the upper layer was calculated and 
presented as ApoA1/Albumin ratio as a measure of purity (B). AU: Arbitrary units. (n=3). Data represented 
as means ± SEM * p < 0.05 compared with all other centrifugation times. 
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Figure 20 represents the electrophoresis gel of upper and lower fractions isolated after 5, 16, 
18 and 20 hours, compared to whole serum. Albumin was localized predominantly in the lower 
fraction with upper fractions having reduced contamination following centrifugation for at least 
16 hours (Figure 20A). Centrifugation for 16, 18 and 20 hours resulted in a significantly higher 
ApoA1/albumin ratio of 2.82 ± 0.61, 4.41 ± 0.80 and 2.98 ± 0.94 AU, respectively, compared 
to 5 hours (0.43 ± 0.09 AU, p < 0.05) (Figure 20B). 
In order to assess antioxidant function of HDL isolated in each of the upper fractions following 
centrifugation for 5, 16, 18 and 20 hours, the ORAC assay was used (Figure 21). 
 
 
Figure 21. Antioxidant function of HDL isolated using mini-prep isolation employing Gidez method. 
Following HDL isolation in upper fractions, HDL samples for each centrifugation duration time were diluted 
1:100 in phosphate buffer prior to analysis of total antioxidant capacity in the ORAC assay. Total 
antioxidant capacity is expressed when corrected for protein concentration. TE: Trolox equivalents. Data 
represented as means ± SEM. *** p < 0.001 (n=9) compared to all other time points 
The 20hr centrifugation produced fractions with a significantly greater total antioxidant 
capacity of 880.4 ± 84.4 nmol/ml TE compared to all other centrifugation times. 
In summary, the initial removal of ApoB containing lipoproteins using this technique isolated 
pure and functional HDL following centrifugation for 20 hours. This technique was therefore 





The aim of this section was to optimize a method for isolation of HDL from low volume serum 
samples. Requirements for the isolation were a pure HDL sample, devoid of albumin and LDL 
contamination, with sufficient yields for further functionality assays. Reducing albumin 
contamination following traditional ultracentrifugation produced an inefficient yield in pure 
HDL. Initial removal of VLDL and LDL using the method of Gidez et al, followed by 20 hours 
of ultracentrifugation produced pure HDL of sufficient yield and antioxidant function (Gidez et 
al., 1982). This method was therefore adapted to allow for the extraction of pure HDL from an 
initial small volume (200 µl of serum). This represents the ideal technique for studying HDL 
function in human and potentially, in animal studies.  
Traditional HDL isolation using ethanol precipitation 
When employing traditional methods for HDL isolation the antioxidant activity of isolated HDL 
was directly dependent on the presence of albumin in the sample. These results illustrate the 
importance of removing albumin from the HDL sample as it will skew functionality assays 
owing to an inherent antioxidant function (Soriani et al., 1994; Cha and Kim, 1996; Bourdon 
et al., 1999, 2005; Musante et al., 2006). To remove albumin, we employed ethanol 
precipitation. This did not impair HDL antioxidant function, as evidenced by similar antioxidant 
capacity between commercial nascent HDL and precipitated commercial HDL. However, 
ethanol precipitation was not seen as a viable inclusion into the method. Although HDL 
samples were purer, the protein concentration was below 1 µg/µl and this low yield of HDL 
was not viable for use in functionality assays, which often require HDL at physiological 
concentrations exceeding 25 µg/ml.  
In order to better optimize the yield and purification using traditional HDL isolation methods, 
extending centrifugation time to improve HDL purity was explored. Results indicated a time 
dependent relationship with HDL isolation. Short centrifugation periods of 2.5 and 5 hours, 
yielded upper fractions with greater albumin levels compared to the longer centrifugation time 
periods.  An optimal time period of 7 hours produced the greatest quantity of ApoA1 (and 
therefore HDL), in the middle fraction. This quantity of HDL, determined by densitometry, was 
greater than the 2.5, 5 and 16 hour time points but was not significantly different from the 9 
hour time point. LDL was enriched in the upper fraction as expected (Bronzert and Brewer, 
1977). The sustained presence of ApoB containing lipoproteins in the middle fraction was of 
concern as this fraction also contained greater HDL. For functionality assays, the removal of 
ApoB lipoproteins (and therefore LDL) is important as their susceptibility to oxidation and pro-
inflammatory and cytotoxic effects will interfere with quantification of HDL function.  
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Other than LDL contamination, another concern was that density-shift was not effectively 
separating HDL at a defined density. HDL was present in each layer and was expected to 
have been enriched in the lower fraction (Bronzert and Brewer, 1977). This, together with the 
consistent albumin contamination throughout the middle and lower fractions, brought the 
validity of this isolation protocol into question. This observation, along with that of the low yield 
of ethanol precipitated samples, warranted the need for a new novel assay which would 
remove ApoB lipoproteins, remove albumin and produce HDL at a concentration greater than 
1 µg/ µl. It would be important that HDL be separated in an upper fraction, leaving the denser 
albumin in the lower fraction. 
HDL isolation via the Gidez method 
Using the Gidez method of HDL isolation, ApoB containing lipoproteins were removed from 
the initial serums sample (Gidez et al., 1982). Density was adjusted using sodium bromide 
and following density shift, HDL was selectively separated into the upper layer, in a contrast 
to classical methods (Bronzert and Brewer, 1977; Parker Jr et al., 1983). This fulfils one of the 
requirements for the isolation technique which was to ensure pure HDL is isolated from LDL 
and VLDL which could negatively influence HDL functionality assays. 
In addition, this isolation technique allowed for isolation of HDL without albumin contamination, 
which was evident in fractions isolated by previous methods based on classical protocols. 
Similarly to the traditional HDL isolation method, whether extending ultracentrifugation time 
improved yield and purity was explored. In this regard, ultracentrifugation for at least 16 hours 
affected isolation of pure HDL as shown by a prominent ApoA1 band in each of the 16, 18 and 
20 hour lanes in the SDS-PAGE gel. Since there was no significant difference in the HDL 
purity between each time point, HDL antioxidant function was used as a means to distinguish 
which centrifugation duration would be employed for HDL isolation throughout the remainder 
of the study.  
The total antioxidant capacity was significantly higher for the 20 hour centrifugation time vs 5, 
16 and 18 hour time points, when corrected for protein concentration. Therefore HDL, isolated 
using the Gidez method and centrifuged for 20 hours was both devoid of albumin 
contamination and indeed functional to a greater extent than HDL fractions centrifuged for 
shorter periods. This combined with a favourable protein concentration exceeding 1 µg/µl 





A method to isolate pure HDL from low-volume serum samples (as little as 200 µl) was 
successfully optimized. This method employed initial removal of VLDL and LDL using the 
Gidez method followed by density shift ultracentrifugation for 20 hours. Accordingly, this 
method was used to isolate HDL from participant serum samples for the determination of HDL 













CHAPTER FOUR: ASSOCIATION BETWEEN ETHNICITY 
AND OBESITY WITH HIGH-DENSITY LIPOPROTEIN (HDL) 





CHAPTER FOUR: ASSOCIATION BETWEEN ETHNICITY AND OBESITY WITH HIGH-
DENSITY LIPOPROTEIN (HDL) FUNCTION AND SUBCLASS DISTRIBUTION  
The following chapter contains data from the following publication: 
Woudberg NJ, Goedecke JH, Blackhurst D, Frias M, James R, Opie LH, Lecour S. Association 
between ethnicity and obesity with high-density lipoprotein (HDL) function and subclass 
distribution. Lipids Health Dis. 2016;15:1 
INTRODUCTION 
Although the leading cause of death in Sub-Saharan Africa remains communicable diseases, 
the prevalence of ischemic heart disease is increasing and it is predicted to be the leading 
cause of death in low-income countries by 2030 (Mathers and Loncar, 2006; Moran et al., 
2013; Collaborators, 2015). The changes in standardized health care, progressive changes in 
socio-economic status and greater Westernization have raised the burden of preventable CVD 
(Akinboboye et al., 2003; Mayosi et al., 2009; Sliwa et al., 2012). In addition, nearly 23% of 
the worldwide burden of ischaemic heart disease can be attributed to obesity, the prevalence 
of which has doubled since 1980 (World Health Organization, 2014). Obesity is associated 
with insulin resistance, which may increase the risk of type II diabetes and dyslipidaemia, as 
evidenced by an increase in triglycerides and LDL-C and a decrease in HDL-C in these 
patients (Terry et al., 1989; Williams et al., 1995; Nieves et al., 2003; Goff Jr, 2005). 
Ethnic differences in lipid profiles and CVD risk have been documented, attributed to, in part, 
genetic, socioeconomic and lifestyle differences (Mayosi et al., 2009; Ellman et al., 2015). 
Black South African women and African Americans exhibit protective lipid profiles, 
characterised by low LDL-C, low triglyceride and low total cholesterol concentrations (Després 
et al., 2000; Punyadeera et al., 2001). In addition, cholesterol-attributable mortality is higher 
in South African white compared to black populations, with only 1.8% mortality attributable to 
‘sub-optimal’ cholesterol levels in black populations (Norman et al., 2007). It was previously 
thought that a favourable lipid profile in black populations would also be characterised by 
higher HDL-C concentrations (Seedat et al., 1992; Steyn et al., 1996). However, recent studies 
conducted in black South African women highlighted a lower or equivalent level of HDL-C than 
their white counterparts (Punyadeera et al., 2001; Goedecke et al., 2010; Sliwa et al., 2012; 
Ellman et al., 2015).  
The Framingham Heart study suggests an inverse relationship between HDL-C levels and 
CVD risk (Gordon et al., 1977). However, recent clinical trials aiming to reduce cardiovascular 
complications by raising HDL-C levels have shown disappointing results (Boden et al., 2011; 
Schwartz et al., 2012). Elucidation of the complexity of the HDL molecule, has led to a shift 
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from measuring the quantity of HDL-C to assessing the composition, the distribution of 
individual HDL subclasses and HDL functionality to try to explain the relationship between 
HDL and cardiovascular risk (Rizzo et al., 2014; Santos-Gallego, 2015). The risk of ischemic 
heart disease in African populations has largely been defined by classical risk factors, 
including the cholesterol component of HDL.  
Given the prevailing doubts about the cardiovascular value of HDL-C, the present study 
used blood collected from a sample population of black and white, obese and normal-
weight South African women, and aimed to explore whether ethnicity and obesity were 




2. MATERIALS AND METHODS 
2.1 Subjects 
The sample population consisted of 40 normal-weight (BMI 18-24.9 kg/m2) and obese (BMI > 
30 kg/m2) self-reported black and white South African women, who had been enrolled for 
previous studies and described in details (Goedecke et al., 2009, 2010). Inclusion criteria 
included (1) age from 18 to 45 years; (2) no known diseases or taking medication for 
dyslipidemia, diabetes, hypertension, HIV/AIDS, or any other metabolic disorders; and (3) not 
currently pregnant, lactating, or postmenopausal. The study was approved by the Research 
Ethics Committee of the Faculty of Health Sciences of the University of Cape Town HREC 
REF 053/2003.  
Basic anthropometric measurements, including height and weight, were taken. Body fat 
percentage was measured using dual-energy x-ray absorptiometry, while visceral and 
abdominal subcutaneous adipose tissue were measured using computed tomography as 
previously described (Goedecke et al., 2010). Fasting serum samples were taken and stored 
at -80⁰C prior to use.  
2.2 HDL isolation (as optimized in Chapter 3) 
HDL was isolated from 200 µl aliquots of serum as follows: Serum samples were added to a 
mixture containing 1 part 500iu/ml heparin (Mucosal, Fresenius) and 2 parts 1.12 (mol/L) 
manganese chloride solution. Samples were centrifuged at 10 000g for 1 hour at 4°C. The 
supernatant was dialysed against phosphate buffered saline (PBS, pH 7.4) in Spectra/Por 2 
RC membrane (12 000-14 000 kDa) (GIC Scientific, 132676) and 200 µl aliquots were then 
dissolved in sodium bromide (275.5 mg/ml of supernatant), transferred to thick-wall 
polycarbonate ultracentrifuge tubes (Beckman, 343775) and centrifuged at 223 000g for 20 
hours at 4°C and the upper 70 µl layer was extracted. Purity was confirmed using 12.5% 
reducing SDS-PAGE stained with Coomassie Blue. The protein concentration of HDL was 
determined by the modified Lowry method (Markwell et al., 1978). All samples were analysed 
in duplicate. 
2.3 PON1 activity assay 
Serum samples were diluted 1:10 in phosphate buffer containing 2 mmol/L CaCl2 (pH 8). 
Diluted serum was added to 96-well plates in triplicate and paraoxon-ethyl substrate (Sigma, 
D9286) was added. Absorbance at A405 was measured at 30 second intervals over 20 minutes. 
One Unit of activity is defined as 1 nmol of substrate hydrolysed per minute. 
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2.4 PAF-AH activity assay 
PAF-AH activity was measured in participant sera using the PAF Acetylhydrolase Assay Kit 
(Cayman Chemical, 760901). Briefly, serum was added to an equal volume of 5, 5’-dithio-bis-
(2-nitrobenzoic acid) (DTNB; Ellman’s Reagent) and assay buffer in triplicate into clear 96-
well plates. All wells were incubated with 2-thio PAF substrate and absorbance at A412 
measured at 1 minute time intervals for 20 minutes. One Unit of activity is defined as 1 µmol 
of substrate hydrolysed per minute. 
2.5 Western blotting  
Isolated HDL and serum samples from each of the participants were electrophoresed on 
reducing 12.5% SDS-PAGE gels with 1.5 µg of HDL protein or 8 µg of serum loaded per well. 
Samples were run over three separate gels with control samples repeated in each gel. Blots 
were transferred onto nitrocellulose membranes (Bio-Rad, 162-0113). Ponceau S staining 
was scanned and used to validate equal loading of wells. Blots were blocked in 5% low fat 
milk powder in 0.05% Tween in Tris-buffered Saline (TTBS, pH 7.5) and incubated overnight 
in primary mouse anti-PON1 antibody (1:200) (James et al., 2010) and rabbit anti-PAF-AH 
(1:400) (Cayman Chemical, 160603). Blots were then washed in TTBS and incubated in goat 
anti-mouse-HRP conjugated secondary antibody (1:5000) (Bio-Rad, 170 6516) and goat anti-
rabbit-HRP conjugated secondary antibody (1:2500) (Santa Cruz Biotechnology, sc-2313), 
respectively for 1 hour at room temperature. Blots were thoroughly washed in TTBS prior to 
incubation in Amersham TM ECLTM Western blotting detection reagent (GE Healthcare, 
RPN2106). Blots were captured in the GeneGnome gel imager. Densitometry of PON1 and 
PAF-AH blots was quantified using Quantity one software. PON1 and PAF-AH relative 
expression data were corrected for control samples, repeated in each gel. 
2.6 ORAC Assay 
Isolated HDL samples were diluted (1:50) in phosphate buffer (pH 7.4) prior to analysis for the 
ORAC assay described in Chapter three (Section 2.4).  
2.7 Quantification of HDL anti-inflammatory function 
HUVEC were purchased from Lonza and were cultured in T75 culture flasks according to 
supplier specifications. For experimental tests, 30 000 cells were seeded into 12-well culture 
plates and cultured in RPMI-1640 media supplemented with 20% foetal calf serum (Biochrom 
BC/S0615), 1 ng/mL vascular endothelial growth factor (VEGF) (Sigma, V7259) and 
penicillin/streptomycin (Biowest, L0018). Five hours after seeding, the medium was changed 
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and supplemented with HDL isolated according to optimised protocol at 10 µg/mL. Cells were 
treated with HDL overnight prior to stimulation with 20 ng/mL murine TNF-α (PeproTech, 315-
01A) for 8 hours. Cell pellets were harvested and stored in RNA Protect Cell Reagent (Qiagen, 
76526) at -20°C. RNA was isolated using the RNeasy Micro kit (Qiagen, 74004) and cDNA 
was synthesised using the High Capacity cDNA Reverse Transcriptase Kit (Life Technologies, 
4368814). cDNA was quantified using the Qubit High Sensitivity RNA kit (Qiagen, Q32852) 
and Qubit Fluorometer (LifeTechnologies). cDNA was amplified for 25 cycles using the RT2 
SYBR Green qPCR kit (Qiagen, 330500) in the RotorGene6000 (Corbit Lifesciences) with the 
following primers: VCAM-1 (sense), 5’-GAAGATGGTCGTGATCCTTG-3’, and (antisense), 5’-
ACTTGACTGTGATCGGCTTC-3’. GAPDH (sense), 5’-
CCACCCATGGCAAATTCCATGGCA-3’, and (antisense), 5’-
TCTAGACGGCAGGTCAGGTCCACC-3’. Results indicate the mean of at least 3 independent 
experiments ± SEM. 
2.8 Quantification of HDL subclass distribution 
Serum HDL subclass was determined using the Lipoprint® HDL system (Quantimetrix, 
Redondo Beach, CA) (Hoefner et al., 2001). Briefly, serum (25 µl) was mixed with Lipoprint 
loading gel (300 µl), containing Sudan black dye which binds proportionally to the cholesterol 
present in the sample. The mix was placed onto the upper part of the high resolution 3% 
polyacrylamide gel. Photopolymerisation was carried out for 30 minutes at room temperature 
and electrophoresis was performed for 50 minutes at 3mA per gel tube. After a rest period of 
30 minutes, gel tubes were scanned and analysed using the Lipoware software. The VLDL 
and LDL remained at the origin [Retention Factor (Rf) = 0.0] while albumin migrated as the 
leading front (Rf = 1.0). Between these, 10 HDL bands could be detected. HDL-1, HDL-2 and 
HDL-3 were defined as large HDL; HDL-4, HDL-5, HDL-6 and HDL-7 were defined as 
intermediate HDL and HDL-8, HDL-9 and HDL-10 were defined as small HDL. Each subclass 
was quantified and expressed as a percentage of total HDL. 
2.9 Statistical analysis 
Results are presented as mean ± SEM. All variables were normally distributed, therefore two-
way analysis of covariance, adjusting for age, was used to compare PON1 activity, PAF-AH 
activity, antioxidant capacity, relative VCAM expression and HDL subclass distribution 
between normal-weight and obese black and white women. Pearson correlation coefficients 
were used to explore the relationships between measures of HDL function and subclass, 




The body composition, lipid profiles and additional physiological data of the participants have 
been previously published and are summarised in Table 3 (Goedecke et al., 2010). In brief, 
ethnic differences included lower visceral adipose tissue (VAT) and higher subcutaneous 
adipose tissue (SAT) in obese black women compared to obese white women. Critically, black 
women had lower HDL and total cholesterol concentrations than their white counterparts. 
Table 3. Characteristics and serum lipids of participants included in the study 
 
Values are unadjusted means ± SEM. All p values are adjusted for age. a  p < 0.05 and A p < 0.01 white 
normal-weight vs black normal-weight, b p <0.05 and B p < 0.01 white obese vs black obese, c p <0.05 and 
C p < 0.01 normal-weight vs obese white, d p < 0.05 and D p < 0.01 normal-weight vs obese black. Adapted 



















Age (yr) 26 ± 2 34 ± 2B,C 23 ± 2 27 ± 2 
BMI (kg/m2) 23 ± 1 33 ± 1B,C 22.8 ± 0.9 38.5 ± 0.7D 
Body fat (kg) 19.2 ± 1.4 40.4 ± 1.6C 17.1 ± 1.7 44.9 ± 1.5D 
Body fat (%) 29.5 ± 1.4 43.7 ± 1.6C 30.0 ± 1.7 46.7 ± 1.5D 
VAT area (cm2) 62.2 ± 11.3 144.9 ± 13.1B,C 56.9 ± 13.9 95.6 ± 11.8D 
SAT area (cm2) 187.0 ± 19.1  471.6 ± 22.0B,C 175.2 ± 23.4 594.2 ± 19.9d 
Serum lipids     
HDL-C (mmol/L) 1.7 ± 0.1
a 1.5 ± 0.1B 1.3 ± 0.1 1.0 ± 0.1 
LDL-C (mmol/L) 2.0 ± 0.2 2.5 ± 0.2 2.1 ± 0.2 2.1 ± 0.2 
Total-C (mmol/L) 4.1 ± 0.2 4.6 ± 0.3B 3.6 ± 0.3 3.5 ± 0.2 
Triglycerides (mmol/L) 0.9 ± 0.1 1.0 ± 0.1 0.5 ± 0.1 0.8 ± 0.1 
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3.1 PON1 activity in normal-weight and obese black and white women 
In normal-weight white women, PON1 activity was 0.53 ± 0.12 U/L, which is in a similar range 
to data previously reported in the literature (Kunutsor et al., 2016). PON1 activity of normal-
weight and obese, black and white women is presented in Figure 22A. Black women had 
significantly higher PON1 activity levels than white women (0.78 ± 0.10 U/L vs 0.49 ± 0.09 
U/L, p < 0.05), with the effect being more pronounced in obese black women compared to 
obese white women (0.84 ± 0.13 U/L vs 0.45 ± 0.14 U/L, p < 0.05) (Figure 22A). Irrespective 
of ethnicity, PON1 activity did not differ between normal-weight and obese women. 
In order to explore whether differences in PON1 activity levels were simply due to differences 
in PON1 protein expression in HDL, Western blotting was performed on isolated HDL and 
serum. There were no significant differences in HDL-associated PON1 protein levels between 
black and white women, nor between normal-weight and obese women (Figure 22B and C). 
Similarly, there were no differences in PON1 serum expression between black and white 
women, nor between normal-weight and obese women (Figure 22D and E).  
Table 4 shows that PON1 activity correlated positively with LDL levels in both black and white 
women (p < 0.05), positively with total cholesterol (p < 0.005) in black women and negatively 





























Figure 22. PON1 activity and protein expression in white and black women. PON1 activity of diluted sera 
was measured at A405 over a 20 minute time interval using the paraoxon-ethyl substrate. One unit of activity 
is defined as 1 nmol of substrate disintegrated per minute (A). Isolated HDL (B-C) and participant sera (D-
E) were run on reducing 12.5% SDS-PAGE gels and transferred to nitrocellulose membrane. Ponceau S 
staining was used to confirm equal loading. Blots were probed with mouse anti-PON1 antibody. Results 
are representative of randomized experiments (B) and (D). Densitometry of PON1 expression in HDL (C) 





3.2 PAF-AH activity in normal-weight and obese black and white women 
In normal-weight white women, PAF-AH activity was 12.0 ± 1.1 U/L, which is in a similar range 
to data previously reported in the literature (Gomes et al., 2008). Obese black women had 
significantly lower PAF-AH activity levels than obese white women (9.34 ± 1.15 U/L vs 13.89 
± 1.21 U/L, p < 0.05) (Figure 23A). PAF-AH activity did not differ between normal-weight and 
obese women. 
When examining PAF-AH protein expression in isolated HDL, we found that obese black 
women had significantly lower levels of HDL-associated PAF-AH than obese white women 
(5.5 ± 1.7 vs 10.9 ± 1.8 Arbitrary units, AU, p < 0.05) (Figure 23B and C), which corresponded 
to their lower PAF-AH activity (r = 0.54, p < 0.005). However, there were no differences 
between black and white obese and normal-weight women in PAF-AH serum expression 
(Figure 23D and E).  
PAF-AH was positively correlated with LDL (p < 0.005) and total cholesterol (p < 0.005) 
concentrations in both black and white women (Table 4). In black women only, higher PAF-








Figure 23. PAF-AH activity and protein expression in white and black women. PAF-AH activity of diluted 
sera was measured at A412 over a 20 minute time interval using the PAF Acetylhydrolase Assay Kit. One 
unit of activity is defined as 1 µmol of substrate disintegrated per minute (A). Isolated HDL (B-C) and 
participant sera (D-E) were run on reducing 12.5% SDS-PAGE gels and transferred to nitrocellulose 
membrane. Ponceau S staining was used to confirm equal loading. Blots were probed with rabbit anti-PAF-
AH antibody. Results are representative of randomized experiments (B) and (D). Densitometry of PAF-AH 





3.3 Anti-inflammatory function of isolated HDL 
In isolated HDL from white normal-weight women VCAM expression measured in HUVEC 
cells was 0.98 ± 0.15 AU. No obesity-related or ethnic differences were observed for anti-
inflammatory function of isolated HDL (Figure 24). 
 
Figure 24. Anti-inflammatory function of black and white women. HUVEC cells were treated overnight with 
10 µg/ml subject HDL. Cells were exposed to 20 ng/ml tumour necrosis factor (TNF) for 8 hours. Cell lysates 
were harvested and stored in RNAprotect reagent prior to RNA extraction, followed by cDNA synthesis and 
quantitative real time PCR. AU: Arbitrary units and VCAM: Vascular cell adhesion molecule. Results are 
presented relative to a no-HDL treatment control. Results are represented as means ± SEM. 
3.4 Antioxidant capacity of isolated HDL 
In isolated HDL from white normal-weight women total antioxidant capacity, assessed by the 
ORAC assay, was 653 ± 132 nmol/ml TE. No obesity-related or ethnic differences were 






Figure 25. Antioxidant capacity of 
black and white women. Isolated 
subject HDL was diluted in 
phosphate buffer and measured 
using the Oxygen Radical 
Absorbance Capacity (ORAC) 
assay. TE: Trolox equivalents. 





3.5 HDL subclass distribution in normal-weight and obese black and white women 
Figure 4 shows the distribution of large, intermediate and small HDL subclasses, quantified 
using the Lipoprint® system. Scans (Figure 26A) were quantified, producing unique HDL 
subclass profiles (Figure 26B-F).  HDL subclass distribution was different between obese and 
normal-weight women with less large HDL (-10%, p < 0.05) and significantly more intermediate 
HDL (+6%, p < 0.05) in the obese women compared to the normal-weight women (Figure 
26G). This effect was largely driven by differences between the normal-weight and obese 
white women (43.1 ± 3.4% vs 32.8 ± 3.8 % for large HDL, p < 0.05) (Figure 26G). There were 
no differences in the percentages of small HDL subclasses between groups.  
In the white women, the greater proportion of large HDL subclasses was associated with 
higher BMI, fat mass, VAT and SAT, as well as higher LDL and triglyceride concentrations (p 
< 0.05, Table 4). In black women, the greater proportion of large HDL was associated with a 
younger age (p < 0.05) and higher HDL-C (p < 0.005). Conversely, a greater proportion of 
intermediate HDL was associated with lower BMI, fat mass, VAT and SAT in white women. A 
greater proportion of small HDL was associated with increased BMI and fat mass in white 
women.  
There were no associations between measures of HDL functionality and HDL subclass 
distribution in the combined population sample. However, a greater proportion of large HDL 
subclasses were associated with lower PAF-H activity was observed in white women only (r = 







Figure 26. Distribution of HDL subclasses in participant sera. Subject sera was analysed using the 
Lipoprint® system and analysed using Lipoware software. Representative scan (A) and scan result (B) 
of Liposure control indicating HDL subclass bands. Representative scan results from white and black 
obese and normal-weight women (C-F). Percentages of large, intermediate and small HDL subclasses 




Table 4. Associations between HDL functionality measures, HDL subclass, body composition and serum lipids in black and white 
South African women 
 
Values are Pearson correlation coefficients. BMI: Body Mass Index;  VAT: Visceral Adipose Tissue and  SAT: Subcutaneous Adipose Tissue   




In this study, the aim was to examine whether ethnicity and obesity may be associated with 
differences in HDL functionality and subclass distribution. Data showed that, despite lower levels 
of HDL-C, black women had higher PON1 activity levels compared to white women. In contrast, 
the activity and protein expression of PAF-AH was lower in obese black compared to obese white 
women. Obesity was not associated with a difference in the activity of these enzymes, but was 
associated with a shift in HDL subclass from large to intermediate and small HDL, an effect which 
was largely driven by differences between normal-weight and obese white women. 
The relatively low incidence of myocardial infarction in the South African black population has 
long been thought to be related to higher HDL-C levels in comparison to white populations. 
However, recent studies provide evidence for lower HDL-C in South African black populations 
compared South African white populations, despite clear reduced risk of acute myocardial 
infarction (Goedecke et al., 2010; Sliwa et al., 2012). Recent research suggests that the quality 
of HDL, rather than its quantity, may be a more important factor to consider as a CVD risk factor 
(see review, (Rizzo et al., 2014)). 
Low serum PON1 activity levels have been associated with an increased risk for major adverse 
cardiovascular events (MACE), including MI and stroke in an American study (Tang et al., 2012). 
The novel finding of higher PON1 activity levels in black women compared to white women, 
independent of protein expression levels is in contrast to other studies in the USA that found that 
African Americans had lower or similar PON1 activity levels than their white counterparts, despite 
similar HDL-C concentrations (Gaillard et al., 2011; S. J. Healy et al., 2015).  
Accordingly, it is hypothesised that the low rate of cholesterol-attributable mortality (Norman et al. 
2007), and particularly the low incidence of myocardial infarction in black populations (Sliwa et 
al., 2012) may be explained by higher PON1 activity levels. However, this hypothesis would need 
to be tested as a study in a mixed race South African population found that PON1 activity was not 
associated with CVD risk (Macharia et al., 2014).  
Data also indicated that increased PON1 activity in black women was not related to a greater 
amount of HDL-associated PON1 protein, which may relate to genetic factors. PON1 
polymorphisms, such as the promotor region small nucleotide polymorphism (SNP) L-55M, 
causes a reduction in serum PON1 activity, and is much less frequent in oriental and black 
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populations (Phuntuwate et al., 2005; Mackness and Mackness, 2015). Additionally, PON1 
polymorphisms can result in lower activity with PON1 serum protein levels unchanged 
(Phuntuwate et al., 2005).  
Associations between lower PON1 activity and typical markers of risk, including higher LDL and 
triglyceride concentrations, which have been reported previously in an American white young 
adult population were shown (Breton et al., 2014). Of interest was a negative correlation between 
PON1 activity and HDL-C in white but not black women. Failure to show this association in black 
women is unexpected because HDL is physiologically associated with PON1 and has been shown 
in other studies to be negatively correlated with HDL-C (Mackness et al., 1993b; Razav et al., 
2012). As PON1 activity remains consistently high in black women, it is possible that PON1 activity 
may be a marker of HDL function in black women, independent of HDL-C levels.  
PAF-AH is another HDL-associated enzyme whose primary physiological role is maintenance of 
PAF metabolism and anti-thrombotic functions (Stafforini et al., 1987; McIntyre et al., 2009). Data 
has shown significantly lower PAF-AH activity in obese black women compared to obese white 
women. Overall, PAF-AH activity was correlated with PAF-AH expression in HDL while PAF-AH 
serum expression remained unchanged amongst the groups. Obese black women therefore 
expressed significantly less HDL-associated PAF-AH than obese white women. Furthermore, 
reduced PAF-AH activity was associated with increased fat mass and SAT in black women only. 
PAF-AH is mainly associated with LDL and a smaller proportion with HDL, which translate into 
different physiological functions of PAF-AH activity (Tselepis and Chapman, 2002). Reduced 
HDL-associated PAF-AH activity has been shown to be associated with increased risk of CVD 
(Kakafika et al., 2003). Accordingly, the data suggests that reduced HDL-associated PAF-AH 
activity in obese black women may be associated with a reduction in anti-atherogenic HDL 
function. However, previous studies have shown that PON1 activity modulates HDL-associated 
PAF-AH activity (Kakafika et al., 2003). It is therefore, proposed that higher PON1 activity in obese 
black women may circumvent reductions in PAF-AH activity. However, further studies are needed 
to test this hypothesis.  
Surprisingly, despite the findings regarding PON1 activity, there were no significant group 
differences in antioxidant capacity of isolated HDL. This was similarly found in a study comparing 
diet-induced weight loss in overweight American participants (Aicher et al., 2012). It is proposed 
that, in the ORAC assay, measurement of total antioxidant capacity may produce different results 
to a specific antioxidant assay such as PON1 activity, owing to contributions of additional HDL 
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components. Similarly, no differences in the expression of VCAM in HUVEC cells treated with 
isolated HDL were found. Since HDL has been shown to reduce expression of a number of 
endothelial adhesion molecules, additional markers would need to be used to further confirm the 
findings in this study.  
This is the first report of the distribution of HDL subclasses in an African population. In this study, 
a similar profile of HDL subclass distribution was observed between black and white women. 
However, obesity was associated with reduced large HDL subclasses and concomitant higher 
intermediate and small subclasses; largely driven by differences between normal-weight and 
obese white women. In support of this finding, markers of increased adiposity, BMI, fat mass, 
percentage fat, VAT and SAT correlated with differences in large and intermediate subclasses in 
white, but not black women. These findings were confirmed by Spearman non-parametric testing. 
This shift has been previously shown in non-African male and female obese populations, where 
a decrease in average HDL particle size and increased concentrations of smaller HDL subclasses 
were reported (James et al., 1997; Tian et al., 2006; Magkos et al., 2008).  In this case, HDL 
subclass distribution does not explain changes in functionality related to ethnicity. HDL 
subclasses were not significantly different between normal-weight and obese black women, while 
HDL subclasses differed by obesity in white women. A similar trend was observed in LDL 
subclasses in the same population of women, where differences in LDL subclass in normal-weight 
and obese women were observed in white, but not black women (Goedecke et al., 2010). 
Longitudinal data on a black South African cohort also indicate that despite increases in weight, 
HDL-C concentrations remained consistently low in black women (Chantler et al., 2015). In spite 
of this, it was shown that black women display greater HDL antioxidant functionality in comparison 
to white women, indicating the importance in measurement of HDL quality instead of total HDL 
cholesterol levels. 
In addition to the limited number of patients recruited in this study, another important limitation to 
acknowledge is the different background, social status, education, lifestyle that has not been 
taken into account and that may contribute to differences observed between ethnicities 
5. CONCLUSIONS 
Despite lower HDL-C, black women had higher PON1 activity levels compared to white women. 
In contrast, the activity and protein expression of PAF-AH was lower in obese black compared to 
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obese white women. Obesity was associated with a shift in HDL subclass from large to 
intermediate and small HDL. It is acknowledged that the small sample size limits the conclusions 
which can be drawn, however data suggest that obesity and ethnicity may affect HDL functionality 
and HDL subclass. It is therefore suggested that future studies examining the association 
between HDL and cardiovascular risk should focus on examining the role of HDL subclass and 
functionality. A number of functionality assays were considered in this study, however, additional 
measures such as reverse cholesterol efflux can be considered in similar studies in the future. 
Longitudinal studies are required to determine if HDL subclass and function are indeed important 
risk factors for CVD. In addition, future studies will be required to establish baseline values for 
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CHAPTER FIVE: EFFECTS OF EXERCISE TRAINING (12-WEEKS) ON HDL FUNCTIONALITY 
AND SUBCLASS, IN OBESE BLACK SOUTH AFRICAN WOMEN 
1. INTRODUCTION 
Data presented in Chapter 4 highlighted that despite having lower HDL-C than their white 
counterparts, black South African women displayed greater PON1 activity. The functionality of 
HDL in African women therefore differs from their white counterparts, suggesting that, although 
African women have lower HDL-C levels, the quality of their HDL may be superior to the white 
African women (Woudberg et al. 2016). In addition, obesity was associated with shifts in HDL 
subclass distribution, with lower large HDL and greater intermediate and small HDL subclasses 
associated with obese compared to normal-weight women. Common interventions to limit obesity 
include diet and aerobic and/or resistance exercise training. Exercise training interventions result 
in a reduction in weight, body fat mass and cardiovascular risk factors such as blood pressure, 
total cholesterol, LDL-C and increases in HDL-C (Wood et al., 1988; Lavie and Milani, 1997; 
Hawley, 2004; Slentz et al., 2004; Curioni and Lourenco, 2005; Ohta et al., 2005). Indeed, as little 
as 30 minutes of exercise per day can also increase the concentration of HDL-C in diabetic 
patients (Argani et al., 2014).  
Recent studies have suggested that exercise training may influence HDL function but the 
association between exercise, changes in HDL function and subclass in obese women is still 
unclear (Blazek et al., 2013).  
The aim of the study was therefore to examine the effects of exercise training (12-weeks) 




2. MATERIALS AND METHODS 
2.1 Participants 
Forty-five women were recruited during 2015 and 2016 from the Western Cape, South Africa. 
Inclusion criteria included: 20-35 years in age, obese (BMI 30-40 kg/m2), weight stable for 6 
months, black South African (both biological parents isiXhosa), sedentary (not participating in 
exercise training (>1 session of >20 min per week) within the last 12 months), on injectable 
contraceptive (depot medroxyprogesterone acetate, 400 mg) for a minimum of 2 months, no 
known illness or chronic disease, not taking any medications, and had no surgical procedures 
within the last 6 months. This study was approved by the Human Research Ethics Committee at 
the University of Cape Town (HREC REF:054/2015) and participants provided written consent 
prior to testing.  
2.2 Study design 
Women were block randomized into either control (n=22) or exercise (n=23) conditions. The 
exercise intervention consisted of 12 weeks of supervised aerobic and resistance exercise 
training, whilst the control participants were instructed to continue their normal physical activity 
and dietary patterns.  Participants attended two pre- and post-testing testing sessions. During the 
first session, anthropometrical measurements were taken and participants completed a maximal 
graded exercise test for the assessment of maximal oxygen consumption (VO2max). After a 
minimum of 48 hour recovery from the previous testing session, participants returned for a second 
session that included fasting (10-12 hours) venous blood collection. Venous blood samples were 
later analysed for HDL-C concentration, HDL functionality and subclass distribution. 
2.3 Exercise intervention 
The exercise intervention consisted of 12-weeks of supervised aerobic and resistance training at 
a moderate-vigorous intensity for 40-60 minutes, 4 days per week by a trained facilitator. 
Exercises included cardiovascular exercises in the form of aerobic dance, boxing, running, 
skipping, and stepping that were performed at a moderate-vigorous intensity (75-80% maximal 
heart rate, HRmax). Resistance exercises included the participants using their own body weight 
and progressed to the use of equipment (e.g. bands and free weights). These exercises included, 
squats, lunges, bicep curls, push up and shoulder press with a prescribed intensity of 60-70% 
HRmax. A heart rate monitor (Polar A300, Kempele, Finland) was worn by participants at all training 
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sessions to ensure the prescribed exercise intensity was maintained throughout the 12-week 
period.  
2.4 Nutritional and physical activity standardization 
Prior to participation in the study, all participants were informed (verbal and written) of the 
importance of maintaining their normal dietary patterns throughout the 12-week training period. 
Prior to the start of all testing sessions participants refrained from any physical activity for 72 
hours, and the consumption of alcohol and caffeine for 24 hours. 
2.5 Graded exercise test 
VO2max was measured using a treadmill-based (C, Quasar LE 500 CE, HP Cosmos, Nussdorf-
Traunstein, Germany) graded exercise test. Participants were familiarized to the equipment prior 
to the test. The test commenced at 3km.h-1 and a 6% gradient and increased every minute to a 
gradient of 16%, thereafter the pace and gradient were increased steadily until volitional 
exhaustion. Heart rate was recorded each minute throughout the protocol and the highest heart 
rate for this test was used as HRmax. Pulmonary gas exchange was measured by determining O2 
and CO2 concentrations and ventilation to calculate VO2 using a metabolic gas analysis system 
(CPET, Cosmed, Rome Italy). The system was calibrated according to the manufacturer’s 
instructions.  
2.6 HDL isolation 
HDL was isolated from aliquots of serum as previously described in Chapter four (Section 2.2).  
2.7 Quantification of HDL subclass distribution 
Serum HDL subclass was determined using the Lipoprint® HDL system (Quantimetrix, Redondo 
Beach, CA) as described in Chapter four (Section 2.8). 
2.8 Quantification of HDL reverse cholesterol efflux capacity 
HDL induced reverse cholesterol efflux was quantified using a modified method 
(Sankaranarayanan et al., 2011). Briefly, RAW264.7 cells, generously donated by Prof Gil Dealtry 
(Nelson Mandela Metropolitan University), were proliferated in RPMI-1640 media supplemented 
with 10% foetal calf serum and penicillin/streptomycin prior to seeding (100 000 cells/well) in 24-
well culture plates for 16 hours. Labelling media was prepared by adding 4 µCi/ml of [3H] 
cholesterol (Perkin Elmer, NET139001MC) to RPMI-1640 medium containing 2 µg/ml of acyl-CoA 
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cholesterol acyltransferase (ACAT) inhibitor (Sandoz, Sigma, S9318) and supplemented with 5% 
foetal calf serum. Cells were then incubated in labelling media for 24 hours. Cells were washed 
with minimum essential eagle (MEM) in HEPES buffer prior to addition of 25 µg/ml of isolated 
HDL in MEM-HEPES for 4 hours. Cell culture media was extracted and added to Ultima Gold 
scintillant (Perkin Elmer, 6013327). Counts per minute (CPM) were enumerated using TriCarb® 
Liquid Scintillation Analyzer and QuantaSmartTM software with 2 Sigma terminator 0.5 and 30 
minute count time. Reverse cholesterol efflux capacity was calculated as label present in the cell 
media relative to the untreated control.  
2.9 Quantification of HDL anti-inflammatory function 
HDL anti-inflammatory function was measured as previously described in Chapter four (Section 
2.7). 
2.10 PON1 activity assay 
Serum PON1 activity was measured as described in Chapter four (Section 2.3).  
2.11 PAF-AH activity assay 
Serum PAF-AH activity was measured as described in Chapter four (Section 2.4).  
2.12 Western blotting  
Isolated HDL and serum samples from each of the participants were electrophoresed on reducing 
12.5% SDS-PAGE gels with 1.2 µg of HDL protein or 8 ug of serum loaded per well. Samples 
were run over multiple gels with control samples repeated in each gel. Blots were transferred onto 
nitrocellulose membranes (Bio-Rad, 162-0113). Ponceau S staining was used to validate equal 
loading of wells. Blots were blocked in 5% low fat milk powder in 0.05% TTBS, pH 7.5 and 
incubated overnight in primary mouse anti-PON1 antibody (1:200) (James et al., 2010), and rabbit 
anti-PAF-AH (1:400) (Cayman Chemical, 160603). Blots were then washed in TTBS and 
incubated in goat anti-mouse-HRP conjugated secondary antibody (1:5000) (Bio-Rad, 170 6516) 
and goat anti-rabbit-HRP conjugated secondary antibody (1:2500) (Santa Cruz Biotechnology, 
sc-2313), respectively for 1 hour at room temperature. Blots were thoroughly washed in TTBS 
prior to incubation in Amersham TM ECLTM Western blotting detection reagent (GE Healthcare, 
RPN2106). Blots were captured in the GeneGnome gel imager. Densitometry of PON1 and PAF-
AH blots was quantified using Quantity one software. PON1 and PAF-AH relative expression data 
were corrected for control samples, repeated in each gel. 
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2.13 Statistical analysis 
Results are presented as mean or as percentage changes relative to baseline ± SEM. All variables 
were tested for normality prior to analysis. Non-normally distributed data were log transformed 
prior to statistical analysis and included serum PON1, serum and HDL PAF-AH expression. Two-
way repeated measures analysis of variance was used to compare changes in anthropometry, 
VO2max, HDL-C, cholesterol efflux capacity, anti-inflammatory function, PON1 activity, PAF-AH 
activity and HDL subclass distribution over the 12-week period between the exercise and control 
groups, using Fischer posthoc analysis. Unpaired t-tests were used to test differences in 
percentage changes in cholesterol efflux capacity, anti-inflammatory function, PON1 activity, 
PAF-AH activity and HDL subclass distribution over the 12-week period between control and 
exercise conditions. Pearson’s correlation coefficients for the associations between 
anthropometry, fitness, HDL-C, HDL function and subclass were determined at baseline in the 
combined sample, and for percentage changes in the combined sample. p < 0.05 was deemed 






3.1 Changes in anthropometry, fitness and HDL-C 
Exercise training adherence, expressed as the percentage attendance of total number of 
sessions, was 80.3±3.0% (range of 60.4-100%.). Exercise training resulted in a significant 
increase in fitness (VO2max) compared to control (p <0.05 for interaction, Table 5), BMI, waist and 
hip circumference and waist/hip ratio (WHR) decreased in response to the 12-week intervention 
in the exercise group only (p <0.05 for interaction). HDL-C values were within the physiological 
range (Piepoli et al., 2016), whilst VO2max was lower than values associated with healthy, 
exercising South Africans (Keytel et al., 2005). HDL-C did not vary between groups or over time 
(p = 0.238 for interaction). 












Results represent means ± SEM. Unadjusted p values testing for significance of the grouping variable 
(Control vs Exercise), time (intervention duration) and the interaction (Group*Time). For Fischer post-hoc 




3.2 Shift in HDL subclass distribution following exercise intervention 
The distribution of HDL subclasses in response to the exercise intervention are presented in 
representative scan sections of large (Figure 27A and B), intermediate (D and E) and small (G 
and H) subclass distributions, and as percentages of large, intermediate and small HDL-C (Figure 
27C, F and I). At baseline, the distribution of large, intermediate and small HDL subclasses were 
not different between groups (p = 0.803, p = 0.701 and p = 0.485, respectively). The distribution 
of intermediate HDL subclasses was similar between groups in response to the intervention (p = 
0.523 for interaction) whilst there was a decrease in the distribution of small HDL subclasses in 
the exercise group (p < 0.005 for interaction). When examining differences in percentage changes 
in HDL subclass distributions, the change in the distribution of large and small HDL subclasses 
differed between groups in response to the intervention (p < 0.05). Small HDL subclasses 


















Figure 27. Distribution of HDL subclasses in participant sera in response to the intervention. Participant sera was analysed using the Lipoprint® system and analysed using 
Lipoware software. Representative scan results of control (A,D and G) and exercise (B, E and H) sera pre and post testing. Changes in the percentages of large (C), intermediate 
(F) and small (I) HDL subclasses. Results as percentage changes relative to a baseline. Results are means ± SEM.* p < 0.05 and ** p < 0.005  significance for t-test.   
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3.3 Changes in HDL function in response to the 12-week exercise intervention 
Cholesterol efflux capacity  
At baseline cholesterol efflux capacity did not differ between control and exercise groups (3.77 ± 
0.22 vs 3.63 ± 0.20 AU, p =0.808 respectively). HDL-mediated cholesterol efflux capacity did not 
change in response to a 12-week exercise intervention and the percentage changes did not differ 











Figure 28. Changes in reverse cholesterol efflux capacity of control and exercise participants in response to 
the intervention. [3H-Cholesterol] was effluxed from RAW264.7 cells for 4 hours prior to scintillation counting. 
Cholesterol efflux capacity represents the mean radiolabel present in culture media relative to that of an 
untreated control. Results are represented as percentage changes relative to a baseline. Results are means ± 
SEM. 
Anti-inflammatory function 
At baseline HDL anti-inflammatory function (expressed as relative reduction in VCAM expression 
in HUVEC cells) did not differ between control and exercise groups (0.47 ± 0.07 vs 0.50 ± 0.09 
AU, p =0.504 respectively) (Figure 29). HDL anti-inflammatory function did not change in 
response to a 12-week exercise intervention and the percentage changes did not differ between 

















Figure 29. Changes in anti-inflammatory function of control and exercise participants in response to the 
intervention. HUVEC cells were treated with 10 µg/ml participant HDL prior to 20 ng/ml tumour necrosis factor 
(TNF) treatment for 8 hours. Results are calculated relative to a no-HDL treatment control. Cell lysates were 
harvested and stored in RNA protect reagent prior to RNA extraction, followed by cDNA synthesis and 
quantitative real time PCR. Results as percentage changes relative to a baseline. VCAM: Vascular Cell 
Adhesion Molecule. Results are means ± SEM.  
PON1 activity 
At baseline, serum PON1 activity did not differ between the control and the exercise groups (0.90 
± 0.07 vs 0.83 ± 0.05 U/L, p = 0.173, respectively). After 12 weeks, serum PON1 activity 
decreased in response to the exercise intervention only (p < 0.05 for interaction). The percentage 
change was therefore significantly different between exercise and control groups (p < 0.05, Figure 
30A). In contrast, changes in serum and HDL PON1 expression levels did not differ between 
groups (p = 0.751 and p = 0.464 respectively, Figure 30B-E) or in response to the intervention (p 
= 0.888 and p = 0.697 for interaction, respectively). The association between PON1 activity and 
expression was explored at baseline in all participants and serum PON1 activity was positively 
correlated with serum and HDL PON1 expression (r = 0.48, p < 0.05, and r = 0.57, p < 0.005 
respectively). However, percentage changes in PON1 activity were not associated with changes 








Figure 30. Changes in paraoxonase activity and protein expression in control and exercise participants in 
response to the intervention. Paraxonase activity of diluted sera was measured at A405 over a 20 minute time 
interval using the paraoxon-ethyl substrate. One unit of activity is defined as 1 nmol of substrate disintegrated 
per minute (A). Participant sera (B and D) and isolated HDL (C and E) were run on reducing 12.5% SDS-PAGE 
gels and transferred to nitrocellulose membrane. Ponceau S staining was used to confirm equal loading. Blots 
were probed with mouse anti-PON1 antibody. Results are representative of randomized experiments (B) and 
(C). Results are percentage changes in densitometry relative to a baseline in sera (D) and HDL (E). Results are 





At baseline, serum PAF-AH activity did not differ between the control and the exercise groups 
(12.7 ± 1.4 vs 15.2 ± 1.2 U/L, p = 0.311, respectively). There was no difference in PAF-AH activity 
between groups in response to the intervention (p = 0.112 for interaction) and no difference in the 
percentage change in PAF-AH activity between groups (Figure 31A p = 0.093). In contrast, the 
percentage change in serum PAF-AH expression differed between groups, with a decrease in the 
exercise group only (Figure 31D p < 0.005). Changes in HDL PAF-AH expression were not 
different between groups over time (p = 0.493). When exploring the association between PAF-AH 
activity and expression no associations were found between PAF-AH activity and serum and HDL 
PAF-AH expression at baseline (r = 0.02, p = 0.921, and r = 0.09, p = 681 respectively) or between 
changes in activity and expression over the 12-week intervention (r = 0.38, p = 0.055, and r = 






Figure 31. Changes in PAF-AH activity and protein expression in control and exercise participants in response 
to the intervention. PAF-AH activity of diluted sera was measured at A412 over a 20 minute time interval using 
the PAF Acetylhydrolase Assay Kit. One unit of activity is defined as 1 µmol of substrate disintegrated per 
minute (A). Participant sera (B and D) and isolated HDL (C and E) were run on reducing 12.5% SDS-PAGE gels 
and transferred to nitrocellulose membrane. Ponceau S staining was used to confirm equal loading. Blots were 
probed with rabbit anti-PAF-AH antibody. Results are representative of randomized experiments (B) and (C). 
Results are percentage changes in densitometry relative to a baseline in sera (D) and HDL (E).  
**p<0.005 significance for t-test.
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3.4 Relationships between anthropomorphic measures, fitness and HDL function and 
subclass  
At baseline, higher BMI was associated with lower cholesterol efflux capacity (p < 0.05), less large 
HDL subclasses and lower HDL-C (p < 0.05) (Table 6). There were no significant associations 
between the changes in fitness, body composition and HDL-C and changes in HDL function 
(Table 6), however, a decrease in BMI and increase in HDL-C in the combined sample was 
associated with an increase in the percentage of large HDL subclasses.  
3.5 Relationships between measures of HDL functionality and HDL subclass 
At baseline, RCT was positively associated with anti-inflammatory function. Similarly, higher HDL 
anti-inflammatory function was associated with a greater percentage of large HDL and lower 
percentage of intermediate HDL subclasses (p < 0.05, Table 6). In addition, an increase in 
cholesterol efflux capacity and PON1 activity were associated with increases in the percentage 




Table 6. Associations between HDL functionality and subclass measures with body composition and HDL-C in all 
participants at baseline 
 
Values are Pearson correlation coefficients. BMI: Body Mass Index and WHR: Waist/hip ratio. * p < 0.05, ** p < 0.005 

















BMI  0.202 -0.199 -0.265 -0.423* -0.260 -0.148 -0.053 -0.375* 0.311 0.298 
WHR   -0.108 -0.377* -0.253 -0.517 -0.174 -0.130 -0.222 0.037 0.304 
VO2max    -0.053 0.148 -0.287 -0.209 0.048 -0.138 0.109 0.090 








      0.484 -0.093 0.535* -0.545* -0.377 
PON1 
activity 
       0.183 -0.044 -0.018 0.073 
PAF-AH 
activity 
        0.277 -0.280 -0.191 
Large HDL          -0.775** -0.845** 
Intermediate 
HDL 
          0.318 
Small HDL            
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Table 7. Associations between changes in HDL functionality and subclass measures with body composition and HDL-C in all 
participants  
Values are Pearson correlation coefficients. BMI: Body Mass Index and WHR: Waist/hip ratio * p < 0.05, ** p < 0.005


















ΔBMI  0.636** 0.044 0.165 0.094 -0.175 -0.075 0.225 -0.401* 0.147 0.295 
ΔWHR   -0.091 -0.096 -0.006 -0.258 -0.120 0.171 -0.366* 0.227 0.095 
ΔVO2max    -0.007 0.087 -0.306 -0.317 -0.284 0.191 0.061 -0.274 








      -0.156 -0.236 -0.112 0.193 0.096 
ΔPON1 
activity 
       0.051 -0.275 -0.153 0.509* 
ΔPAF-AH 
activity 
        0.252 -0.077 -0.239 
ΔLarge HDL          -0.561** -0.652** 
ΔIntermediate 
HDL 
          -0.112 




The aim of this study was to explore whether exercise training would result in modification of 
the quality of HDL, the functionality and subclass distribution. Although HDL-C was 
unchanged, a 12-week exercise training intervention in obese black South African women 
resulted in reductions in PON1 activity and PAF-AH expression and percentages of small HDL 
subclasses. Notably, changes in PON1 activity and cholesterol efflux capacity were 
associated with changes in HDL subclass distribution. 
Exercise interventions are routinely prescribed for obese individuals with the aim of reducing 
the risk of cardio-metabolic complications, and have been shown to promote an increase in 
HDL-C (Kelley and Kelley, 2006; Kodama et al., 2007; Argani et al., 2014). The current study, 
however, did not find any change in HDL-C following the intervention. No previous studies 
have examined the benefits of exercise on HDL-C levels in an African population, who often 
have lower basal HDL-C levels, compared to other populations (Sliwa et al., 2008; Goedecke 
et al., 2010).  
Exercise intervention associated with changes in HDL subclass distribution 
In the present study, it was explored whether exercise training may alter HDL subclass 
distribution in obese black South African women. Here, evidence suggests that exercise 
training may revert HDL subclass distribution back to a “non-obese” state in a black South 
African sample population. These results are supported by a decrease in small HDL and an 
increase in large HDL in the exercise training group compared to the non-training control 
group. Additionally, negative associations between the percentage of large HDL subclasses 
and markers of greater BMI and WHR at baseline and associations between an increase in 
large HDL subclasses and decrease in BMI in all participants support these findings. In a 
similar sample population (Chapter four), it was previously reported that an association 
between obesity and lower levels of large and high levels of smaller HDL subclasses exists 
(Woudberg et al. 2016). It is proposed that BMI and weight loss may mediate changes in HDL 
subclass distribution, however, in this study, changes in body weight (-1.0 ± 0.6%) and WHR 
(-1.7 ± 0.8%) were minor. Results are supported by a study in elderly non-obese participants 
where a 6-week endurance training resulted in an increase in large HDL subclasses (Riedl et 
al., 2010). Other studies including exercise interventions showed that exercise training 
resulted in changes in HDL subclasses, favouring increases in larger HDL subclasses (Ribeiro 
et al., 2008; Casella-Filho et al., 2011).  
 
Exercise intervention associated with changes in HDL function 
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Cholesterol efflux capacity, the primary function of HDL in vivo, did not change following the 
intervention. Data are consistent with previous studies conducted in African American 
populations (Aicher et al., 2012). In this study, a 6 month diet programme of reduced fat and 
energy, combined with low-intensity exercise, showed improvements in fitness and weight 
loss, however, these changes were not associated with changes in cholesterol efflux capacity 
(Aicher et al., 2012). In contrast, cholesterol efflux capacity was associated with baseline BMI. 
Similarly, in a study examining the relationship between body composition and HDL RCT, 
found that an increase in waist circumference was an accurate predictor of impairment in 
cholesterol efflux capacity (Attia et al., 2010). Comparing cholesterol efflux between obese 
and lean subjects, it was found that there was an association between increased BMI and 
lower cholesterol efflux capacity in obese subjects (Sasahara et al., 1998). Commensurate 
with these findings, improvement in cholesterol efflux capacity in individuals undergoing 
exercise interventions were only significant in those individuals with significant weight loss, 
and associations between an increase in body weight and a decrease in cholesterol efflux 
were observed (Lesna et al., 2009).  Accordingly, the lack of clinically significant changes in 
anthropometry in our study may explain the lack of change in HDL cholesterol efflux capacity 
in response to the intervention. 
In this study, the exercise intervention did not improve HDL anti-inflammatory function. In 
contrast, a 21-day dietary and exercise intervention, which resulted in a 3.2% decrease in 
BMI, found that HDL anti-inflammatory function was improved in response to the intervention 
in obese men (Roberts et al., 2006). These data suggest that substantial weight loss, not 
observed in this study, rather than exercise may influence changes in HDL anti-inflammatory 
function. 
The unexpected findings of this study were the decrease in both the antioxidative and anti-
thrombotic activities of PON1 and PAF-AH, respectively, in response to the exercise 
intervention. This is in contrast to other studies that found improvements in PON1 activity and 
overall HDL antioxidant function after moderate aerobic exercise interventions carried out over 
3 or 4 months in metabolic syndrome and type 2 diabetic patients respectively (Ribeiro et al., 
2008; Casella-Filho et al., 2011). The reasons for the different response in PON1 activity to 
the exercise intervention in our study are not entirely clear, but may be due to the fact that the 
participants in our study were normolipidemic, and/or relate to differences in the type and 
intensity of the intervention. Black South African women exhibited higher PON1 activity when 
compared to obese white South African women, independent of serum PON1 expression 
levels (Chapter four) (Woudberg et al. 2016). PON1 activity is largely modulated by genetic 
and environmental factors such as smoking and intake of antioxidants, and these factors may 
contribute to differences between studies (reviewed by (da Costa Vieira et al., 2001). In the 
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current study, changes in PON1 activity were not associated with changes in anthropometry, 
nor with changes in fitness, suggesting that the beneficial aspects of exercise training may 
result in a compensatory reduction in PON1 activity owing to reduction in oxidative stress. 
Indeed, studies in overweight adolescents and type 2 diabetic patients have both reported 
how exercise interventions may improve cardiovascular health by reducing oxidative stress 
(Vinetti et al., 2015; Li et al., 2017).  
In the present study, exercise was also associated with a decrease in the serum expression 
of PAF-AH. Again, this is in apparent contrast to the literature, which indicated that a short 
term (3 weeks) diet and exercise intervention in obese subjects increased PAF-AH activity 
(Roberts et al., 2006). PAF-AH is associated with HDL and LDL, with much of the beneficial 
aspects specific to the HDL fraction (Tselepis and Chapman, 2002). A positive association 
between PAF-AH activity in LDL-C has previously been shown in a similar population 
(Woudberg et al. 2016) and indicate that activity levels may not relate specifically to the HDL-
associated fraction of PAF-AH. Unlike previous research in obese black South African women 
(Chapter four) (Woudberg et al. 2016), the current study showed no association between HDL-
PAF-AH expression and PAF-AH activity. These results make it difficult to ascribe whether the 
exercise training-induced change in serum expression and activity were related to the 
beneficial HDL-associated PAF-AH activity.  
Considering the function and subclass of HDL-C together is relevant as both can be modified 
concurrently and may be associated with each other (Hernáez et al., 2017). The study has 
demonstrated an association between a decrease in small and intermediate HDL subclasses 
and a decrease in PON1 activity and cholesterol efflux capacity, respectively. PON1 is 
preferentially associated with smaller HDL subclasses, suggesting that decreases in PON1 
activity are associated with decreases in the distribution of small HDL subclasses (Davidson 
et al., 2009). Different HDL subclasses have inherent functional differences however 
associations between measures of HDL size and function have seldom been undertaken, and 
have not done using the Lipoprint® System (Kontush et al., 2003; Zerrad-Saadi et al., 2009; 
Kontush and Chapman, 2010; Camont et al., 2013; Gugliucci et al., 2013; Hernáez et al., 
2017). Therefore, novel evidence shows that changes in traditional measures of HDL function 
can be linked to new measures of HDL size.  
Unfortunately, this study was limited with a relatively small sample size, which certainly limits 
conclusions regarding HDL anti-inflammatory function in particular. Unfortunately, the findings 
regarding the associations between changes in body composition, HDL function and subclass 
were not maintained when analysed using Spearman non-parametric testing. Although, 
participants were instructed to maintain their normal dietary patterns, the participant dietary 
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details will be published in a subsequent publication and not in this study. There was, however, 
good adherence to the exercise training, allowing for adequate interpretation of its effects on 
HDL function and subclass distribution. 
5. CONCLUSION 
Despite no change in HDL-C concentration, our study provides the first evidence that exercise 
training may revert the HDL subclass distribution to a “non-obese” state as well as alter HDL 
antioxidative and anti-thrombotic function. HDL cholesterol efflux capacity was associated with 
BMI at baseline, however, was not associated with the minor changes in body composition as 
a result of exercise training. This suggests that improvements in HDL function and subclass 
are related to obesity and weight loss and not necessarily only to exercise per se. This study 
provides evidence how exercise training may alter HDL function and subclass distribution in 
an African population. Measures of HDL function and subclass were shown to be associated 
in this study. This suggests that studying HDL subclass and function may therefore be a more 
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CHAPTER SIX: DIFFERENCES IN HDL COMPOSITION, SUBCLASS AND FUNCTION 
ASSOCIATED WITH HYPERTENSION AND HEART FAILURE 
1. INTRODUCTION 
Studies conducted in Chapter 4 and 5 have highlighted the association of HDL subclass and 
function with major CVD risk factors such as ethnicity and obesity.  
Hypertension is another major risk factor for CVD with hypertension related complications 
accounting for at least 9.4 million annual deaths worldwide (WHO, 2013). An increase in 
hypertension prevalence in developing countries is associated with the adoption of 
Westernized diets and a decrease in physical activity (Bello, 2013). In 2015, the highest 
contributor to disability adjusted life years (DALY’s) was high systolic blood pressure, and 
deaths due to raised blood pressure have increased in the last 25 years (GBD 2015 Disease 
and Injury Incidence and Prevalence Collaborators, 2016; Forouzanfar et al., 2017; Noubiap 
et al., 2017). Critically, central and sub-Saharan Africa remain as regions with the highest age-
adjusted DALY’s with 20-25% of adult Nigerians estimated as hypertensive (Ogah, 2006; 
Forouzanfar et al., 2017).  
Chronic elevated systolic blood pressure is the principal cause of left ventricular hypertrophy 
(LVH) and evidence suggests that LVH progresses to hypertensive HF (Verdecchia et al., 
1990; Izzo, 2004). Indeed, hypertension remains a major cause of HF in developing countries 
(Mendez and Cowie, 2001; Onwuchekwa and Asekomeh, 2009). In a cohort of 1 515 patients, 
hypertensive HF was the most common form of HF in Abuja, Nigeria (Ojji et al., 2013). 
In hypertensive patients, HDL-C is lower (Paynter et al., 2011) and HDL subclass size is lower 
(Zhang et al., 2015), however, little is known how hypertension and hypertensive HF may 
affect HDL function. The pathogenesis of hypertension proposes a number of causal factors 
relating to diet, renal function, stress and endothelial dysfunction due to impaired nitric oxide 
release and oxidative stress (Oparil et al., 2003). It is therefore proposed that HDL function 
may be impaired in hypertensive patients since HDL is important in controlling oxidative stress 
in the endothelium and maintaining normal endothelial function. HDL stimulates eNOS activity 
through the binding of S1P to its specific receptors (Nofer et al., 2004; Igarashi et al., 2007; 
Besler et al., 2011).  
The aim of the study was therefore to explore whether HDL composition, function and 
subclass distribution in Nigerian patients diagnosed with hypertension and 




2. MATERIALS AND METHODS 
2.1 Subjects 
The sample population consisted of 80 outpatients from the University of Abuja Teaching 
Hospital and were recruited as previously described (Ojji et al., 2013).  Briefly, patients were 
grouped into three primary groups: i) control patients (n=30) who complained of non-specific 
chest pain but were non-hypertensive with no cardiac risk factors; ii) hypertensive patients 
(n=28) displaying no hypertrophy and iii) hypertensive patients with HF (n=22) diagnosed 
using echocardiography. Hypertension was defined according the Seventh Report of the Joint 
National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure (JNC 7) guidelines (US Department of Health and Human Sevices, 2004). HF  was  
diagnosed  according  to  the  European  Society  of  Cardiology Guidelines (Nieminen et al., 
2005), and  functional status of the HF subjects  was  according  to  the  guidelines of the  New 
York Heart  Association Functional classification (NHYA  1964). Exclusion criteria included 
patients with dyslipidaemia and diabetes mellitus and any patients who were active smokers. 
The study was approved by the Research Ethics Committees of the Faculty of Health Sciences 
of the University of Cape Town (HREC REF: 745/2016) and the University of Abuja teaching 
Hospital (REF: HREC/PR/530). Fasting serum samples were taken and stored at -80ºC prior 
to use.  
2.2 HDL isolation 
HDL was isolated from aliquots of serum as previously described in Chapter four (Section 2.2).  
2.3 Measurement of apolipoproteins A1 and M content in HDL 
Isolated HDL and serum samples from each of the participants were electrophoresed on 
reducing 12.5% SDS-polyacrylamide (SDS-PAGE) gels with 1.5-2 µg of HDL protein loaded 
per well. Samples were run over multiple gels with control samples repeated in each gel. Blots 
were transferred onto nitrocellulose membranes (Bio-Rad, 162-0113). Ponceau S staining 
was used to validate equal loading of wells. Blots were blocked in 5% low fat milk powder in 
0.05% TTBS, pH 7.5, and incubated overnight in separate primary antibody solutions: rabbit 
anti-ApoM, (Abcam, 47711) (1:1000) and mouse anti-ApoA1, (Calbiochem, 178422) (1:1000). 
Blots were then washed in TTBS and incubated in goat anti-rabbit, (Li-Cor, 92632221) and 
goat anti-mouse, (Li-Cor®, 92632210) cocktail for 1 hour at room temperature. Blots were 
thoroughly washed in TTBS prior to visualization using the Li-Cor® digital scanner. Blots were 
captured in the GeneGnome gel imager and Li-Cor digital scanner. Densitometry of blots was 
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quantified using Quantity one and Li-Cor® software. ApoA1 and ApoM relative expression 
data were corrected for control samples, repeated in each gel. 
2.4 Measurement of S1P content in isolated HDL 
The concentration of S1P in isolated HDL was measured using mass spectroscopy as 
described previously (Brulhart-Meynet et al., 2015). Briefly, analyses were performed on liquid 
chromatography mass spectroscopy (LC-MS/MS) system consisting of a 5500 QTrap® triple 
quadrupole linear ion trap (QqQLIT) mass spectrometer equipped with a TurboIon SprayTM 
interface (AB Sciex, Framingham, MA, USA) and an Ultimate 3000 Series (Thermo Fisher 
Scientific Inc., Whaltham, MA, USA). Data acquisition and analysis were performed using 
AnalystTM software (version 1.6.2; AB Sciex, Framingham, MA, USA). 
Substances were separated using a Chromolith RP-18 analytical column (100 mm x 3 mm 
Merck, Darmstadt, Germany). Mobile phase was constituted of a mixture of water (A) and 
methanol (B). A gradient was used starting from 50 to 100% in 1.5 minutes, maintained during 
8 minutes, and re-equilibrated at 50% in 0.1 minutes during 1.4 minutes for an overall analysis 
time of 11 minutes. The autosampler was kept at 6°C. 
The TurboIon SprayTM interface was operated in the negative ionization mode. The 
parameters of the source were used with the following settings using nitrogen as curtain and 
nebulizer gas: capillary voltage -4.0 kV, temperature 625°C, curtain gas 20 psi, collision gas -
8, ion source gas-1 45 psi, and ion source gas-2 45 psi. For the multiple reaction monitoring 
parameters, a dwell time of 50 ms, a declustering potential of -100 eV, and a collision energy 
of -40 eV were used. The precursor ion was at 378.2 m/z. The product ion of 78.8 m/z was 
selected. The MS/MS experiments were based on collision-induced dissociation occurring in 
the collision cell (quadrupole 2), with nitrogen as collision gas set at 10. 
2.5 Quantification of HDL subclass distribution 
Serum HDL subclass was determined using the Lipoprint® HDL system (Quantimetrix, 
Redondo Beach, CA) as described in Chapter four (Section 2.8). 
2.6 PON1 activity assay    






2.7 Quantification of HDL anti-inflammatory function 
HDL anti-inflammatory function was measured as previously described in Chapter four 
(Section 2.7). 
2.8 Quantification of HDL-induced endothelial stimulation 
In order to quantify HDL function relating to maintaining normal endothelial function, induction 
of eNOS in endothelial cells stimulated with isolated HDL was assessed. Mouse endothelial 
cell line bEnd.3 cells, generously provided from Prof Brenda Kwak (University of Geneva), 
were cultured on plates coated with 1.5% gelatin (Sigma, G1890) in Dulbecco’s Modified Eagle 
Medium (DMEM) (Gibco, 41966-029) containing foetal bovine serum (FBS) (Biochrom,S0415) 
and 1% penicillin/streptomycin (Gibco, 15140122) at 37ºC, 5% CO2. Once cells reached 100% 
confluence, cells were incubated in DMEM containing 1% FBS overnight. Media was changed 
to DMEM with no FBS for 1 hour prior to treatment with subject HDL (100 µg/ml) for 10 
minutes. Cells monolayers were treated with lysis buffer containing Tris-HCl (50mM, pH 7.4), 
NaCl (150mM), glycerol (10%), EDTA (2mM), ethylene glycol-bis(β-aminoethyl ether)-
N,N,N',N'-tetraacetic acid (EGTA) (2mM), Triton X-100 (1%v/v), β-glycerophosphate (40mM), 
sodium fluoride (50mM), a mixture of protease inhibitors (Roche, Mannheim, Germany) and 
phenyl-methyl-sulfonyl fluoride (1mM). Cell lysates were incubated at 4ºC for three 10 minute 
intervals interspersed with vortexing. Lysates were centrifuged at 10 000g for 10 minutes at 
4ºC and supernantants retained. Protein concentration was determined using the method 
described by Bradford (Bradford, 1976).  
Cell lysates (20 µg/lane) were loaded onto reducing 10% SDS-PAGE gels and transferred 
onto nitrocellulose membranes. Ponceau S staining was used to validate equal loading of 
wells. Blots were blocked in 5% low fat milk powder in TTBS for 1 hour at room temperature. 
Blots were washed in TTBS and incubated in rabbit anti-phosphoeNOS (Cell signalling, 9571, 
Ser1177). Membranes were stripped and reprobed with rabbit anti-total eNOS (Cell signalling, 
32027). Relative bands were visualised and densities quantified with the ChemidocTM system 
(Biorad, 1708265). Pathway activation was quantified using the ratio between phospho-eNOS 
with total eNOS. 
2.9 Statistical analysis 
Non-normally distributed data including: patient age, BMI, systolic and diastolic blood 
pressures, lipid profiles, ApoA1, ApoM expression, S1P content, HDL subclass distribution, 
PON1 activity and anti-inflammatory function were presented as medians ± interquartile range 
(IQR). K-Wallis and Mann-Whitney nonparametric testing was used to compare differences 
between groups. For comparisons between groups regarding echocardiographic 
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measurements, samples were log transformed prior to one-way analysis of covariance with 
Scheffe posthoc testing. For endothelial stimulation, comparisons to non-treated controls were 
tested using students t-tests and results are presented as means ± SEM. All Statistical 





3.1 Patient clinical characteristics 
Patient groups did not differ by BMI and gender. Hypertensive patients with and without HF 
were older and presented with a higher systolic and diastolic blood pressure (p < 0.001) as 
well as a higher total cholesterol level (p < 0.05) than control patients, (Table 8). In contrast, 
triglycerides, LDL-C and HDL-C did not differ between the groups 
Table 8: Clinical characteristics of patients 
 
BMI: Body mass index. Results presented as medians ± IQR. A  p < 0.005 compared to Control, a  p < 0.05 










3.2 Patient echocardiographic characteristics 
Echocardiographic measurements indicate that hypertensive and HF patients had higher end 
diastolic diameter (EDD), end systolic diameter (ESD), left atrial area (LAA), right atrial area 
(RAA) and lower tricuspid annular pulmonary excursion (TAPSE) than both control and 
hypertensive patients, Table 9. Additionally, hypertensive and HF patients had higher early 
mitral filling (ME) than control patients (p < 0.05). There were no differences in atrial filling 
(MA) between hypertensive and hypertensive and HF patients while hypertensive patients had 
greater inter-ventricular septal diameter in diastole (IVSD) compared to control patients (p < 
0.05). 














IVSD: Inter-ventricular septal diameter in diastole. EDD: End Diastolic Diameter. ESD: End Systolic 
Diameter. LAA: Left Atrial Area. RAA: Right Atrial Area. ME: Early Mitral Filling. MA: Atrial Filling. DT: 
Deceleration Time. TAPSE: Tricuspid Annular Pulmonary Excursion. Results presented as medians ± IQR. 
A p < 0.005 compared to Control, a p < 0.05 compared to Control. B p < 0.005 compared to hypertensive, b p 






Parameter Control Hypertensive Hypertensive and HF p value 
IVSD 0.80 ± 0.11 1.07 ± 0.59a 0.82 ± 0.32 0.011 
EDD 4.52 ± 0.89 4.44 ± 1.02 6.65 ± 0.39A,B <0.001 
ESD 2.38 ± 0.66 2.50 ± 0.47 6.01 ± 1.25A,B <0.001 
LAA 15.1 ± 4.0 15.7 ± 1.8 26.3 ± 7.2A,b <0.001 
RAA 13.6 ± 2.4 11.1 ± 0.8 27.2 ± 8.2A,B <0.001 
ME 0.64 ± 0.21 0.64 ± 0.06 0.91 ± 0.34a 0.007 
MA 0.48 ± 0.23 0.60 ± 0.31 0.32 ± 0.27 0.120 
DT 168 ± 24 195 ± 69 91 ± 27A,B <0.001 
TAPSE 23.5 ± 3.4 22.7 ± 5.6 15.6 ± 4.9A,b 0.001 
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3.3 Hypertension and HDL composition 
Control and hypertensive with/without HF patients had equivalent expression levels of ApoA1 
(0.95 ± 1.45, 1.02 ± 2.56 and 1.25 ± 1.35, respectively). ApoM expression was lower in 
hypertension and HF patients compared to control (3.4 ± 1.6 vs 4.5 ± 1.7 AU, p = 0.07, Figure 





















Figure 32. Apolipoprotein A1 and M expression patient HDL. HDL from control, hypertension and 
hypertension and HF patients was isolated and were run on reducing 12.5% SDS-PAGE gels and 
transferred onto nitrocellulose membranes.  Blots were probed with mouse-ApoA1 and rabbit-ApoM. 
Representative blots of ApoA1 and ApoM expression. Densitometry was quantified using Li-Cor® software. 
AU: Arbitrary units and HF: Heart failure. Results represent medians ± IQR.  
The S1P level in HDL isolated from control patients was  201 ± 73 pmol per mg of HDL, which 
is in a similar range to data previously reported in the literature (Brinck et al., 2016). S1P 
concentration was lower in hypertension and HF patients compared to control (165 ± 55 vs 
201 ± 73 pmol/mg, p < 0.05 vs control, Figure 33), but it did not differ from the hypertensive 
group.  
ApoA1 28 kDa   ► 












Figure 33. S1P content of isolated patient HDL. HDL from control, hypertension and hypertension and HF 
patients was isolated and S1P content in isolated HDL was quantified using liquid chromatography mass 
spectroscopy. AU: Arbitrary units and HF: Heart failure. Results represent medians ± IQR. S1P: pmol/mg 
of total protein. * p < 0.05 compared to control. 
3.4 Hypertension and HDL subclass distribution 
The distribution of large, intermediate and small HDL subclasses, quantified by the Lipoprint® 
System is presented in Figure 34. Representative profiles are shown in Figure 34A-C for the 
subclass distributions of control, hypertension and hypertension and HF patients. The 
subclass distribution profile was significantly different in hypertension and HF patients 
compared to control patients with lower large (48 ± 15 vs 63 ± 7%, p < 0.005), higher 








Figure 34. Patient HDL subclass distribution. Patient sera were analysed using the Lipoprint® system and 
Lipoware software. Representative scan results from control, hypertensive and hypertensive and HF 
patients (A-C, respectively). Percentages of large, intermediate and small HDL subclasses (D). VLDL: Very 
low-density lipoprotein. HF: Heart failure Results represent medians ± IQR. ** p < 0.005 * p < 0.05 compared 





3.5 Hypertension and HDL functionality 
Hypertension and HDL antioxidative function 
As a measure of the antioxidative function of HDL, the serum activity of PON, an HDL-
associated antioxidative enzyme was quantified (Figure 35). PON activity in control patients 
was 0.38 ± 0.20 U/L, which was in a similar range to data previously reported in the literature 
and in Chapters four and five of this thesis (Kunutsor et al., 2016). PON activity did not differ 












Figure 35. Patient PON1 activity. PON1 activity was measured in patient serum. One Unit of activity is 
defined as 1 nmol of substrate disintegrated per minute. HF: Heart failure. Results represent medians ± 
IQR.  
Hypertension and HDL anti-inflammatory function 
The anti-inflammatory function of patient HDL was assessed by quantifying relative reduction 
in TNF-α mediated activation of VCAM expression in HUVEC cells (Figure 36). There were, 








Figure 36. Patient HDL anti-inflammatory 
function.  Determined by Vascular Cell 
Adhesion Molecule (VCAM) expression 
relative to tumour necrosis factor (TNF) 
treated cells, pre-treated with isolated 
HDL. Human Umbillical Vein Endothelial 
Cells (HUVEC) were treated with isolated 
HDL followed by TNF-α. HDL anti-
inflammatory function was calculated as 
VCAM expression in HUVEC cells relative 
to a control untreated with HDL while a 
non-TNF treated control was also run. HF: 
Heart failure AU: Arbitrary units. Results 




Hypertension and activation of eNOS by HDL 
In order to assess how known impairment of normal endothelium function under hypertensive 
conditions may have associations with HDL, a cell culture model was used to quantify eNOS 
activation by HDL (Figure 37). The relative intensity of phosphorylated eNOS, relative to total 
eNOS was used to calculate eNOS activation. The effects of isolated patient HDL on eNOS 
activation was compared to activation in cells not treated with HDL. Only control patient HDL 
significantly increased eNOS activation compared to untreated cells (1.27 ± 0.12 vs 0.94 ± 
0.08, p < 0.05). HDL isolated from hypertension and hypertension and HF patients failed to 





















Figure 37. Patient HDL induced activation of endothelial nitric oxide synthase (eNOS). Isolated HDL was 
used to treat bEND.3 cells for 10 minutes. Cell lysates were harvested and run on reducing 10% SDS-PAGE 
gels. Gels were transferred onto nitrocellulose membranes and were probed with rabbit anti-phosphoeNOS  
and reprobed with rabbit anti-total eNOS. Representative blot of eNOS activation following treatment of 
HDL from control, hypertensive and hypertensive and HF patients as well as a non-treated control (A). 
Activation of eNOS was calculated as intensity of phosphorylated bands relative to total eNOS (B). HF: 
Heart failure, NT: No treatment and AU: Arbitrary units. Results represent means ± SEM. * p < 0.05 
compared to non-treated control.  
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3.6 Relationships between measures of HDL composition, function and subclass and 
patient characteristics 
In order to explore whether HDL composition, function and subclass may be associated with 
differences in patient characteristics, all patients were combined and Spearman correlation 
coefficients were calculated and presented in the matrix in Table 10. Greater age was 
associated with higher systolic and diastolic blood pressure and percentage of intermediate 
HDL subclasses and with lower percentages of large HDL subclasses (p < 0.005). Higher 
ApoA1 content was associated with lower relative VCAM expression (greater anti-
inflammatory function) (p < 0.05). There was no association between measures of HDL 
function and subclass distribution. 
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Table 10. Associations between HDL composition, functionality and subclass measures with patient characteristics





















Age  0.045 0.810** 0.710** 0.058 -0.436 -0.427 0.333 -0.018 -0.700* 0.727* 0.284 
BMI   0.284 0.140 -0.196 -0.182 0.145 -0.500 -0.364 Null -0.064 0.147 
Systolic BP    0.880** -0.067 -0.481 -0.535 0.050 -0.261 -0.485 0.407 0.139 
Diastolic BP     -0.098 -0.382 -0.452 -0.093 -0.280 -0.485 0.451 0.212 
ApoA1 
expression 
     -0.176 0.041 -0.571 -0.636* 0.042 -0.067 0.337 
ApoM expression       -0.064 0.027 0.182 0.354 -0.282 0.037 
S1P content        -0.023 -0.091 0.263 -0.191 0.064 
PON1 activity         0.379 -0.424 0.492 0.138 
Anti-inflammatory 
function 
         -0.054 0.054 -0.156 
Large HDL           -0.973** -0.642* 
Intermediate HDL            0.615* 
Small HDL             




The aim of the current preliminary study was to examine how hypertension and HF may be 
associated with a change in HDL composition, subclass and function. It was found that 
hypertension and HF patients had a reduced S1P content, lower distributions of large HDL 
subclasses and possibly displayed impaired activation of endothelial eNOS. This preliminary 
study therefore provides novel evidence how hypertension and HF may be associated with 
differences in HDL composition and function.  
Hypertension risk is high in African populations (Mendez and Cowie, 2001; Onwuchekwa and 
Asekomeh, 2009). It is estimated that up to 42% of adult Nigerians may be hypertensive (Ulasi 
et al., 2011; Mozaffarian et al., 2015). In developing countries, the cause of HF is mainly due 
to hypertension, in contrast to higher income countries, whereby HF has predominantly 
ischemic causes (Celermajer et al., 2012). Casual factors in hypertension include endothelial 
dysfunction and oxidative stress (Oparil et al., 2003). It is therefore, surprising how relatively 
few studies have considered how HDL functional impairment and structural changes may be 
linked with hypertension.   
In the current study, hypertensive and HF patients had lower S1P levels than controls. It is 
hypothesized that this may be attributed to a lower ApoM expression, although there were no 
significant associations between S1P content and ApoM expression. ApoM is an HDL protein 
which has a conformation that allows for specific binding to S1P and therefore HDL serves as 
the primary carrier of S1P. The ApoM-S1P complex mediates the vasoprotective functions of 
HDL in vivo (Christoffersen et al., 2011). The S1P component of HDL has been shown to 
induce nitric oxide release (Nofer et al., 2004); prevent ischemic injury and trigger 
cardioprotective signalling pathways (Theilmeier et al., 2006; Frias et al., 2012); reduce OxLDL 
related cytotoxicity in HUVEC cells (Kimura et al., 2001); induce prostacyclin release via 
activation of cyclooxygenase-2 (Liu et al., 2012) and prevent LDL oxidation (Kontush et al., 
2007). Reduced HDL-associated S1P in HF patients would therefore have deleterious 
consequences for patients. In addition, we found an association (r = -0.535, p < 0.05) between 
higher S1P and lower systolic blood pressure. This further suggests that S1P content may be 
linked with the pathophysiology of hypertension. 
S1P signalling pathways have been implicated in the pathogenesis of hypertension (Meissner 
et al., 2017). Activation of eNOS by S1P is important in maintaining endothelial structural 
integrity, reducing vasoconstriction and promoting pro-survival pathways (reviewed by Xing et 
al. 2015). In the present study, isolated HDL from both hypertensive and hypertensive and HF 
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patients, failed to significantly activate endothelial eNOS in a cell culture model, an effect 
which may be associated with a reduction in HDL-associated S1P in these patients. 
The importance of eNOS in hypertension was first demonstrated in knockout mice who 
developed hypertension (Huang et al., 1995). Literature suggests that there are associations 
between polymorphisms in the eNOS gene in patients with chronic heart disease and these 
were linked to endothelial dysfunction (Yakovleva et al., 2008; Teplyakov et al., 2010). 
Polymorphisms in the eNOS gene have since been proposed to potentially explain the high 
genetic risk for hypertension and HF in African Americans (Yancy, 2000; Li et al., 2004). 
Similarly, the high risk of hypertension in African populations may be potentially explained by 
impaired eNOS activation, as a result of diminished S1P content as shown in this study 
(Mendez and Cowie, 2001; Sliwa et al., 2008; Onwuchekwa and Asekomeh, 2009). 
The present study found no differences in HDL anti-inflammatory function between groups. 
The present study was limited by low sample numbers, however, it was shown that 43% of all 
diseased patients displayed pro-inflammatory HDL. Increasing the population numbers may 
improve and validate this finding further. Additionally, it was found that greater expression of 
ApoA1 was associated with improved anti-inflammatory function. This suggests that changes 
in HDL anti-inflammatory function may be mediated by changes in ApoA1 expression. This 
was similarly shown in pro-inflammatory HDL, which was characterised by a decrease in 
ApoA1 content (Van Lenten et al., 1995; Cabana et al., 1996; Lewis et al., 2004). Failure to 
show differences in ApoA1 content between groups may further explain why no between-
group differences in HDL anti-inflammatory function were observed. 
Interestingly, the present study found no difference in PON1 activity between groups. In 
contrast, patients with enhanced morning surge of high blood pressure had lower PON1 
activity (Kaypaklı et al., 2016). Similarly, increased oxidative stress was associated with 
decreased PON1 activity in white coat hypertensive patients (Kishimoto et al., 2004). Patients 
with essential hypertension displayed polymorphism in the PON1 gene (Turgut Cosan et al., 
2016). However, PON1 polymorphisms, such as the promotor region SNP L-55M, causes a 
reduction in serum PON1 activity and are much less frequent in oriental and black populations 
(Phuntuwate et al., 2005; Mackness and Mackness, 2015). Additionally, in a population of 
black and white African women, black women displayed higher PON1 activity when compared 
to white women, (Chapter four) (Woudberg et al. 2016). It is therefore suggested that these 
findings may explain why diseased patients maintained healthy levels of PON1 activity. Future 




Pertinent to understanding HDL in relation to disease, is the consideration of HDL subclasses. 
HDL subclass distribution shifts are associated with obesity (Chapter four) (James et al., 1997; 
Magkos et al., 2012) and most recently, with hypertension (Paynter et al., 2011; Zhang et al., 
2015). In this latter study, hypertensive status was associated, in an aged population, with 
lower percentages of large and higher percentages of small HDL subclasses (Zhang et al., 
2015). A similar shift in HDL subclass distribution was similarly shown in patients with coronary 
heart disease (Oravec et al., 2011). The current study is the first to examine how HDL subclass 
distribution may differ in patients with hypertensive HF compared to healthy patients. Similar 
to the studies mentioned above, our data show the same shift in HDL subclasses in 
hypertensive and HF patients compared to controls.  
A major limitation of the study design was that the control patients were significantly younger 
than both disease patient groups. Indeed, age was associated with increased systolic and 
diastolic blood pressure and with decreased large HDL subclasses. This latter observation 
makes it difficult to determine whether the differences in HDL subclass distribution between 
HF patients and control are related to disease status or age. Indeed, HDL subclass size 
reduction and changes in subclass distribution are linked to aging (Dobiasova et al., 1992; 
Tian et al., 2010; Rajalahti et al., 2016). Another major limitation to our study was the low 
sample numbers which limits the conclusions that may be drawn. However, as a preliminary 
study, it is the first study to examine differences in HDL composition, function and subclass in 
an African hypertensive sample population.  
5. CONCLUSION 
There is a high prevalence and risk of hypertension and hypertensive HF in Africa. 
Pathophysiological consequences of hypertension may be associated with impaired HDL 
function. In spite of no differences in HDL-C, hypertensive and HF patients displayed lower 
S1P content in HDL compared to control patients. In addition, all hypertensive patients HDL 
displayed impaired activation of endothelial eNOS. Hypertensive and HF patients displayed a 
shift in HDL subclass distribution, with lower large and greater intermediate and small HDL 
subclasses compared to controls. This study therefore provides novel evidence that 
hypertension and HF may have consequences for HDL structure, function and subclass 
distribution. Additional studies will be required to better understand the exact role of the 















CHAPTER SEVEN: CONCLUSIONS AND PERSPECTIVES 
1. SUMMARY OF FINDINGS 
The primary aim of the PhD thesis was to examine how different CVD risk factors may be 
associated with changes in HDL quality instead of HDL-C quantity. Modern research into 
lipidology is beginning to suggest a more pronounced focus on HDL functionality, composition 
and subclasses (HDL quality)  (Egom et al., 2013; Santos-Gallego, 2015). To better address 
this, the overall study was subdivided to focus on three sample populations, each with defined 
CVD risk factors. 
1. A sample population of normal-weight and obese black and white South African women to 
explore whether ethnicity and obesity were associated with changes in HDL function and 
subclass distribution (Chapter four). 
2. A sample population of black obese women, half of which will underwent an exercise 
intervention to explore whether exercise alters HDL function and subclass distribution 
(Chapter five). 
3. A sample population of hypertensive population of Nigerian patients with or without HF 
along with healthy controls to explore how hypertension and HF were associated with changes 
in HDL composition, subclass distribution and function (Chapter six). 
Each sample population revealed different aspects of the association between CVD risk 
factors and HDL. The common finding among all three was that CVD risk was not associated 
with HDL-C concentrations. In the first sample population, black South African women had 
lower HDL-C levels than their white counterparts. This however, did not translate into any 
impairment in HDL function. To our knowledge, we demonstrated for the first time in an African 
sample population, that any potential reduction in risk for ischemic heart disease in black 
Africans may be attributed to greater HDL function (Rossouw, 1983; Akinboboye et al., 2003; 
Mayosi, 2007; Sliwa et al., 2008; Agyemang et al., 2009; Woudberg et al., 2016). This was 
evident in higher PON1 activity (Figure 38). The second major finding from this sample 
population was an inverse association between, large HDL subclasses and a higher BMI. This 
was commensurate with findings in European obese populations (James et al., 1997; Magkos 
et al., 2008).  
Following on from this first sample population, it was explored how an exercise training 
intervention, in obese black South African women, may revert HDL function and subclass to a 
“non-obese” state. HDL-C was not altered by the 12-week exercise training intervention, 
however, there were associations between exercise training and HDL function and subclass. 
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These associations included inverse associations between RCT and large HDL with lower BMI 
while exercise training was linked to a decrease in small HDL subclasses. This aptly follows 
on from the previous study indicating that exercise training alters HDL subclass distribution, 
via weight loss, however this weight loss was minimal following the exercise intervention 
(Figure 38). Critically, we showed for the first time, a significant association between HDL 
functionality and HDL subclass distribution, measured by the Lipoprint® System. The 
Lipoprint® System was established 16 years ago and has never been applied to an African 
sample population. HDL subclasses have their own defined functions, therefore links between 
traditional measures of HDL function and a relatively new method quantifying HDL subclass, 
are critical to the future of HDL research (Camont et al., 2013). 
 
Figure 38. Summary of major findings from the first (Chapter four) and second (Chapter five) sample 
populations. Obesity was associated with lower HDL subclass size, whilst an exercise training intervention 
reverts HDL subclass distribution to a non-obese state. Ethnicity was associated with a difference in HDL 
function wherein black South African women had greater PON1 activity than their white counterparts. 
In the final sample population, we expanded our focus to include measures of HDL 
composition, quantifying the expression of ApoA1, ApoM and S1P. The sample population 
comprised healthy controls, hypertensive patients and hypertensive and HF patients. Similarly 
to previous sample populations, there were no differences in HDL-C between groups and no 
associations between HDL-C and the risk of CVD. Hypertensive HF patients, in particular, 
demonstrated diminished HDL function and modifications in HDL composition. Patients had a 
reduction in ApoM and S1P content compared to controls, which we hypothesize, could 
contribute to functional impairment in endothelial eNOS activation. Similar to our findings in 
obesity, hypertension as a CVD risk factor was again associated with a lower percentage of 




Figure 39. Summary of major findings from the third sample population (Chapter six).  Hypertension and 
hypertension with HF patients have lower ApoM expression, compared to healthy controls. This possibly 
leads to reduced S1P content, which impairs HDL-induced activation of eNOS. In addition, hypertension 
and HF is associated with lower HDL subclass size compared to healthy controls.  
All three of the studies therefore underline the relevance of focussing on HDL quality over 
quantity. In all sample populations, patients at differing levels of CVD risk showed similar HDL-







The main limitation linked to all three studies were the numbers of patients and participants 
included in each sample population. These opportunistic studies were not specifically powered 
for the outcomes described in the thesis. We acknowledge that this limits the conclusions and 
interpretation of the findings. Particularly in the Nigerian sample population, missing 
echocardiographic data greatly limited the depth and significance of our findings. In this case, 
echocardiographic data validated the model of hypertensive HF but could not be associated 
with HDL subclass and function as had been originally planned. 
Whilst sample numbers were low, making the studies largely “preliminary” in nature, the 
relevance becomes important when considering the novelty of the studies. In all sample 
populations, HDL subclass and function were considered concurrently as potential biomarkers 
of CVD risk which contrasts to recent literature, in which markers of HDL function and HDL 
subclass were considered separately (Khera et al., 2011; Tang et al., 2012; Rohatgi, et al., 
2014; Tian et al., 2014; Martin et al., 2015). Considering both markers together may be 
particularly relevant in an African setting, due to the increasing prevalence of myocardial 
infarction and ischemic heart disease, likely linked to the epidemiological transition (Kakou-
Guikahue et al., 2016; Traina et al., 2017). Finding novel biomarkers of CVD risk in such a 
population is critical. 
In addition, data from this thesis provides a foundation for future studies. In the first part of the 
thesis, a novel method of HDL isolation of pure HDL samples from low serum volumes was 
established (Chapter three). In the same way, HDL subclass analysis and new measures of 
HDL functionality measurement have been established in robust and repeatable experimental 
models. These techniques can therefore be applied to a number of different sample 
populations considering HDL quality in relation to CVD. Across the thesis the number of 
analytical tests progressively increased. This allowed for a deeper analysis of HDL 
functionality. 
Study design 
As stated previously, the studies included in the thesis were opportunistic studies, therefore, 
whilst there was input into the HDL analysis strategy, overall design of the larger studies was 
not possible. For the first two population studies, young black and white South African women 
were selected for inclusion. Women were only selected in the original study to focus 
specifically on insulin resistance in women, reducing gender-related variability. It is 
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acknowledged that background, social status, education, lifestyle that had not been taken into 
account and that may contribute to differences observed between ethnicities. In the first 
sample population, associations between HDL subclass and obesity were described, 
however, this trend was largely driven by findings in white women only. Further studies should 
be undertaken to understand why these effects were not reflected in the black women. 
Therefore, ideally, as a follow-up regarding an exercise training intervention in obese women, 
both black and white obese women should have been included. The project whose samples 
were used in the thesis had already been established and focused more on black South 
African women and their risk of type 2 diabetes due to increased insulin resistance (Jennings 
et al., 2008; Knight et al., 2011). Despite this flaw in the cohesiveness of the design, we still 
demonstrated changes in HDL subclass in black African women in response to an exercise 
training intervention. These responses were indeed, mediated by small, but significant, 
changes in BMI. 
In the Nigerian sample population, control samples were not age matched to their diseased 
counterparts. Whilst the prevalence of HF is increased in aged populations, it is important to 
ensure populations are age matched for statistically relevant comparisons (Bleumink et al., 
2004). To test age as a confounder, we performed Spearman correlation matrices. 
Percentages of large HDL subclasses correlated negatively with age suggesting that the 
difference between groups was driven by an older age in the hypertensive HF patients.  
The results of this thesis were based on the findings from cross-sectional and intervention 
studies. It is therefore difficult to state whether HDL function or HDL subclass distribution may 
be a useful marker to assess possible risk of heart disease. The studies did not examine the 
Framingham risk score but rather focussed on specific risk factors of heart disease and how 
these may be causally related to differences in HDL quality. The observations are therefore 
descriptive and not predictive. As such, we cannot accurately state which measure of HDL 
function or indeed whether specific HDL subclasses correlate to an increase or a decrease of 
CVD risk per se.  
Methodology 
The activities of PON1 and PAF-AH enzymes were quantified in serum only. Both are 
associated in vivo with HDL, with PON1 in particular, almost completely HDL bound (James 
and Deakin, 2004). However, attributing activities of specific enzymes as strict HDL “functions” 
is challenging. To address this, we performed western blotting in both isolated HDL and in 




The prevalence of polymorphisms in the PON1 gene, particularly those which are ethnicity-
specific, make a genetic aspect of the research potentially interesting. Future work regarding 
PON1 activity and expression would be improved by examining genetic aberrations in the 
expression of the PON1 gene in a large cohort of patients. 
Our studies utilized the Lipoprint® System for the first time in African sample populations. As 
a caveat, it is important to consider that nomenclature for HDL subclass depends on the 
methods used for quantification and separation (Asztalos et al. 2011). It is therefore worth 
considering that this study therefore designates HDL subclasses as large, intermediate and 
small. Much of the existing literature describes two principal HDL subclasses, HDL2 and 
HDL3. It is well established that HDL2 is the larger of the HDL subclasses and HDL3 is the 
smaller (Williams et al., 1992; Rosenson et al., 2011). To better demonstrate these differences 
in traditional methods of HDL subclass isolation, and the Lipoprint® System, pure HDL2 and 
HDL3, generously donated by Dr Miguel Frias, were separated on the Lipoprint® System and 
distributions of large, intermediate and small subclasses quantified (Figure 40). 
HDL2 is largely represented by large HDL but HDL3 is not clearly defined. It was expected 
that HDL3 would be represented by intermediate or small HDL subclasses. For this reason, 
Lipoprint® data can only be compared with similar data as the system does not strictly 
represent HDL3 by intermediate or small HDL subclasses. This was a potential limitation of 
the study, however, the ease of use of the system, approval for the system’s use in clinical 
diagnosis in the United States and increased interest from private clinical laboratories in South 
Africa will further increase application in the broader scientific community. Therefore, it will 
























Figure 40. Distribution of HDL subclasses of pure HDL2 and HDL3 analysed in the Lipoprint® System. Data 
was analysed using Lipoware software. Representative scan results of HDL2 (A) and HDL3 (C). 
Percentages of large, intermediate and small HDL subclasses designated by the Lipoprint® System for 





3. HDL QUALITY AS A USEFUL BIOMARKER: FUTURE RESEARCH 
Our data in this thesis suggest how HDL quality may more closely relate to CVD risk factors 
than HDL quantity. Discussed by Santos-Gallego, HDL-C concentration does not consistently 
reflect the concentration of the HDL molecule, which can be fully or partially loaded with 
cholesterol (Santos-Gallego, 2015). Only 5% of total HDL-C is derived from macrophage 
cholesterol efflux, demonstrating how HDL-C is a poor indicator of RCT function (Santos-
Gallego, 2015). HDL-C also does not represent other important HDL functions, including 
vasodilatory or anti-inflammatory functions (Santos-Gallego, 2015). Therefore, it is worth 
considering how HDL quality may translate into a useful biomarker. 
Reverse cholesterol efflux 
Of the multiple HDL functions, RCT has been the most extensively studied as a potential 
biomarker (Khera et al., 2011; Santos-Gallego et al., 2011; Rohatgi, et al., 2014). RCT 
successfully predicted severity of coronary artery disease events while HDL-C failed to do so 
(Khera et al., 2011). Analysis from the JUPITER trial recently indicated that RCT was inversely 
associated with incident of cardiovascular events in patients on potent statin therapy (Khera 
et al., 2017). RCT has therefore shown potential as a viable biomarker in high profile studies,. 
However, similarly to the assessment of HDL anti-inflammatory function, RCT relies on cell-
culture based models. Robustness and standardization of these techniques are very limited. 
Results will be affected by multiple variables including cell lines, cell passages, culture 
conditions and reagent use. Cell-culture is also not cost effective and is not suitable for a 
clinical diagnosis setting, due to time constraints linked to the method. In addition, RCT 
measurements traditionally rely on the use of radioactive materials. New regulations will 
restrict the usage of these materials in clinical laboratories. However, new techniques using 
alternative fluorescent labels of cholesterol have been optimized (Sankaranarayanan et al., 
2011).  
HDL S1P content 
A second option is consideration of HDL S1P content, which has been suggested as a useful 
biomarker, reviewed by (Egom et al., 2013). MI and coronary artery disease patients had a 
lower S1P-HDL concentration, which could be raised using in vitro S1P loading (Sattler et al., 
2010, 2015). S1P uptake deficiency of HDL in coronary artery disease patients presented as 
a potential marker of HDL dysfunction (Sattler et al., 2010). This observation was extended to 
patients with coronary in stent restenosis (Jing et al., 2015) and in type 2 diabetic patients 
(Brinck et al., 2016). S1P is inversely correlated with HbA1c in type 2 diabetic patients, and 
the concentration of S1P is correlated with cardiac specific anti-apoptotic capacity (Brinck et 
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al., 2016). S1P levels in HDL serum fractions successfully discriminated subjects with 
ischemic heart disease from those without (Argraves et al., 2011).  
To measure S1P accurately in a diagnostic setting, clinical laboratories would need to use 
liquid chromatography mass spectroscopy. Mass spectroscopy as a diagnostic tool has 
potential, however, use is limited due to a substantial initial investment estimated as much as 
400 000 Euros in 2012 (Van den Ouweland and Kema, 2012). Additional costs include routine 
maintenance, training of specialized staff and a constant supply of liquid nitrogen (Van den 
Ouweland and Kema, 2012). Method standardization, availability of commercial certified 
reference materials and establishing concordance among methods should allow for increased 
application of mass spectroscopy as routine tests in clinical laboratories, notwithstanding the 
aforementioned cost concerns (Kushnir et al., 2011). 
PON1 activity 
PON1 activity measurement is a third potential option as an HDL-specific biomarker. Low 
serum PON1 activity was associated with increased risk for Major Adverse Cardiovascular 
Events (MACE) and coronary artery disease (Granér et al., 2006; Tang et al., 2012). The 
predictive power of PON1 activity was significant in detecting the development of vascular 
complications in type 2 diabetic patients (Mogarekar et al., 2016). Results of a systematic 
review and meta-analysis, showed that polymorphisms in the PON1 gene were significantly 
associated with heart diseases, including MI and coronary artery disease (Hernández-Díaz et 
al., 2016). Using patients from the Prevention of Renal and Vascular End-Stage Disease 
(PREVEND) study, a log-linear relationship between PON1 activity and CVD risk was 
demonstrated (Kunutsor et al., 2016). Incorporation of PON1 activity as a diagnostic test is 
simple, reliable, repeatable, fast, readily automated and inexpensive (Ferre et al., 2002).The 
only perceived draw-back is the toxicity of the paraoxon-ethyl substrate. 
HDL subclass distribution using the Lipoprint® System 
Finally, the Lipoprint® System, utilized for the first time in an African setting, is a relatively new 
technique for rapid (11 samples/ 2 hours) measurement of HDL and LDL subclass in serum 
samples (Hoefner et al., 2001). The ease of use of this method and a relatively low initial 
investment of $25 000 make this technique a particularly attractive tool for clinical purpose. 
The use of this equipment does not require extensive training and samples will not require any 
pre-treatment prior to analysis. HDL and LDL subclass analysis has been applied to patient 
populations with CVD and suggested as a potential biomarker in patients with CVD risk factors 
(Lofgren et al., 2004; Nakou et al., 2008; Goedecke et al., 2010; Oravec et al., 2011, 2014; 
Makariou et al., 2012; Filippatos et al., 2013; Woudberg et al., 2016). The LDL subclass test 
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has been approved by the Food and Drug Administration (FDA) for use as a diagnostic test in 
the United States. Further studies with large number of patients at risk of CVD may lead to 
approval of the HDL subclass test as more data becomes available.  
Diagnosis of HF is routinely done using echocardiography. Unfortunately, echocardiography 
is not easily accessible in low-income countries (Ogah et al., 2006). In addition, specialised 
training as well as the variability in data interpretation subject to the operator with 
echocardiography analysis highlights the need to establish simple novel biomarkers which can 
distinguish HF patients from those with hypertension (Ojji et al., 2013). HDL subclass may 
therefore be attractive biomarkers in this setting. In the third sample population, our preliminary 
study suggested that it may be possible, with greater patient numbers, that a decrease in large 




4. FINAL CONCLUSIONS 
The thesis has conclusively demonstrated how HDL quality and not HDL-C concentrations 
differ in individuals at risk of CVD. CVD risk factors such as obesity and hypertension were 
associated with less large HDL subclasses combined with greater intermediate and small HDL 
subclasses. Exercise training, as an intervention for obese individuals, reverted HDL subclass 
distribution to a “non-obese” state. Markers of HDL function were associated with ethnicity, 
were modified by exercise training and were impaired in patients at high risk of CVD. Future 
research considering CVD risk factors can therefore consider HDL quality as a potential 
biomarker of CVD risk. Literature data suggests that PON1 activity and HDL subclass 
distribution be used as potential biomarkers for CVD risk due to the low cost, reproducibility 
and ease of use. In order for this to be fully realised, longitudinal studies on large patient 
cohorts will need to be carried out to confirm the predictive power of these potential 
biomarkers. Similar to the studies included in this thesis, studying both measures of HDL 
function and subclass concurrently will be beneficial and important for assessing CVD risk, 
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